HIV Detail Information

Tipranavir (ID: DG00178) Resistance Data of HIV
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13IV+p.L33F+p.N37S+p.R41K+p.K43R+p.M46ML+p.I54V+p.K55R+p.R57K+p.I62V+p.L63P+p.I64IM+p.A71V+p.G73S+p.V82C+p.L89V+p.L90M+p.I93L
Missense mutation 12 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13IV, L33F, N37S, R41K, K43R, M46ML, I54V, K55R, R57K, I62V, L63P, I64IM, A71V, G73S, V82C, L89V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.G16A+p.L19V+p.L33F+p.E34Q+p.K43I+p.M46L+p.G51A+p.I54M+p.L63P+p.I64M+p.A71V+p.I72M+p.G73A+p.I84V+p.L90M
Missense mutation 12 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, G16A, L19V, L33F, E34Q, K43I, M46L, G51A, I54M, L63P, I64M, A71V, I72M, G73A, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K14KT+p.I15V+p.L19T+p.K20T+p.V32I+p.E35D+p.M36I+p.N37X+p.K43IT+p.M46I+p.F53FL+p.K55KR+p.R57G+p.L63P+p.C67F+p.H69HLQ+p.K70T+p.A71V+p.P79A+p.I84V+p.L90M+p.Q92R
Missense mutation 12 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K14KT, I15V, L19T, K20T, V32I, E35D, M36I, N37X, K43IT, M46I, F53FL, K55KR, R57G, L63P, C67F, H69HLQ, K70T, A71V, P79A, I84V, L90M, Q92R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.L19I+p.K20I+p.L33V+p.E35D+p.M36I+p.N37D+p.R41K+p.K45KR+p.M46I+p.I47A+p.F53Y+p.I62V+p.I64V+p.T74S+p.I84V+p.I85IV+p.L89I+p.L90M
Missense mutation 10 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L19I, K20I, L33V, E35D, M36I, N37D, R41K, K45KR, M46I, I47A, F53Y, I62V, I64V, T74S, I84V, I85IV, L89I, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I15V+p.K20R+p.M36I+p.N37D+p.M46I+p.I54V+p.K55KR+p.R57RK+p.Q58E+p.D60E+p.L63P+p.I64IL+p.A71V+p.V82A+p.I84V+p.L90M+p.I93L
Missense mutation 10 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I15V, K20R, M36I, N37D, M46I, I54V, K55KR, R57RK, Q58E, D60E, L63P, I64IL, A71V, V82A, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11I+p.T12P+p.I13V+p.I15V+p.L19P+p.K20T+p.V32I+p.L33F+p.E35G+p.M36I+p.I54V+p.I62V+p.L63P+p.K70T+p.A71I+p.G73S+p.P79A+p.I84V+p.L89V+p.L90M
Missense mutation 10 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, T12P, I13V, I15V, L19P, K20T, V32I, L33F, E35G, M36I, I54V, I62V, L63P, K70T, A71I, G73S, P79A, I84V, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10FI+p.K20R+p.L33F+p.E35D+p.M36I+p.N37D+p.I54V+p.I62V+p.L63P+p.I64L+p.A71V+p.G73T+p.V82VI+p.I84V+p.L90M+p.I93L
Missense mutation 14 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10FI, K20R, L33F, E35D, M36I, N37D, I54V, I62V, L63P, I64L, A71V, G73T, V82VI, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.G16EK+p.L33F+p.M46I+p.F53FL+p.I54S+p.Q58E+p.D60DN+p.Q61QH+p.I62IV+p.L63PS+p.A71V+p.G73S+p.V77I+p.V82A+p.L89V+p.L90M
Missense mutation 10 Potential low-level resistance [2]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, G16EK, L33F, M46I, F53FL, I54S, Q58E, D60DN, Q61QH, I62IV, L63PS, A71V, G73S, V77I, V82A, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L33F+p.R41K+p.M46L+p.I54V+p.K55R+p.Q58E+p.D60E+p.Q61E+p.L63P+p.A71T+p.I72T+p.G73C+p.V82A+p.I84V+p.L90M
Missense mutation 11 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L33F, R41K, M46L, I54V, K55R, Q58E, D60E, Q61E, L63P, A71T, I72T, G73C, V82A, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L33I+p.E35G+p.M36I+p.R41K+p.M46MI+p.I54V+p.K55KR+p.R57RK+p.Q58E+p.D60E+p.L63P+p.A71T+p.I72IV+p.G73S+p.I84V+p.L90M+p.I93L
Missense mutation 13 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L33I, E35G, M36I, R41K, M46MI, I54V, K55KR, R57RK, Q58E, D60E, L63P, A71T, I72IV, G73S, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.K20KR+p.L33F+p.E34ED+p.M36MV+p.N37ND+p.M46I+p.I54MV+p.I62V+p.L63P+p.I66F+p.C67F+p.I72L+p.G73T+p.V75I+p.I84V+p.L90M+p.I93IM+p.C95V
Missense mutation 12 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, K20KR, L33F, E34ED, M36MV, N37ND, M46I, I54MV, I62V, L63P, I66F, C67F, I72L, G73T, V75I, I84V, L90M, I93IM, C95V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K14R+p.I15V+p.G16GE+p.K20T+p.E21EK+p.R41K+p.M46I+p.I47V+p.F53L+p.I54V+p.Q61QP+p.L63P+p.I64V+p.K70R+p.A71V+p.I84V+p.I85V+p.I93L
Missense mutation 13 Potential low-level resistance [2]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14R, I15V, G16GE, K20T, E21EK, R41K, M46I, I47V, F53L, I54V, Q61QP, L63P, I64V, K70R, A71V, I84V, I85V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L19I+p.K20R+p.E35D+p.M36I+p.K43KE+p.M46L+p.G48V+p.I54CST+p.R57K+p.Q58E+p.I62V+p.L63P+p.A71V+p.I72V+p.V82A+p.I93L
Missense mutation 10 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19I, K20R, E35D, M36I, K43KE, M46L, G48V, I54CST, R57K, Q58E, I62V, L63P, A71V, I72V, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12TP+p.L24I+p.L33F+p.E34Q+p.E35D+p.M36I+p.R41K+p.M46L+p.I54V+p.K55KR+p.D60DE+p.I62V+p.L63P+p.A71V+p.I72IV+p.T74P+p.V82A+p.I84V+p.I93L
Missense mutation 12 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12TP, L24I, L33F, E34Q, E35D, M36I, R41K, M46L, I54V, K55KR, D60DE, I62V, L63P, A71V, I72IV, T74P, V82A, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11VI+p.I15V+p.K20R+p.E34EQ+p.E35ED+p.M36I+p.K43T+p.M46I+p.I54L+p.K55KR+p.D60E+p.I62IV+p.L63P+p.H69HR+p.A71V+p.I72V+p.G73T+p.V82AT+p.I84V+p.L90M+p.I93L
Missense mutation 11 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11VI, I15V, K20R, E34EQ, E35ED, M36I, K43T, M46I, I54L, K55KR, D60E, I62IV, L63P, H69HR, A71V, I72V, G73T, V82AT, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11VI+p.T12TP+p.I13IV+p.I15IV+p.K20X+p.L33F+p.E35D+p.M36L+p.N37D+p.K43KT+p.M46L+p.I62V+p.L63P+p.C67F+p.H69HY+p.A71V+p.I72ILM+p.G73S+p.V82A+p.I84V+p.I85V+p.L90M
Missense mutation 14 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11VI, T12TP, I13IV, I15IV, K20X, L33F, E35D, M36L, N37D, K43KT, M46L, I62V, L63P, C67F, H69HY, A71V, I72ILM, G73S, V82A, I84V, I85V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.I13V+p.L33I+p.E35D+p.M36I+p.I47IM+p.I54V+p.Q58QE+p.I62V+p.L63P+p.A71V+p.V82F+p.I85IV+p.L89V+p.L90M+p.I93L
Missense mutation 13 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13V, L33I, E35D, M36I, I47IM, I54V, Q58QE, I62V, L63P, A71V, V82F, I85IV, L89V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LFV+p.L33LI+p.N37NH+p.M46I+p.I54V+p.D60E+p.I62V+p.L63P+p.I64IV+p.I66V+p.I72IT+p.G73T+p.V77I+p.I84V+p.I85V+p.L90M+p.I93L+p.C95V
Missense mutation 11 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LFV, L33LI, N37NH, M46I, I54V, D60E, I62V, L63P, I64IV, I66V, I72IT, G73T, V77I, I84V, I85V, L90M, I93L, C95V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LV+p.V11I+p.I13V+p.K20V+p.L24M+p.V32I+p.L33F+p.E35G+p.M36I+p.I54L+p.K55N+p.D60E+p.L63P+p.C67CG+p.A71I+p.I72L+p.G73S+p.P79S+p.I84V+p.L89V+p.L90M+p.T91S+p.Q92K
Missense mutation 14 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, V11I, I13V, K20V, L24M, V32I, L33F, E35G, M36I, I54L, K55N, D60E, L63P, C67CG, A71I, I72L, G73S, P79S, I84V, L89V, L90M, T91S, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.G16A+p.L33F+p.N37D+p.M46L+p.I54V+p.K55R+p.R57K+p.L63P+p.A71V+p.I72M+p.G73S+p.V82T+p.L90M
Missense mutation 12 Potential low-level resistance [2]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, G16A, L33F, N37D, M46L, I54V, K55R, R57K, L63P, A71V, I72M, G73S, V82T, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L33F+p.M36L+p.P39Q+p.R41K+p.K43R+p.M46I+p.I47V+p.F53L+p.I54V+p.I62V+p.L63P+p.A71V+p.V82L+p.I93L
Missense mutation 12 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L33F, M36L, P39Q, R41K, K43R, M46I, I47V, F53L, I54V, I62V, L63P, A71V, V82L, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T4P+p.L10V+p.I13V+p.L19I+p.L33F+p.E35D+p.M36I+p.N37C+p.M46I+p.L63P+p.A71T+p.I84V+p.N88D+p.Q92R+p.I93L
Missense mutation 11 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4P, L10V, I13V, L19I, L33F, E35D, M36I, N37C, M46I, L63P, A71T, I84V, N88D, Q92R, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V11VI+p.I15IV+p.K20I+p.E34Q+p.M46I+p.I47V+p.F53FL+p.I54M+p.R57G+p.D60E+p.Q61H+p.L63P+p.A71V+p.G73T+p.V77I+p.P79DN+p.I84V+p.I85V+p.L90M+p.I93L
Missense mutation 12 Potential low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V11VI, I15IV, K20I, E34Q, M46I, I47V, F53FL, I54M, R57G, D60E, Q61H, L63P, A71V, G73T, V77I, P79DN, I84V, I85V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6WR+p.L10I+p.K20R+p.L33F+p.E35D+p.M36I+p.N37S+p.I54V+p.L63P+p.I72V+p.V82A+p.I84V
Missense mutation 14 Potential low-level resistance [2]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6WR, L10I, K20R, L33F, E35D, M36I, N37S, I54V, L63P, I72V, V82A, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I3F+p.L10I+p.K20R+p.V32I+p.L33F+p.E34K+p.E35D+p.M36I+p.N37D+p.R41K+p.K43E+p.K45R+p.I54M+p.D60K+p.L63P+p.A71V+p.I72T+p.V77I+p.I84V+p.L90M+p.I93L
Missense mutation 28 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I3F, L10I, K20R, V32I, L33F, E34K, E35D, M36I, N37D, R41K, K43E, K45R, I54M, D60K, L63P, A71V, I72T, V77I, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I3IV+p.L10I+p.V11VI+p.I13V+p.I15V+p.K20M+p.E35G+p.M36I+p.I54V+p.R57G+p.D60E+p.I62V+p.L63P+p.A71V+p.N88D+p.L90M
Missense mutation 23 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I3IV, L10I, V11VI, I13V, I15V, K20M, E35G, M36I, I54V, R57G, D60E, I62V, L63P, A71V, N88D, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10C+p.T12K+p.I13V+p.K20T+p.V32I+p.L33V+p.M36I+p.K43I+p.M46I+p.I47V+p.I62IV+p.L63P+p.A71V+p.V82T+p.I84V+p.L89V+p.L90LM+p.I93L
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10C, T12K, I13V, K20T, V32I, L33V, M36I, K43I, M46I, I47V, I62IV, L63P, A71V, V82T, I84V, L89V, L90LM, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10FI+p.I13IL+p.L19T+p.K20R+p.D25DN+p.L33F+p.E35D+p.M36I+p.R41RK+p.M46L+p.I54V+p.K55R+p.Q58E+p.I62V+p.L63P+p.A71V+p.T74P+p.I84V+p.L90M+p.Q92R
Missense mutation 33 Intermediate resistance [2]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10FI, I13IL, L19T, K20R, D25DN, L33F, E35D, M36I, R41RK, M46L, I54V, K55R, Q58E, I62V, L63P, A71V, T74P, I84V, L90M, Q92R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.E35D+p.M36I+p.N37S+p.R41K+p.I62V+p.L63P+p.I64M+p.A71V+p.I84V+p.L90M+p.I93L
Missense mutation 35 Intermediate resistance [3]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E35D, M36I, N37S, R41K, I62V, L63P, I64M, A71V, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.G16A+p.L33F+p.R41K+p.K43T+p.M46L+p.F53L+p.Q61E+p.I62V+p.L63P+p.A71V+p.T74P+p.V77I+p.V82A+p.L90M+p.I93L
Missense mutation 35 Intermediate resistance [3]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16A, L33F, R41K, K43T, M46L, F53L, Q61E, I62V, L63P, A71V, T74P, V77I, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.G16A+p.N37D+p.P39PQ+p.R41RK+p.M46I+p.I47V+p.R57K+p.L63P+p.I72V+p.L76V+p.I84C+p.L89I
Missense mutation 24 Low-level resistance [2]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, G16A, N37D, P39PQ, R41RK, M46I, I47V, R57K, L63P, I72V, L76V, I84C, L89I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.G16E+p.L33F+p.M46I+p.F53FL+p.I54S+p.Q58E+p.D60DN+p.Q61QHR+p.L63PS+p.A71V+p.G73S+p.V77I+p.V82AT+p.L89V+p.L90M
Missense mutation 24 Low-level resistance [2]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, G16E, L33F, M46I, F53FL, I54S, Q58E, D60DN, Q61QHR, L63PS, A71V, G73S, V77I, V82AT, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.I15IV+p.L19V+p.L33F+p.K43KT+p.K45KR+p.I54V+p.I62IV+p.L63P+p.A71V+p.T74P+p.V82L+p.I84V+p.L90M+p.I93IM
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15IV, L19V, L33F, K43KT, K45KR, I54V, I62IV, L63P, A71V, T74P, V82L, I84V, L90M, I93IM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.I15V+p.K20T+p.V32I+p.L33F+p.E35EK+p.I47V+p.R57G+p.L63P+p.I66F+p.A71V+p.G73S+p.V77I+p.L89V+p.L90M
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15V, K20T, V32I, L33F, E35EK, I47V, R57G, L63P, I66F, A71V, G73S, V77I, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K14KR+p.G16A+p.L33F+p.K43T+p.M46L+p.I54V+p.I62IV+p.L63P+p.A71V+p.T74P+p.V82A+p.I84V+p.L90M+p.T91S
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K14KR, G16A, L33F, K43T, M46L, I54V, I62IV, L63P, A71V, T74P, V82A, I84V, L90M, T91S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20I+p.L33V+p.E35D+p.M36I+p.N37T+p.M46I+p.I54V+p.Q58QE+p.I62V+p.L63P+p.I64IV+p.A71V+p.T74P+p.V82L+p.L90M+p.I93L
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20I, L33V, E35D, M36I, N37T, M46I, I54V, Q58QE, I62V, L63P, I64IV, A71V, T74P, V82L, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20R+p.L33F+p.E35D+p.M36I+p.N37E+p.K43T+p.M46I+p.I54V+p.R57K+p.D60E+p.Q61E+p.I62V+p.L63P+p.I64IV+p.G68E+p.A71T+p.I72T+p.G73AT+p.V82F+p.L90M+p.I93L
Missense mutation 28 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20R, L33F, E35D, M36I, N37E, K43T, M46I, I54V, R57K, D60E, Q61E, I62V, L63P, I64IV, G68E, A71T, I72T, G73AT, V82F, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20R+p.V32VI+p.L33F+p.E34N+p.E35D+p.M36I+p.N37ND+p.P39S+p.R41K+p.K43T+p.I47V+p.I54M+p.I62V+p.L63PT+p.I64V+p.A71T+p.T74S+p.V77I+p.V82T+p.I84V+p.I85IV+p.L90M+p.I93L
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20R, V32VI, L33F, E34N, E35D, M36I, N37ND, P39S, R41K, K43T, I47V, I54M, I62V, L63PT, I64V, A71T, T74S, V77I, V82T, I84V, I85IV, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15IV+p.K20R+p.E35D+p.M36I+p.M46L+p.I54V+p.Q58E+p.D60E+p.Q61E+p.I62IV+p.L63P+p.I64V+p.E65ED+p.I66IV+p.A71V+p.V82F+p.I84V+p.I85V+p.I93L
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15IV, K20R, E35D, M36I, M46L, I54V, Q58E, D60E, Q61E, I62IV, L63P, I64V, E65ED, I66IV, A71V, V82F, I84V, I85V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15L+p.L19I+p.E35D+p.M36I+p.R41K+p.M46I+p.K55R+p.I62V+p.L63P+p.A71T+p.I72T+p.I84V+p.I85V+p.L90M
Missense mutation 17 Low-level resistance [3]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15L, L19I, E35D, M36I, R41K, M46I, K55R, I62V, L63P, A71T, I72T, I84V, I85V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.G17D+p.L19W+p.K20I+p.M36I+p.M46I+p.I47V+p.I54V+p.I62V+p.L63P+p.A71V+p.I72N+p.G73T+p.I84V+p.I85V+p.L90M+p.I93L
Missense mutation 11 Potential low-level resistance [4]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, G17D, L19W, K20I, M36I, M46I, I47V, I54V, I62V, L63P, A71V, I72N, G73T, I84V, I85V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20I+p.E35N+p.M36I+p.N37D+p.M46L+p.I54V+p.K55R+p.Q58E+p.I62V+p.L63P+p.A71V+p.G73S+p.V82L+p.L90M
Missense mutation 28 Low-level resistance [2]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20I, E35N, M36I, N37D, M46L, I54V, K55R, Q58E, I62V, L63P, A71V, G73S, V82L, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.E35D+p.M36I+p.K43T+p.I47V+p.G48M+p.F53L+p.I54V+p.I62V+p.L63P+p.I66F+p.A71V+p.V82T+p.I84V+p.Q92R
Missense mutation 16 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36I, K43T, I47V, G48M, F53L, I54V, I62V, L63P, I66F, A71V, V82T, I84V, Q92R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.E35DN+p.M36L+p.N37D+p.R41K+p.I62V+p.L63LP+p.I64V+p.I66V+p.A71V+p.I72IT+p.G73T+p.N83D+p.I84V+p.L90M+p.C95V
Missense mutation 20 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35DN, M36L, N37D, R41K, I62V, L63LP, I64V, I66V, A71V, I72IT, G73T, N83D, I84V, L90M, C95V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.L33F+p.E35D+p.M36I+p.N37S+p.K43KT+p.I54V+p.L63P+p.I72V+p.V82T+p.I84V
Missense mutation 46.2 Intermediate resistance [2]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, L33F, E35D, M36I, N37S, K43KT, I54V, L63P, I72V, V82T, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.L33I+p.M36I+p.I54V+p.Q58E+p.D60E+p.L63P+p.A71V+p.V82L+p.I84V+p.L90M+p.I93L
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, L33I, M36I, I54V, Q58E, D60E, L63P, A71V, V82L, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.V32I+p.L33F+p.E35D+p.M36I+p.N37D+p.R41IK+p.M46I+p.I47V+p.I54V+p.I62V+p.L63P+p.A71V+p.I72V+p.G73T+p.P79S+p.I84V+p.L90M
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, V32I, L33F, E35D, M36I, N37D, R41IK, M46I, I47V, I54V, I62V, L63P, A71V, I72V, G73T, P79S, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L19I+p.K20R+p.E34D+p.E35D+p.M36I+p.R41K+p.M46I+p.I47V+p.I54M+p.L63P+p.A71T+p.I84V+p.I85V+p.L90M+p.I93L
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19I, K20R, E34D, E35D, M36I, R41K, M46I, I47V, I54M, L63P, A71T, I84V, I85V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L19I+p.K20R+p.E35D+p.M36I+p.M46I+p.I54V+p.Q58E+p.D60E+p.L63P+p.A71V+p.I72IT+p.V82T+p.I84V+p.I85V+p.L90M+p.Q92K+p.I93L
Missense mutation 36 Intermediate resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19I, K20R, E35D, M36I, M46I, I54V, Q58E, D60E, L63P, A71V, I72IT, V82T, I84V, I85V, L90M, Q92K, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12N+p.I13V+p.L33F+p.M46L+p.I54IV+p.Q61QH+p.L63P+p.I64V+p.A71V+p.T74P+p.V77I+p.V82F+p.I84V+p.L90M+p.I93L
Missense mutation 24 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12N, I13V, L33F, M46L, I54IV, Q61QH, L63P, I64V, A71V, T74P, V77I, V82F, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12P+p.L19LS+p.K20R+p.E35D+p.M36I+p.N37D+p.M46I+p.I54V+p.I62IV+p.L63P+p.I66V+p.H69R+p.G73T+p.V82T+p.I84V+p.I93L+p.C95F
Missense mutation 32 Intermediate resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12P, L19LS, K20R, E35D, M36I, N37D, M46I, I54V, I62IV, L63P, I66V, H69R, G73T, V82T, I84V, I93L, C95F.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12S+p.I13V+p.K20R+p.L33LF+p.E35D+p.M36I+p.N37E+p.K43IT+p.I54L+p.R57K+p.I62V+p.L63P+p.K70KE+p.A71I+p.V82A+p.I84V+p.L89V+p.L90M+p.Q92K+p.I93L
Missense mutation 17 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12S, I13V, K20R, L33LF, E35D, M36I, N37E, K43IT, I54L, R57K, I62V, L63P, K70KE, A71I, V82A, I84V, L89V, L90M, Q92K, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12TI+p.I13V+p.L19LI+p.K20R+p.L33F+p.E35D+p.M36I+p.N37D+p.K43T+p.M46L+p.I54V+p.K55KR+p.I62V+p.L63P+p.A71IV+p.I72IT+p.G73S+p.V82A+p.L90M+p.I93L
Missense mutation 21 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12TI, I13V, L19LI, K20R, L33F, E35D, M36I, N37D, K43T, M46L, I54V, K55KR, I62V, L63P, A71IV, I72IT, G73S, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.E21D+p.A22V+p.L24M+p.E35DN+p.M36I+p.N37D+p.R41RK+p.M46L+p.I54V+p.R57RK+p.Q61HN+p.I62V+p.L63P+p.I64V+p.I66V+p.A71V+p.I72T+p.G73T+p.N83D+p.I84V
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, E21D, A22V, L24M, E35DN, M36I, N37D, R41RK, M46L, I54V, R57RK, Q61HN, I62V, L63P, I64V, I66V, A71V, I72T, G73T, N83D, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.I13V+p.G16A+p.V32I+p.L33F+p.M36IL+p.K43T+p.M46L+p.F53L+p.I54L+p.K55R+p.R57G+p.I62V+p.L63P+p.A71V+p.I72R+p.G73S+p.T74P+p.V82I+p.I84V+p.L89V+p.L90M+p.T91S+p.G94S
Missense mutation 18 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, G16A, V32I, L33F, M36IL, K43T, M46L, F53L, I54L, K55R, R57G, I62V, L63P, A71V, I72R, G73S, T74P, V82I, I84V, L89V, L90M, T91S, G94S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.I13V+p.K20R+p.L24I+p.L33F+p.E35D+p.M36I+p.N37E+p.K43T+p.M46L+p.I54V+p.I62V+p.L63P+p.I64V+p.I66IN+p.A71V+p.T74P+p.V82A+p.I84V+p.T91S+p.Q92K+p.T96TP
Missense mutation 26 Low-level resistance [2]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, K20R, L24I, L33F, E35D, M36I, N37E, K43T, M46L, I54V, I62V, L63P, I64V, I66IN, A71V, T74P, V82A, I84V, T91S, Q92K, T96TP.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.I13V+p.L33F+p.M46I+p.I54V+p.K55R+p.Q58E+p.I62V+p.L63P+p.I66F+p.A71V+p.T74P+p.V82T+p.I84V+p.L90M+p.T91FS
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, L33F, M46I, I54V, K55R, Q58E, I62V, L63P, I66F, A71V, T74P, V82T, I84V, L90M, T91FS.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.T12K+p.I13V+p.K20V+p.V32I+p.L33F+p.E35G+p.M36I+p.N37D+p.M46I+p.I47V+p.I54M+p.R57K+p.Q58E+p.L63P+p.I64V+p.I66V+p.A71V+p.G73S+p.I84V+p.L89V+p.L90M
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, T12K, I13V, K20V, V32I, L33F, E35G, M36I, N37D, M46I, I47V, I54M, R57K, Q58E, L63P, I64V, I66V, A71V, G73S, I84V, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.T12K+p.I13V+p.K20V+p.V32I+p.L33LF+p.E35G+p.M36I+p.N37ND+p.M46I+p.I47V+p.I54M+p.R57K+p.Q58E+p.L63P+p.I64V+p.A71IV+p.G73S+p.I84IV+p.L89V+p.L90M
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, T12K, I13V, K20V, V32I, L33LF, E35G, M36I, N37ND, M46I, I47V, I54M, R57K, Q58E, L63P, I64V, A71IV, G73S, I84IV, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.T12S+p.I13V+p.K14R+p.L19P+p.K20V+p.V32I+p.E34D+p.E35N+p.M36I+p.K43T+p.M46L+p.I47V+p.I54M+p.R57G+p.I62V+p.L63P+p.A71V+p.G73D+p.T74S+p.I84V+p.L89V+p.L90M
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, T12S, I13V, K14R, L19P, K20V, V32I, E34D, E35N, M36I, K43T, M46L, I47V, I54M, R57G, I62V, L63P, A71V, G73D, T74S, I84V, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11L+p.I13V+p.I15V+p.G16A+p.V32I+p.L33F+p.E34Q+p.E35D+p.M36I+p.K43T+p.M46I+p.I47V+p.F53L+p.I54L+p.K55R+p.D60E+p.I62V+p.L63P+p.I66V+p.A71I+p.G73T+p.V77I+p.I84V+p.L90M+p.I93L
Missense mutation 100 High-level resistance [3]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11L, I13V, I15V, G16A, V32I, L33F, E34Q, E35D, M36I, K43T, M46I, I47V, F53L, I54L, K55R, D60E, I62V, L63P, I66V, A71I, G73T, V77I, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11L+p.I13V+p.I15V+p.Q18H+p.K20I+p.E35G+p.M36I+p.N37D+p.I54V+p.L63P+p.A71V+p.I72L+p.G73GS+p.I84V+p.L90M
Missense mutation 19 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11L, I13V, I15V, Q18H, K20I, E35G, M36I, N37D, I54V, L63P, A71V, I72L, G73GS, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11L+p.K20R+p.V32I+p.L33F+p.E34S+p.E35D+p.M36V+p.N37S+p.M46I+p.I47V+p.I54M+p.R57K+p.Q58E+p.I62V+p.L63P+p.A71I+p.V77T+p.V82I+p.I84V+p.I85V+p.L89M+p.L90M+p.I93L
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11L, K20R, V32I, L33F, E34S, E35D, M36V, N37S, M46I, I47V, I54M, R57K, Q58E, I62V, L63P, A71I, V77T, V82I, I84V, I85V, L89M, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11VI+p.I13V+p.I15V+p.K20KR+p.V32I+p.L33M+p.N37T+p.K43I+p.I54V+p.D60N+p.I62V+p.L63P+p.I64V+p.A71V+p.T74E+p.V82L+p.I84V+p.Q92R
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11VI, I13V, I15V, K20KR, V32I, L33M, N37T, K43I, I54V, D60N, I62V, L63P, I64V, A71V, T74E, V82L, I84V, Q92R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11VI+p.I13V+p.K14KR+p.G16A+p.V32I+p.L33F+p.K43T+p.M46L+p.I54L+p.I62V+p.L63P+p.A71V+p.T74P+p.V82VA+p.I84V+p.L90M+p.T91S
Missense mutation 24 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11VI, I13V, K14KR, G16A, V32I, L33F, K43T, M46L, I54L, I62V, L63P, A71V, T74P, V82VA, I84V, L90M, T91S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.I13V+p.L33F+p.E34ED+p.M36MV+p.M46L+p.I54V+p.Q58E+p.D60E+p.I62V+p.L63P+p.I66IV+p.K70KT+p.A71M+p.I72IM+p.V77I+p.V82T+p.I84V+p.L89M+p.I93L
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13V, L33F, E34ED, M36MV, M46L, I54V, Q58E, D60E, I62V, L63P, I66IV, K70KT, A71M, I72IM, V77I, V82T, I84V, L89M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LFV+p.V11I+p.I13V+p.I15IV+p.K20V+p.L24M+p.V32I+p.L33F+p.E35G+p.M36I+p.I54L+p.K55N+p.Q58QE+p.D60E+p.L63P+p.A71I+p.I72L+p.G73S+p.P79S+p.V82L+p.I84V+p.L89V+p.L90M+p.T91S+p.Q92K
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LFV, V11I, I13V, I15IV, K20V, L24M, V32I, L33F, E35G, M36I, I54L, K55N, Q58QE, D60E, L63P, A71I, I72L, G73S, P79S, V82L, I84V, L89V, L90M, T91S, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LV+p.I13IV+p.V32I+p.L33F+p.M36ML+p.M46I+p.I47V+p.I54M+p.I64V+p.K70KE+p.A71V+p.V82X+p.I84IV
Missense mutation 36 Intermediate resistance [2]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, I13IV, V32I, L33F, M36ML, M46I, I47V, I54M, I64V, K70KE, A71V, V82X, I84IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LV+p.V32I+p.L33M+p.R41K+p.M46I+p.I47V+p.I54M+p.K55KR+p.Q58E+p.L63P+p.K70T+p.A71V+p.T74TP+p.V82T+p.L89F+p.L90M+p.I93L
Missense mutation 30 Intermediate resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, V32I, L33M, R41K, M46I, I47V, I54M, K55KR, Q58E, L63P, K70T, A71V, T74TP, V82T, L89F, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.G16A+p.L24I+p.V32I+p.L33F+p.E34EF+p.N37ND+p.M46L+p.I54V+p.L63P+p.A71V+p.I72V+p.V77I+p.V82T+p.I84V
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, G16A, L24I, V32I, L33F, E34EF, N37ND, M46L, I54V, L63P, A71V, I72V, V77I, V82T, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.I15V+p.G16A+p.K20R+p.V32I+p.L33F+p.M36I+p.K43T+p.M46I+p.I47V+p.I54M+p.L63P+p.A71V+p.V82T+p.L90M
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, I15V, G16A, K20R, V32I, L33F, M36I, K43T, M46I, I47V, I54M, L63P, A71V, V82T, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.I15V+p.K20R+p.V32I+p.L33F+p.E35D+p.M36I+p.N37S+p.R41K+p.K43IT+p.M46I+p.I47V+p.F53L+p.R57K+p.L63P+p.A71V+p.G73S+p.V82A+p.L90M+p.I93L+p.C95CF
Missense mutation 15 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, I15V, K20R, V32I, L33F, E35D, M36I, N37S, R41K, K43IT, M46I, I47V, F53L, R57K, L63P, A71V, G73S, V82A, L90M, I93L, C95CF.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.I15V+p.L19I+p.L33F+p.E34T+p.M36L+p.R41K+p.M46I+p.I47V+p.I54V+p.K55R+p.Q61H+p.I62V+p.L63P+p.A71T+p.I72E+p.G73A+p.V77I+p.V82C+p.I85L+p.L90M+p.I93L
Missense mutation 29 Low-level resistance [3]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, I15V, L19I, L33F, E34T, M36L, R41K, M46I, I47V, I54V, K55R, Q61H, I62V, L63P, A71T, I72E, G73A, V77I, V82C, I85L, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.K14R+p.G16E+p.K20R+p.V32I+p.L33F+p.E35D+p.M36I+p.N37E+p.P39PT+p.R41K+p.K43KIT+p.M46I+p.R57K+p.I62V+p.L63AT+p.A71I+p.V77T+p.V82A+p.I84V+p.L90M+p.I93L
Missense mutation 17 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K14R, G16E, K20R, V32I, L33F, E35D, M36I, N37E, P39PT, R41K, K43KIT, M46I, R57K, I62V, L63AT, A71I, V77T, V82A, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.K20R+p.V32I+p.E35D+p.M36I+p.K43T+p.M46I+p.I47V+p.F53L+p.I62V+p.L63P+p.A71L+p.I72V+p.V77Q+p.V82C+p.I84V+p.I93L
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K20R, V32I, E35D, M36I, K43T, M46I, I47V, F53L, I62V, L63P, A71L, I72V, V77Q, V82C, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.K20R+p.V32I+p.L33F+p.E35D+p.M36I+p.N37D+p.M46I+p.F53L+p.I54L+p.L63P+p.I64M+p.C67E+p.A71V+p.I72V+p.V82A+p.N83D+p.L89V+p.L90M+p.I93L
Missense mutation 93 High-level resistance [3]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, K20R, V32I, L33F, E35D, M36I, N37D, M46I, F53L, I54L, L63P, I64M, C67E, A71V, I72V, V82A, N83D, L89V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.V11L+p.I13V+p.K14KR+p.L33F+p.M36MV+p.N37D+p.R41K+p.M46L+p.I54V+p.K55R+p.D60E+p.Q61D+p.L63P+p.H69HY+p.A71V+p.I72T+p.G73S+p.T74P+p.V77I+p.V82T+p.I84V+p.L89V+p.L90M+p.Q92K
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, V11L, I13V, K14KR, L33F, M36MV, N37D, R41K, M46L, I54V, K55R, D60E, Q61D, L63P, H69HY, A71V, I72T, G73S, T74P, V77I, V82T, I84V, L89V, L90M, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10Y+p.I13V+p.K20R+p.L33F+p.E35D+p.M36L+p.R41K+p.K43KT+p.I62V+p.L63P+p.A71V+p.I72M+p.G73S+p.P79HQ+p.V82L+p.I84V+p.L89V+p.L90M
Missense mutation 100 High-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10Y, I13V, K20R, L33F, E35D, M36L, R41K, K43KT, I62V, L63P, A71V, I72M, G73S, P79HQ, V82L, I84V, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T4PS+p.L10F+p.K20R+p.L33F+p.E35D+p.M36IL+p.N37D+p.M46I+p.I54V+p.R57K+p.I62V+p.L63P+p.A71V+p.I72M+p.G73S+p.V82T+p.L90M
Missense mutation 16 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4PS, L10F, K20R, L33F, E35D, M36IL, N37D, M46I, I54V, R57K, I62V, L63P, A71V, I72M, G73S, V82T, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T4S+p.V11I+p.I13V+p.L19V+p.K20IV+p.L33V+p.E35D+p.M36I+p.N37NS+p.M46IL+p.I54V+p.K55R+p.R57K+p.L63P+p.I64V+p.C67F+p.H69R+p.A71I+p.I72F+p.G73T+p.P79A+p.V82VL+p.I84V+p.L90M+p.I93L+p.T96S
Missense mutation 23 Low-level resistance [1]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4S, V11I, I13V, L19V, K20IV, L33V, E35D, M36I, N37NS, M46IL, I54V, K55R, R57K, L63P, I64V, C67F, H69R, A71I, I72F, G73T, P79A, V82VL, I84V, L90M, I93L, T96S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T4TN+p.L10Y+p.I13V+p.L19Q+p.K20MT+p.E35DN+p.M36I+p.K43KT+p.M46L+p.I54V+p.I62V+p.L63P+p.A71T+p.T74S+p.I84V+p.L89V+p.Q92K
Missense mutation 50 Intermediate resistance [2]
Resistant Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4TN, L10Y, I13V, L19Q, K20MT, E35DN, M36I, K43KT, M46L, I54V, I62V, L63P, A71T, T74S, I84V, L89V, Q92K.
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G16E+p.M36MI+p.P39S+p.R41K+p.R57G+p.L63T+p.A71V+p.I93L
Missense mutation 0.8 Susceptible [5]
p.R57G+p.L63AT+p.E65D+p.I72V+p.V77I
Missense mutation 0.8 Susceptible [5]
p.K14R+p.Q18E+p.E35D+p.M36I+p.R57G+p.I62V+p.L63P+p.I72V+p.I93L
Missense mutation 1.1 Susceptible [5]
p.I13V+p.R57G+p.L63D+p.I64V+p.E65D+p.K70R+p.I72T
Missense mutation 0.7 Susceptible [5]
p.T12TA+p.I13V+p.G17E+p.K20I+p.M36I+p.R41K+p.R57G+p.L63P+p.H69K+p.K70KR+p.I72L+p.L89I
Missense mutation 0.6 Susceptible [5]
p.T12TP+p.I13IV+p.K14KR+p.N37S+p.R57K+p.L63P+p.I64V+p.C67X
Missense mutation 0.9 Susceptible [5]
p.E35D+p.N37S+p.R57K+p.I62IV+p.L63P
Missense mutation 1 Susceptible [5]
p.N37T+p.R57K+p.I62V+p.L63ST+p.A71T+p.I72V+p.V77I+p.I93L
Missense mutation 1.2 Susceptible [5]
p.E35D+p.M36I+p.N37D+p.R57K+p.D60DE+p.I62V+p.L63P+p.V77I+p.I93L
Missense mutation 1.3 Susceptible [5]
p.I13V+p.L19I+p.K20T+p.E35G+p.M36I+p.R41K+p.R57G+p.I62V+p.L63T+p.I64V+p.I72T+p.T74S+p.V77I+p.L90M
Missense mutation 6.7 Susceptible [5]
p.T12PS+p.I13V+p.L19LI+p.N37A+p.R57G+p.L63P+p.I64V
Missense mutation 0.9 Susceptible [5]
p.E35D+p.N37S+p.R41K+p.R57G+p.I62IV+p.L63A+p.I72IV
Missense mutation 0.7 Susceptible [5]
p.R57G+p.L63P+p.I72E+p.V77I+p.I93L
Missense mutation 0.7 Susceptible [5]
p.I13V+p.I15L+p.L33V+p.N37S+p.R41K+p.K45KR+p.R57K+p.L63X+p.I64V
Missense mutation 0.9 Susceptible [5]
p.T12S+p.L19I+p.E35D+p.R57K+p.L63P+p.H69Q+p.A71AT
Missense mutation 1 Susceptible [5]
p.L10LF+p.K14KR+p.E35D+p.R41RK+p.R57RG+p.L63P
Missense mutation 1.1 Susceptible [5]
p.T12P+p.N37S+p.R57G+p.L63A+p.I72V+p.V77I+p.I93L
Missense mutation 0.6 Susceptible [5]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 GeneSeq assay; PhenoSense GT assay
Experiment for
Drug Resistance		 Viral load assay
Mechanism Description Amino acid changes in IN may contribute to drug resistance or sensitivity.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D30N+p.N37NT+p.I62IV+p.L63P+p.V75VI+p.V77I+p.N88D+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D30N, N37NT, I62IV, L63P, V75VI, V77I, N88D, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E34Q+p.N37C+p.R41K+p.M46I+p.I50V+p.I62V+p.L63T+p.A71V+p.L76V+p.V77I+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E34Q, N37C, R41K, M46I, I50V, I62V, L63T, A71V, L76V, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.K43KR+p.R57G+p.L63P+p.V82VI+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, K43KR, R57G, L63P, V82VI, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.M36I+p.I62IV+p.L63P+p.A71AV+p.G73GS+p.V77VI+p.I84IV+p.L90LM
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, I62IV, L63P, A71AV, G73GS, V77VI, I84IV, L90LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.M36I+p.N37D+p.R41RK+p.I64V+p.H69Y
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, N37D, R41RK, I64V, H69Y.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.M36I+p.R57G+p.I62IV+p.L63P+p.I64L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, R57G, I62IV, L63P, I64L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.M36I+p.R57G+p.L63P+p.I64L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, R57G, L63P, I64L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.N37D+p.R57G+p.I62V+p.L63P+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37D, R57G, I62V, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.N37D+p.R57K+p.L63P+p.A71T+p.I72IV+p.V77I+p.I93L
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37D, R57K, L63P, A71T, I72IV, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.N37T+p.I62V+p.L63P+p.I93L
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37T, I62V, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.N37Y+p.R41K+p.R57K+p.L63LP+p.V77I
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37Y, R41K, R57K, L63LP, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.R41K+p.L63P+p.I64L+p.A71AV+p.I84IV
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, R41K, L63P, I64L, A71AV, I84IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.R41RK+p.R57G+p.Q61H+p.I64IV+p.V77L+p.I93L
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, R41RK, R57G, Q61H, I64IV, V77L, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.R57G+p.L63P+p.H69Q
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, R57G, L63P, H69Q.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.R57G+p.L63P+p.I64V+p.I72IM
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, R57G, L63P, I64V, I72IM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.R57G+p.L63P+p.I72V
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, R57G, L63P, I72V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35X+p.N37X+p.L38LM+p.R41RK+p.R57G+p.I62IV+p.L63HP+p.A71AV+p.V77I+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35X, N37X, L38LM, R41RK, R57G, I62IV, L63HP, A71AV, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G16E+p.K55KR+p.R57G+p.I72IR+p.V77VI
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G16E, K55KR, R57G, I72IR, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G16E+p.L19LI+p.D30N+p.E35D+p.M36L+p.K45KR+p.L63H+p.I64V+p.I85V
Missense mutation 0.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G16E, L19LI, D30N, E35D, M36L, K45KR, L63H, I64V, I85V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G17E+p.D60E+p.L63P+p.I64V+p.K70R+p.V77VI
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G17E, D60E, L63P, I64V, K70R, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13A+p.K14R+p.K20I+p.M36I+p.N37D+p.R41K+p.H69K+p.L89I
Missense mutation 1 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13A, K14R, K20I, M36I, N37D, R41K, H69K, L89I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IA+p.I15IV+p.N37NS+p.R57G+p.I72IV
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IA, I15IV, N37NS, R57G, I72IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IM+p.I15IV+p.L19LI+p.R41K+p.Q61QR+p.L63LP+p.I72V+p.V77I+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IM, I15IV, L19LI, R41K, Q61QR, L63LP, I72V, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.G16GE+p.L19V+p.K20I+p.L63P+p.K70R+p.A71T
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, G16GE, L19V, K20I, L63P, K70R, A71T.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.I15IV+p.K20X+p.D60E+p.Q61E+p.L63P+p.I64M
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, I15IV, K20X, D60E, Q61E, L63P, I64M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.I15IV+p.M36MI+p.R57G+p.I72IV
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, I15IV, M36MI, R57G, I72IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.K14KR+p.E35D+p.M36I+p.N37ND+p.R41K+p.D60DE+p.Q61QE+p.I62IV+p.L63X+p.I64ILM+p.C67CY+p.H69K+p.L89M+p.I93IL
Missense mutation 0.8 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, K14KR, E35D, M36I, N37ND, R41K, D60DE, Q61QE, I62IV, L63X, I64ILM, C67CY, H69K, L89M, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.K14KR+p.N37CS+p.R41RK+p.I64V+p.V77I
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, K14KR, N37CS, R41RK, I64V, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.K20KIM+p.M36MI+p.N37D+p.R41K+p.D60E+p.I62V+p.L63P+p.I64IL+p.H69Y+p.I72E
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, K20KIM, M36MI, N37D, R41K, D60E, I62V, L63P, I64IL, H69Y, I72E.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.M36I+p.N37D+p.R57G+p.L63AS
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, M36I, N37D, R57G, L63AS.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.N37NS+p.R41K+p.L63A+p.I64V+p.H69Y+p.V77I
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, N37NS, R41K, L63A, I64V, H69Y, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.N37T+p.I62V+p.L63HQ+p.I72IV
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, N37T, I62V, L63HQ, I72IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.R41K+p.K55R+p.R57G+p.L63H+p.I64V+p.E65D+p.V77I
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, R41K, K55R, R57G, L63H, I64V, E65D, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.D30N+p.K43T+p.M46I+p.D60E+p.Q61E+p.L63P+p.V77I+p.I93L
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, D30N, K43T, M46I, D60E, Q61E, L63P, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.D30N+p.R57K+p.D60E+p.L63P+p.A71V+p.V75VI
Missense mutation 0.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, D30N, R57K, D60E, L63P, A71V, V75VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.E35D+p.N37T+p.L63P+p.I64V
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, E35D, N37T, L63P, I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.I15IV+p.Q18QH+p.R57RK+p.I62IV+p.L63P+p.I64IV+p.V77I
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15IV, Q18QH, R57RK, I62IV, L63P, I64IV, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.I15V+p.K20R+p.M36I+p.R41K+p.H69K+p.L89M+p.I93L
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15V, K20R, M36I, R41K, H69K, L89M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.I15V+p.K20R+p.N37NS+p.L63P+p.V77I
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15V, K20R, N37NS, L63P, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.I15V+p.K20R+p.N37S+p.L63P+p.V77I
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15V, K20R, N37S, L63P, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.I15V+p.P39Q+p.R57K+p.L63P+p.I64V
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15V, P39Q, R57K, L63P, I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.I64V+p.I72V
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I64V, I72V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.I64V
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14KR+p.G16E+p.K20R+p.E35D+p.M36I+p.N37X+p.R41K+p.L63LIV+p.H69K+p.L89M
Missense mutation 0.8 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14KR, G16E, K20R, E35D, M36I, N37X, R41K, L63LIV, H69K, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14KR+p.I15V+p.L19I+p.M36I+p.K43R+p.R57K+p.L63P+p.L89M
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14KR, I15V, L19I, M36I, K43R, R57K, L63P, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.G16E+p.K20I+p.E35D+p.M36I+p.R41K+p.M46ML+p.H69K+p.L89M
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, G16E, K20I, E35D, M36I, R41K, M46ML, H69K, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.G16E+p.K20R+p.E35D+p.M36I+p.P39PS+p.R41K+p.H69K+p.L89M+p.I93L
Missense mutation 0.7 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, G16E, K20R, E35D, M36I, P39PS, R41K, H69K, L89M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.I15V+p.G16A+p.E35D+p.N37D+p.L63P
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, I15V, G16A, E35D, N37D, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.I15V+p.Q18K+p.K20T+p.V32I+p.E35D+p.M36I+p.N37D+p.R57K+p.L63P+p.I64V+p.A71T+p.I72IV+p.V77I+p.V82I+p.L90M+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, I15V, Q18K, K20T, V32I, E35D, M36I, N37D, R57K, L63P, I64V, A71T, I72IV, V77I, V82I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.I62V+p.L63P+p.I72IM
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, I62V, L63P, I72IM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.K20I+p.E35D+p.M36I+p.R41K+p.H69K+p.V82I+p.L89M
Missense mutation 0.8 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20I, E35D, M36I, R41K, H69K, V82I, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.K20I+p.E35D+p.M36I+p.R41K+p.I62IV+p.L63LHP+p.H69K+p.V82I+p.L89M
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20I, E35D, M36I, R41K, I62IV, L63LHP, H69K, V82I, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.K20I+p.E35D+p.M36I+p.R41K+p.I64L+p.H69K+p.V82VI+p.L89M
Missense mutation 1 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20I, E35D, M36I, R41K, I64L, H69K, V82VI, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.K20I+p.M36I+p.R41K+p.I64M+p.H69K+p.K70R+p.V82I+p.L89M
Missense mutation 0.6 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20I, M36I, R41K, I64M, H69K, K70R, V82I, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.K20I+p.V32VA+p.M36I+p.R41K+p.H69K+p.L89M
Missense mutation 0.8 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20I, V32VA, M36I, R41K, H69K, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.K20IV+p.M36I+p.N37ND+p.R41K+p.L63S+p.H69K+p.L89M
Missense mutation 0.8 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20IV, M36I, N37ND, R41K, L63S, H69K, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.K20KIM+p.R41RK+p.I64V+p.V77IL
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, K20KIM, R41RK, I64V, V77IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.L19I+p.K20I+p.E35Q+p.M36I+p.R41K+p.R57K+p.C67E+p.H69K+p.V82I+p.L89M
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, L19I, K20I, E35Q, M36I, R41K, R57K, C67E, H69K, V82I, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K20KM+p.E35D+p.M36I+p.R57RK+p.I64V
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K20KM, E35D, M36I, R57RK, I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K45R+p.I62IV+p.L63S+p.I64M+p.V77I
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K45R, I62IV, L63S, I64M, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.L19I+p.E35D+p.N37X+p.L63P
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, L19I, E35D, N37X, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.L19V+p.M36MI+p.R41K+p.Q61N+p.I64V+p.E65D+p.I72E
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, L19V, M36MI, R41K, Q61N, I64V, E65D, I72E.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.L33LV+p.R41RK+p.L63LP+p.I64IV+p.I72IM
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, L33LV, R41RK, L63LP, I64IV, I72IM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.M36I+p.R57G+p.L63P+p.A71T+p.V77I+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, M36I, R57G, L63P, A71T, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.M46MI+p.L63P+p.I64V+p.K70R+p.I72V+p.V77VI+p.L90M+p.I93IL
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, M46MI, L63P, I64V, K70R, I72V, V77VI, L90M, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.N37D+p.R57G+p.L63S+p.H69R
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, N37D, R57G, L63S, H69R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.N37NS+p.L63P+p.I72E
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, N37NS, L63P, I72E.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.N37ST+p.I62IV+p.L63P+p.K70R+p.A71AT+p.I72IM
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, N37ST, I62IV, L63P, K70R, A71AT, I72IM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.N37T+p.L63E+p.I64V+p.E65D+p.V77I
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, N37T, L63E, I64V, E65D, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.N37T+p.L63P+p.T74TA
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, N37T, L63P, T74TA.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.P39PT+p.R57G+p.L63P+p.V77VI
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, P39PT, R57G, L63P, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.P39Q+p.I62V+p.L63P+p.V77I
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, P39Q, I62V, L63P, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.Q18H+p.L63P
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, Q18H, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.R41K+p.L63P+p.H69R+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, R41K, L63P, H69R, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.R57G+p.L63P+p.K70R+p.I72IV+p.V77VI
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, R57G, L63P, K70R, I72IV, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15IV+p.I64IV
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15IV, I64IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15IV+p.K43KR+p.I62V+p.L63P+p.I72IV+p.V77I+p.L90LM+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15IV, K43KR, I62V, L63P, I72IV, V77I, L90LM, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15IV+p.M36I+p.R41K+p.R57RK+p.L63LP+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15IV, M36I, R41K, R57RK, L63LP, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15IV+p.N37X+p.L38IM+p.R41RK+p.R57G+p.I62V+p.I64IV+p.H69HY+p.I72IMV+p.V77VI
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15IV, N37X, L38IM, R41RK, R57G, I62V, I64IV, H69HY, I72IMV, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15IV+p.Q18H+p.E21EG+p.N37S+p.K43KR+p.R57K+p.L63P+p.V77VI
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15IV, Q18H, E21EG, N37S, K43KR, R57K, L63P, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15IV+p.R41K+p.R57K+p.L63P+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15IV, R41K, R57K, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.E35D+p.L63P+p.A71AV+p.I72IT+p.V82L+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, L63P, A71AV, I72IT, V82L, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.E35D+p.M36T+p.N37E+p.R57G+p.I62V+p.L63P
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, M36T, N37E, R57G, I62V, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.E35D+p.N37S+p.R57G+p.L63P+p.I72V+p.V77I
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, N37S, R57G, L63P, I72V, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.E35D+p.P39PS+p.R57G
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, P39PS, R57G.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.E35D+p.R57G+p.L63LP
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, R57G, L63LP.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.E35D+p.R57G+p.L63P
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, R57G, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.E35D+p.R57G
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, R57G.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.E35ED+p.M36MI+p.N37X+p.R41RK+p.I62IL+p.L63LP+p.A71AV+p.V77I+p.N83ND+p.C95CR
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35ED, M36MI, N37X, R41RK, I62IL, L63LP, A71AV, V77I, N83ND, C95CR.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.E35ED+p.N37C+p.R41RK+p.L63LP+p.V77I
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35ED, N37C, R41RK, L63LP, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.I62V+p.L63P
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, I62V, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.K20X+p.M36I+p.R41RK+p.I62V+p.L63P+p.A71T+p.I72T+p.L90M
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, K20X, M36I, R41RK, I62V, L63P, A71T, I72T, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.L19IT+p.M36MIL+p.I62V
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, L19IT, M36MIL, I62V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.L19T+p.M36I+p.R41K+p.L63Q+p.H69K+p.I72IM+p.L89LM+p.L90LS+p.I93L
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, L19T, M36I, R41K, L63Q, H69K, I72IM, L89LM, L90LS, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.L63A+p.V77I+p.I93L
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, L63A, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.M36I+p.I72V
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36I, I72V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.M36I+p.L63C
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36I, L63C.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.M36I+p.N37S+p.R41K+p.L63P+p.H69K+p.L89M+p.I93L
Missense mutation 1.1 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36I, N37S, R41K, L63P, H69K, L89M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.M36I+p.R41K
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36I, R41K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.M36MI+p.N37D+p.L63X+p.H69Y
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36MI, N37D, L63X, H69Y.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.M36MI+p.N37D+p.R57G+p.L63X+p.H69Y
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36MI, N37D, R57G, L63X, H69Y.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.N37D+p.K70R+p.V77I+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, N37D, K70R, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.N37S+p.R41K+p.I54V+p.R57G+p.I62V+p.L63S+p.A71T+p.V82A
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, N37S, R41K, I54V, R57G, I62V, L63S, A71T, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.N37S+p.R41K+p.I64IV
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, N37S, R41K, I64IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.N37T+p.R41K+p.K43KR+p.L63Q
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, N37T, R41K, K43KR, L63Q.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.R57G+p.I62V+p.L63Q+p.V77VI+p.I93L
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, R57G, I62V, L63Q, V77VI, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I3IV+p.I13IV+p.I64V+p.C67CG+p.V77I
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I3IV, I13IV, I64V, C67CG, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I3IV+p.L10V+p.T12S+p.I13V+p.G17GE+p.L19IV+p.K20I+p.E35D+p.M36MI+p.N37S+p.M46I+p.I62V+p.L63P+p.I64V+p.A71AV+p.T74S+p.V77I+p.L90M+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I3IV, L10V, T12S, I13V, G17GE, L19IV, K20I, E35D, M36MI, N37S, M46I, I62V, L63P, I64V, A71AV, T74S, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I3L+p.L10I+p.R41K+p.R57K+p.L63Q+p.I64V+p.I72V+p.V77I
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I3L, L10I, R41K, R57K, L63Q, I64V, I72V, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I3M+p.K14R+p.R41K+p.R57G+p.L63P+p.V77I
Missense mutation 0.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I3M, K14R, R41K, R57G, L63P, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I62IV+p.L63P+p.V77I+p.I93L
Missense mutation 0.8 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I62IV, L63P, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I62V+p.L63S
Missense mutation 0.8 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I62V, L63S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I64V+p.V77I+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I64V, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I64V
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14E+p.L19I+p.L33V+p.N37C+p.R41K+p.K45KR+p.I62V+p.I64V+p.E65K+p.H69Y+p.A71AV+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14E, L19I, L33V, N37C, R41K, K45KR, I62V, I64V, E65K, H69Y, A71AV, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14KR+p.E35D+p.N37NS+p.R41K
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, E35D, N37NS, R41K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14KR+p.I15IV+p.L19T+p.R41K+p.I64IV
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, I15IV, L19T, R41K, I64IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14KR+p.L19I+p.D60DE+p.L63X+p.H69HY+p.V77I
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, L19I, D60DE, L63X, H69HY, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14KR+p.R57K+p.L63P+p.V77I+p.I84IV+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14KR, R57K, L63P, V77I, I84IV, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.E35D+p.M36I+p.N37E+p.R57G+p.L63P+p.A71V+p.V77I+p.L90M+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, E35D, M36I, N37E, R57G, L63P, A71V, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.I15V+p.R41K+p.R57G+p.L63Q+p.A71V+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, I15V, R41K, R57G, L63Q, A71V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.L19I+p.E35D+p.N37D+p.D60E+p.I62V+p.L63P+p.V77I+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, L19I, E35D, N37D, D60E, I62V, L63P, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.N37D+p.R41K+p.I62V+p.L63A+p.V77I+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, N37D, R41K, I62V, L63A, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.N37S+p.R41K+p.I64V+p.Q92K
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, N37S, R41K, I64V, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.R41K+p.L63P+p.A71T+p.I72E+p.V77I+p.I93L
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, R41K, L63P, A71T, I72E, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.R57G+p.L63P+p.I64L+p.I72V+p.V77I
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, R57G, L63P, I64L, I72V, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20I+p.M46I+p.L63P+p.I64V+p.H69HY+p.G73T+p.V77I+p.I85IV+p.L90M
Missense mutation 1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20I, M46I, L63P, I64V, H69HY, G73T, V77I, I85IV, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20KI+p.L63A+p.A71AV+p.V77I+p.L90LM+p.I93IL
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20KI, L63A, A71AV, V77I, L90LM, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20KR+p.E35ED+p.M36I+p.N37D+p.R41RK+p.L63P+p.I64L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20KR, E35ED, M36I, N37D, R41RK, L63P, I64L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20R+p.E35D+p.M36I+p.N37D+p.F53L+p.L63P+p.H69K+p.A71T+p.I72V+p.V77I+p.V82A
Missense mutation 0.3 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20R, E35D, M36I, N37D, F53L, L63P, H69K, A71T, I72V, V77I, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20V+p.F53L+p.L63P+p.A71V+p.G73S+p.V77I+p.I85IV+p.L90M
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20V, F53L, L63P, A71V, G73S, V77I, I85IV, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K43KT+p.I54V+p.L63P+p.A71V+p.I72V+p.V82A
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K43KT, I54V, L63P, A71V, I72V, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K45R+p.I50L+p.I62V+p.L63P+p.A71IT+p.I72V+p.G73GS+p.V77I+p.V82A+p.I93L
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K45R, I50L, I62V, L63P, A71IT, I72V, G73GS, V77I, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.E34ED+p.M36MI+p.M46MI+p.I54IL+p.K55R+p.R57K+p.Q58QE+p.I62V+p.L63LP+p.A71T+p.N83NS+p.I84V+p.L89X
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, E34ED, M36MI, M46MI, I54IL, K55R, R57K, Q58QE, I62V, L63LP, A71T, N83NS, I84V, L89X.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.D30N+p.L33F+p.K45R+p.I54L+p.L63P+p.I66IV+p.P79PS+p.I84V+p.N88D+p.L89LF+p.L90M+p.I93L+p.C95CF
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, D30N, L33F, K45R, I54L, L63P, I66IV, P79PS, I84V, N88D, L89LF, L90M, I93L, C95CF.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.G16GE+p.L24LI+p.D30N+p.L33I+p.E35D+p.M36I+p.N37S+p.K45Q+p.M46MI+p.I54V+p.R57G+p.D60E+p.I62V+p.L63S+p.I64V+p.I72IM+p.Q92QK
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, G16GE, L24LI, D30N, L33I, E35D, M36I, N37S, K45Q, M46MI, I54V, R57G, D60E, I62V, L63S, I64V, I72IM, Q92QK.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K14KR+p.I15IV+p.D30N+p.L33F+p.E34D+p.E35D+p.M36I+p.M46I+p.I50V+p.I54L+p.R57K+p.Q58E+p.L63P+p.A71T+p.N88D+p.I93L
Missense mutation 0.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K14KR, I15IV, D30N, L33F, E34D, E35D, M36I, M46I, I50V, I54L, R57K, Q58E, L63P, A71T, N88D, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K14R+p.I15V+p.K20T+p.D30N+p.L33F+p.E35D+p.M36I+p.R41I+p.K43RS+p.I54L+p.R57K+p.I62V+p.L63P+p.I66V+p.A71V+p.I72T+p.V77I+p.N88D+p.L90M+p.Q92K+p.I93L+p.C95F+p.T96S
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K14R, I15V, K20T, D30N, L33F, E35D, M36I, R41I, K43RS, I54L, R57K, I62V, L63P, I66V, A71V, I72T, V77I, N88D, L90M, Q92K, I93L, C95F, T96S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K20R+p.D30N+p.L33F+p.M36I+p.N37D+p.R41K+p.M46I+p.I54L+p.L63P+p.I64L+p.I66V+p.A71T+p.I72T+p.I84V+p.N88D+p.L90M+p.I93L+p.C95F
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20R, D30N, L33F, M36I, N37D, R41K, M46I, I54L, L63P, I64L, I66V, A71T, I72T, I84V, N88D, L90M, I93L, C95F.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K20R+p.D30N+p.L33I+p.E35D+p.M36I+p.M46L+p.I54V+p.R57K+p.L63P+p.A71V+p.V82A+p.N88D+p.L90M+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20R, D30N, L33I, E35D, M36I, M46L, I54V, R57K, L63P, A71V, V82A, N88D, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K20R+p.D30N+p.V32I+p.L33F+p.M36I+p.N37D+p.M46I+p.I54L+p.L63P+p.I64L+p.I66V+p.A71T+p.I72T+p.I84V+p.N88D+p.L89M+p.L90M+p.I93L+p.C95F
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20R, D30N, V32I, L33F, M36I, N37D, M46I, I54L, L63P, I64L, I66V, A71T, I72T, I84V, N88D, L89M, L90M, I93L, C95F.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K20R+p.V32I+p.L33F+p.M36I+p.L63P+p.A71V+p.V82A+p.L90M
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20R, V32I, L33F, M36I, L63P, A71V, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.L19I+p.K20T+p.V32I+p.E35N+p.M36I+p.M46I+p.G48Q+p.I54L+p.L63P+p.C67E+p.A71V+p.T74S+p.L76V+p.I84V+p.L89V+p.L90M+p.T91S+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L19I, K20T, V32I, E35N, M36I, M46I, G48Q, I54L, L63P, C67E, A71V, T74S, L76V, I84V, L89V, L90M, T91S, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.L19LQ+p.K20I+p.E34Q+p.E35D+p.M36V+p.N37E+p.M46I+p.F53L+p.I54V+p.R57K+p.L63P+p.A71T+p.V77I+p.V82A+p.L90M+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L19LQ, K20I, E34Q, E35D, M36V, N37E, M46I, F53L, I54V, R57K, L63P, A71T, V77I, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.L33I+p.M36I+p.R41K+p.M46L+p.I54L+p.L63P+p.I64V+p.N88D
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L33I, M36I, R41K, M46L, I54L, L63P, I64V, N88D.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13X+p.K20I+p.E34K+p.M36I+p.N37ND+p.M46I+p.I54L+p.R57K+p.I62V+p.L63P+p.L76V+p.P79S+p.I84V
Missense mutation 0.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13X, K20I, E34K, M36I, N37ND, M46I, I54L, R57K, I62V, L63P, L76V, P79S, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I15V+p.K20I+p.M36I+p.K43T+p.M46I+p.I50V+p.F53L+p.I54IL+p.D60E+p.I62V+p.L63P+p.A71V+p.T74P+p.L90M
Missense mutation 0.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I15V, K20I, M36I, K43T, M46I, I50V, F53L, I54IL, D60E, I62V, L63P, A71V, T74P, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.L19I+p.K20R+p.L23I+p.E35D+p.M36I+p.R41K+p.M46I+p.I50V+p.F53L+p.I54V+p.L63P+p.I64V+p.I66V+p.A71I+p.G73T+p.L90M+p.I93L
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, L19I, K20R, L23I, E35D, M36I, R41K, M46I, I50V, F53L, I54V, L63P, I64V, I66V, A71I, G73T, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.M46I+p.R57K+p.I62V+p.L63P+p.A71T+p.I84V+p.L90M+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, M46I, R57K, I62V, L63P, A71T, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.N37A+p.R41K+p.R57G+p.L63T+p.E65D+p.I72T+p.V77I
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, N37A, R41K, R57G, L63T, E65D, I72T, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.R41K+p.M46L+p.L63P+p.L76V
Missense mutation 0.4 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, R41K, M46L, L63P, L76V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.T12I+p.R41K+p.M46I+p.G48V+p.F53Y+p.I54T+p.R57RK+p.L63P+p.A71V+p.I72V+p.V77I+p.V82A+p.I93L
Missense mutation 0.4 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, T12I, R41K, M46I, G48V, F53Y, I54T, R57RK, L63P, A71V, I72V, V77I, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.T12K+p.I13V+p.L19MT+p.K20I+p.M36I+p.R41K+p.M46I+p.I47IV+p.I54V+p.K55R+p.Q58E+p.I62V+p.L63S+p.I64V+p.E65D+p.V82VA
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, T12K, I13V, L19MT, K20I, M36I, R41K, M46I, I47IV, I54V, K55R, Q58E, I62V, L63S, I64V, E65D, V82VA.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.T12Q+p.I13M+p.K20I+p.M46I+p.I54V+p.Q58E+p.L63P+p.I64V+p.C67FL+p.H69R+p.G73T+p.V77I+p.V82A+p.L90M
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, T12Q, I13M, K20I, M46I, I54V, Q58E, L63P, I64V, C67FL, H69R, G73T, V77I, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.T12TK+p.K20I+p.M36I+p.N37D+p.R57K+p.I62V+p.L63P+p.G73C+p.I84V+p.I85V+p.L90M
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, T12TK, K20I, M36I, N37D, R57K, I62V, L63P, G73C, I84V, I85V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.T12TN+p.K14KR+p.L24I+p.L33F+p.M46I+p.I54V+p.I62V+p.L63P+p.H69Q+p.A71I+p.I72L+p.V77I+p.V82T+p.I93M
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, T12TN, K14KR, L24I, L33F, M46I, I54V, I62V, L63P, H69Q, A71I, I72L, V77I, V82T, I93M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.T12TP+p.I13V+p.K14KR+p.K20I+p.E35D+p.M36I+p.N37D+p.M46I+p.I54V+p.L63P+p.A71V+p.I72V+p.V82A+p.L90M+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, T12TP, I13V, K14KR, K20I, E35D, M36I, N37D, M46I, I54V, L63P, A71V, I72V, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11I+p.I15V+p.K20V+p.E34QR+p.E35D+p.M36I+p.N37S+p.R41K+p.G48I+p.I54L+p.K55R+p.Q58E+p.D60NS+p.I62V+p.L63P+p.A71I+p.I72IM+p.G73S+p.L76V+p.I84V+p.L90M+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I15V, K20V, E34QR, E35D, M36I, N37S, R41K, G48I, I54L, K55R, Q58E, D60NS, I62V, L63P, A71I, I72IM, G73S, L76V, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11VI+p.I13V+p.G16A+p.K20T+p.L33LEQ+p.E35EG+p.M46I+p.K55KR+p.R57K+p.Q61H+p.L63P+p.A71V+p.G73S+p.L76V+p.V77VI+p.I84V+p.L89V+p.L90M+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11VI, I13V, G16A, K20T, L33LEQ, E35EG, M46I, K55KR, R57K, Q61H, L63P, A71V, G73S, L76V, V77VI, I84V, L89V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11VI+p.I13V+p.K20I+p.E35D+p.M36I+p.N37ND+p.R41K+p.G48GA+p.I54V+p.I62V+p.L63P+p.A71V+p.I72IL+p.G73GS+p.V82A+p.L90M
Missense mutation 1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11VI, I13V, K20I, E35D, M36I, N37ND, R41K, G48GA, I54V, I62V, L63P, A71V, I72IL, G73GS, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V32I+p.L33F+p.M46I+p.L63P+p.A71V+p.I72IV+p.V82A+p.L90M
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V32I, L33F, M46I, L63P, A71V, I72IV, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10FI+p.L24I+p.L33LF+p.M36ML+p.N37S+p.L38LW+p.R41RK+p.M46L+p.I54V+p.K55R+p.R57K+p.I62IV+p.L63P+p.A71V+p.V82A
Missense mutation 0.7 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10FI, L24I, L33LF, M36ML, N37S, L38LW, R41RK, M46L, I54V, K55R, R57K, I62IV, L63P, A71V, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10FI+p.L33F+p.E34Q+p.M46I+p.I54V+p.I62V+p.L63P+p.I66L+p.C67CW+p.H69HR+p.A71AV+p.I72M+p.G73AT+p.V77I+p.V82A+p.L90M+p.I93L
Missense mutation 0.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10FI, L33F, E34Q, M46I, I54V, I62V, L63P, I66L, C67CW, H69HR, A71AV, I72M, G73AT, V77I, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10H+p.I13IV+p.Q18H+p.L19IM+p.K20T+p.R41K+p.M46I+p.D60E+p.L63P+p.A71I+p.V77I+p.I93L+p.C95CY
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10H, I13IV, Q18H, L19IM, K20T, R41K, M46I, D60E, L63P, A71I, V77I, I93L, C95CY.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.D30N+p.L33F+p.M46L+p.F53L+p.I54L+p.Q58E+p.L63P+p.A71T+p.G73S+p.V77I+p.N88D
Missense mutation 0.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, D30N, L33F, M46L, F53L, I54L, Q58E, L63P, A71T, G73S, V77I, N88D.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.E35D+p.M36I+p.G48V+p.I50V+p.I54V+p.I62V+p.L63A+p.A71V+p.V82T
Missense mutation 0.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E35D, M36I, G48V, I50V, I54V, I62V, L63A, A71V, V82T.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.E35D+p.P39PQS+p.L63P+p.A71AT+p.I93L
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E35D, P39PQS, L63P, A71AT, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.G16A+p.L33F+p.K45R+p.I54L+p.K55R+p.I62V+p.L63P+p.C67CY+p.I72L+p.G73C+p.V77I+p.I84V+p.L90M+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16A, L33F, K45R, I54L, K55R, I62V, L63P, C67CY, I72L, G73C, V77I, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.G16GR+p.D29DN+p.L33LF+p.G48V+p.I54V+p.I62V+p.L63P+p.A71V+p.I72V+p.V77I+p.V82A+p.L90M+p.I93L
Missense mutation 0.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16GR, D29DN, L33LF, G48V, I54V, I62V, L63P, A71V, I72V, V77I, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.G16GR+p.K20R+p.E35D+p.M36I+p.N37D+p.R41K+p.M46L+p.I54V+p.K55KR+p.I62V+p.L63P+p.A71V+p.V82A+p.L89M+p.L90M+p.I93L
Missense mutation 0.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16GR, K20R, E35D, M36I, N37D, R41K, M46L, I54V, K55KR, I62V, L63P, A71V, V82A, L89M, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.D30N+p.R41K+p.L63P+p.I64V+p.V75I+p.V77I+p.N88D+p.L90M+p.I93L
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, D30N, R41K, L63P, I64V, V75I, V77I, N88D, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.G16A+p.Q18H+p.L33F+p.N37D+p.M46I+p.I54V+p.Q61H+p.I62IV+p.L63P+p.A71L+p.I72T+p.L76V+p.V77I+p.V82VA+p.N88G+p.L90M+p.I93L
Missense mutation 1.1 Susceptible [7]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, G16A, Q18H, L33F, N37D, M46I, I54V, Q61H, I62IV, L63P, A71L, I72T, L76V, V77I, V82VA, N88G, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.I15IK+p.D25DN+p.L33F+p.E34KQ+p.R41RK+p.K43T+p.G48V+p.I50V+p.I54S+p.I62V+p.L63T+p.I64V+p.T74S+p.V77I+p.V82A+p.R87RT+p.L89M
Missense mutation 0.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15IK, D25DN, L33F, E34KQ, R41RK, K43T, G48V, I50V, I54S, I62V, L63T, I64V, T74S, V77I, V82A, R87RT, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K14N+p.V32VI+p.L33LF+p.I47IV+p.I50IV+p.I54IV+p.L63P+p.A71AV+p.V82VA+p.L90LM+p.I93L
Missense mutation 1.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K14N, V32VI, L33LF, I47IV, I50IV, I54IV, L63P, A71AV, V82VA, L90LM, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K14R+p.G16E+p.K20I+p.E35D+p.M36I+p.N37D+p.R41N+p.I54V+p.L63H+p.H69K+p.K70R+p.T74S+p.L76V+p.V82A+p.L89I+p.T91S
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K14R, G16E, K20I, E35D, M36I, N37D, R41N, I54V, L63H, H69K, K70R, T74S, L76V, V82A, L89I, T91S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K14R+p.K20I+p.M36I+p.N37S+p.R41K+p.I64L+p.H69K+p.K70R+p.L89M
Missense mutation 0.6 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K14R, K20I, M36I, N37S, R41K, I64L, H69K, K70R, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20I+p.E35Q+p.M36I+p.N37D+p.R41K+p.K43R+p.R57K+p.C67E+p.H69K+p.V82I+p.L89M
Missense mutation 0.8 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20I, E35Q, M36I, N37D, R41K, K43R, R57K, C67E, H69K, V82I, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20I+p.L33V+p.M46L+p.L63P+p.A71T+p.I72V+p.T74K+p.I85V+p.N88D+p.L90M+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20I, L33V, M46L, L63P, A71T, I72V, T74K, I85V, N88D, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20KR+p.M46MIL+p.I50V+p.K55R+p.L63P+p.A71V+p.V82A
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20KR, M46MIL, I50V, K55R, L63P, A71V, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20L+p.M46I+p.Q58E+p.I62V+p.L63P+p.A71T+p.T74S+p.V77I+p.N88S+p.L90M+p.Q92K
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20L, M46I, Q58E, I62V, L63P, A71T, T74S, V77I, N88S, L90M, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20R+p.E35D+p.M36I+p.I62V+p.L63P+p.I64L+p.T74S+p.L90M
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20R, E35D, M36I, I62V, L63P, I64L, T74S, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20R+p.L33F+p.E35D+p.M36I+p.N37DE+p.K45KR+p.M46MI+p.I50IV+p.F53L+p.I54V+p.K55R+p.I62V+p.L63P+p.I66IT+p.A71V+p.V82A+p.N88ND+p.L90M+p.I93L+p.C95F
Missense mutation 1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20R, L33F, E35D, M36I, N37DE, K45KR, M46MI, I50IV, F53L, I54V, K55R, I62V, L63P, I66IT, A71V, V82A, N88ND, L90M, I93L, C95F.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20T+p.D60E+p.L63P+p.C67D+p.A71V+p.V77I+p.L90M+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20T, D60E, L63P, C67D, A71V, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L19LIV+p.L63V+p.I64V+p.C67CS
Missense mutation 1.1 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L19LIV, L63V, I64V, C67CS.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L24L*+p.D25DN+p.R41RK+p.K45R+p.I54M+p.L63P+p.C67CF+p.G73T+p.I84V+p.I93L
Missense mutation 0.7 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L24L*, D25DN, R41RK, K45R, I54M, L63P, C67CF, G73T, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L33F+p.N37D+p.G48I+p.I50V+p.F53L+p.I54V+p.L63T+p.I64V+p.I72V+p.G73S+p.T74A+p.V77I+p.V82A+p.L89V
Missense mutation 0.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L33F, N37D, G48I, I50V, F53L, I54V, L63T, I64V, I72V, G73S, T74A, V77I, V82A, L89V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.R57G+p.I64V+p.V77VI
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, R57G, I64V, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.R57G+p.I64V
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, R57G, I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15IL+p.G16GR+p.N37ND+p.G48V+p.I54V+p.L63C+p.A71I+p.V77I+p.V82A+p.L90M+p.I93L
Missense mutation 0.7 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15IL, G16GR, N37ND, G48V, I54V, L63C, A71I, V77I, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15IL+p.K43KR+p.L63P+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15IL, K43KR, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15IV+p.L23LI+p.D29DG+p.I50IL+p.K55KR+p.L63P+p.I72E+p.G73GS+p.I84IV+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15IV, L23LI, D29DG, I50IL, K55KR, L63P, I72E, G73GS, I84IV, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.G16GE+p.K20R+p.E35D+p.M36I+p.N37NS+p.R41K+p.M46IV+p.G48V+p.I54T+p.L63PT+p.A71V+p.V82A+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, G16GE, K20R, E35D, M36I, N37NS, R41K, M46IV, G48V, I54T, L63PT, A71V, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.K20R+p.E35D+p.M36I+p.R41K+p.M46V+p.G48V+p.I54T+p.L63P+p.A71V+p.G73GS+p.V82A+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, K20R, E35D, M36I, R41K, M46V, G48V, I54T, L63P, A71V, G73GS, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.L19I+p.K20M+p.L24I+p.E35D+p.M36I+p.G48Q+p.F53L+p.I54V+p.L63P+p.K70E+p.A71V+p.I72M+p.G73S+p.V75VI+p.V82A+p.I93IM
Missense mutation 0.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L19I, K20M, L24I, E35D, M36I, G48Q, F53L, I54V, L63P, K70E, A71V, I72M, G73S, V75VI, V82A, I93IM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.L19I+p.K20R+p.M36I+p.R41K+p.M46L+p.I54V+p.L63P+p.A71V+p.L76V+p.V82A+p.L90M+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L19I, K20R, M36I, R41K, M46L, I54V, L63P, A71V, L76V, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.L23I+p.M46L+p.F53L+p.I54V+p.I62V+p.L63V+p.H69R+p.A71V+p.I72K+p.L76V+p.V82A+p.L89M+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L23I, M46L, F53L, I54V, I62V, L63V, H69R, A71V, I72K, L76V, V82A, L89M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.L63A+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L63A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.M36I+p.N37D+p.R57G+p.L63T+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, M36I, N37D, R57G, L63T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.N37D+p.G48GV+p.I54IT+p.R57G+p.L63LP+p.H69HR+p.A71X+p.V77VI+p.V82VA+p.I93IL
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, N37D, G48GV, I54IT, R57G, L63LP, H69HR, A71X, V77VI, V82VA, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I54M+p.L63P+p.H69HY+p.A71V+p.G73GS+p.V82A+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I54M, L63P, H69HY, A71V, G73GS, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K14KR+p.E35D+p.R57K+p.L63P+p.I64V+p.I93L
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14KR, E35D, R57K, L63P, I64V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20I+p.E35D+p.M36I+p.M46I+p.I62V+p.L63P+p.I64V+p.A71V+p.I72V+p.L76V+p.L90M+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20I, E35D, M36I, M46I, I62V, L63P, I64V, A71V, I72V, L76V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.E35D+p.M36I+p.N37E+p.G48V+p.I50V+p.I54A+p.R57RK+p.I62V+p.L63P+p.A71V+p.I72V+p.V82A+p.L90M+p.I93L
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36I, N37E, G48V, I50V, I54A, R57RK, I62V, L63P, A71V, I72V, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L19I+p.K20R+p.L24I+p.E35D+p.M36I+p.M46I+p.I54IV+p.L63P+p.A71V+p.I72V+p.G73S+p.V77I+p.P79A+p.V82T+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19I, K20R, L24I, E35D, M36I, M46I, I54IV, L63P, A71V, I72V, G73S, V77I, P79A, V82T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L19IT+p.G48V+p.I54V+p.I64V+p.V82A+p.L90M
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19IT, G48V, I54V, I64V, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L23I+p.L33LI+p.M36I+p.M46I+p.I54V+p.R57G+p.I62IV+p.L63A+p.A71V+p.T74S+p.V77VI+p.I84IV+p.I85IV+p.L90M+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L23I, L33LI, M36I, M46I, I54V, R57G, I62IV, L63A, A71V, T74S, V77VI, I84IV, I85IV, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L24F+p.M46I+p.D60E+p.I62V+p.L63P+p.A71V+p.I72V+p.G73S+p.V77I+p.L90M+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24F, M46I, D60E, I62V, L63P, A71V, I72V, G73S, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L24I+p.E35D+p.M36MI+p.N37C+p.I54V+p.I62V+p.L63P+p.A71V+p.V77I+p.V82S
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24I, E35D, M36MI, N37C, I54V, I62V, L63P, A71V, V77I, V82S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L24I+p.L33F+p.E35D+p.M36I+p.R41P+p.K45R+p.M46I+p.I50L+p.L63P+p.I64V+p.H69Y+p.A71V+p.V82S+p.I93L
Missense mutation 0.6 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24I, L33F, E35D, M36I, R41P, K45R, M46I, I50L, L63P, I64V, H69Y, A71V, V82S, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L24I+p.L33F+p.N37S+p.M46L+p.I54V+p.K55KR+p.I62IV+p.L63P+p.A71V+p.I72IM+p.G73GCS+p.V82A
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24I, L33F, N37S, M46L, I54V, K55KR, I62IV, L63P, A71V, I72IM, G73GCS, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L24I+p.L63P+p.I64V+p.I72L+p.V77I+p.V82A
Missense mutation 0.4 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24I, L63P, I64V, I72L, V77I, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L24I+p.M46L+p.G48V+p.I54V+p.L63P+p.A71V+p.V77I+p.V82A
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24I, M46L, G48V, I54V, L63P, A71V, V77I, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L24I+p.R41K+p.M46I+p.I54V+p.I64V+p.V77I+p.V82A
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24I, R41K, M46I, I54V, I64V, V77I, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L33F+p.E35D+p.N37D+p.R41K+p.M46L+p.I54L+p.I62V+p.L63P+p.A71IT+p.V75VI+p.V82A+p.L90M+p.I93L
Missense mutation 0.7 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L33F, E35D, N37D, R41K, M46L, I54L, I62V, L63P, A71IT, V75VI, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L33F+p.M36L+p.N37S+p.R41RK+p.K43KT+p.M46MI+p.G48V+p.I54T+p.I62IV+p.L63P+p.I64V+p.A71V+p.V82A+p.T91A
Missense mutation 1.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L33F, M36L, N37S, R41RK, K43KT, M46MI, G48V, I54T, I62IV, L63P, I64V, A71V, V82A, T91A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L63P+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.M36I+p.G48V+p.I54V+p.I62V+p.L63P+p.T74S+p.V82A+p.C95G
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, M36I, G48V, I54V, I62V, L63P, T74S, V82A, C95G.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.M36I+p.N37D+p.R57K+p.I62IV+p.L63P+p.I93L
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, M36I, N37D, R57K, I62IV, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.M36MI+p.L63A+p.I93L
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, M36MI, L63A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.M46I+p.G48V+p.I54T+p.D60E+p.I62V+p.L63P+p.A71L+p.V77I+p.V82A+p.L90M+p.I93L
Missense mutation 1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, M46I, G48V, I54T, D60E, I62V, L63P, A71L, V77I, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.M46L+p.I62V+p.L63P+p.I85V+p.L90M+p.I93L
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, M46L, I62V, L63P, I85V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.N37D+p.G48V+p.F53L+p.I54V+p.L63P+p.A71T+p.V77I+p.V82A+p.L90M+p.I93L
Missense mutation 0.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, N37D, G48V, F53L, I54V, L63P, A71T, V77I, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.N37D+p.R57K+p.I62V+p.L63P+p.A71T+p.I72IMT+p.G73S+p.V77I+p.I85V+p.I93L
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, N37D, R57K, I62V, L63P, A71T, I72IMT, G73S, V77I, I85V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.N37X+p.M46I+p.I54ILM+p.I62V+p.L63P+p.I64V+p.A71V+p.I72IT+p.L76V+p.V77I+p.I84V+p.I85V+p.G86GR+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, N37X, M46I, I54ILM, I62V, L63P, I64V, A71V, I72IT, L76V, V77I, I84V, I85V, G86GR, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.R41RK+p.M46I+p.D60E+p.I62V+p.L63P+p.I64V+p.K70R+p.I72E+p.G73C+p.V77I+p.L90M+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, R41RK, M46I, D60E, I62V, L63P, I64V, K70R, I72E, G73C, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.R41RK+p.M46I+p.R57G+p.D60E+p.I62V+p.L63P+p.I64V+p.K70R+p.I72E+p.G73C+p.V77I+p.L90M+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, R41RK, M46I, R57G, D60E, I62V, L63P, I64V, K70R, I72E, G73C, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12E+p.K20I+p.E35D+p.I62V+p.L63P+p.A71V+p.G73S+p.V77I+p.L90M
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12E, K20I, E35D, I62V, L63P, A71V, G73S, V77I, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12I+p.N37D+p.M46L+p.G48V+p.R57K+p.L63Q+p.I64V+p.A71V+p.I72T+p.V82A+p.I84V
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12I, N37D, M46L, G48V, R57K, L63Q, I64V, A71V, I72T, V82A, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12K+p.I15V+p.G16A+p.K20KT+p.L24I+p.M46I+p.F53FL+p.I54V+p.L63P+p.A71V+p.G73GS+p.V82S
Missense mutation 0.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12K, I15V, G16A, K20KT, L24I, M46I, F53FL, I54V, L63P, A71V, G73GS, V82S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12K+p.L33F+p.R41K+p.K43T+p.M46I+p.I50L+p.I54V+p.K55R+p.I62V+p.L63P+p.A71V+p.I72L+p.G73T+p.V77I+p.V82A+p.L90M+p.I93L+p.C95F
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12K, L33F, R41K, K43T, M46I, I50L, I54V, K55R, I62V, L63P, A71V, I72L, G73T, V77I, V82A, L90M, I93L, C95F.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12P+p.K14R+p.I15IV+p.N37D+p.I62V+p.L63PT+p.C67H+p.A71T+p.V77I+p.Q92QH+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12P, K14R, I15IV, N37D, I62V, L63PT, C67H, A71T, V77I, Q92QH, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12P+p.K14R+p.N37D+p.I62V+p.L63PT+p.C67H+p.A71T+p.V77I+p.Q92QH+p.I93L
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12P, K14R, N37D, I62V, L63PT, C67H, A71T, V77I, Q92QH, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12S+p.I13V+p.L19V+p.K20I+p.L23LI+p.E35EG+p.M36I+p.M46I+p.F53L+p.L63P+p.A71V+p.G73S+p.N88NS+p.L90M
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12S, I13V, L19V, K20I, L23LI, E35EG, M36I, M46I, F53L, L63P, A71V, G73S, N88NS, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12S+p.I15V+p.L19I+p.K20V+p.V32I+p.M46L+p.I54L+p.D60E+p.L63P+p.I66F+p.A71V+p.L90M
Missense mutation 0.2 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12S, I15V, L19I, K20V, V32I, M46L, I54L, D60E, L63P, I66F, A71V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12TK+p.K14R+p.L23I+p.L33LV+p.E35D+p.M36V+p.N37H+p.R41K+p.M46I+p.I50L+p.R57K+p.L63P+p.I64V+p.K70R+p.V82A+p.I85V
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12TK, K14R, L23I, L33LV, E35D, M36V, N37H, R41K, M46I, I50L, R57K, L63P, I64V, K70R, V82A, I85V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12TK+p.L33F+p.K43T+p.M46I+p.I50L+p.I54V+p.K55R+p.I62V+p.L63P+p.A71V+p.I72L+p.G73T+p.V77I+p.V82A+p.L90M+p.I93L+p.C95F
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12TK, L33F, K43T, M46I, I50L, I54V, K55R, I62V, L63P, A71V, I72L, G73T, V77I, V82A, L90M, I93L, C95F.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12TP+p.I13V+p.I15IV+p.L19Q+p.K20I+p.E35D+p.M36I+p.M46I+p.I54V+p.R57RK+p.I62V+p.L63P+p.I64V+p.A71V+p.I72V+p.L76V+p.V82F+p.L90M
Missense mutation 0.8 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12TP, I13V, I15IV, L19Q, K20I, E35D, M36I, M46I, I54V, R57RK, I62V, L63P, I64V, A71V, I72V, L76V, V82F, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12V+p.G17D+p.K20M+p.E35G+p.M36I+p.G48V+p.F53L+p.I54V+p.R57K+p.I62V+p.L63P+p.A71V+p.V82A+p.L90M+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12V, G17D, K20M, E35G, M36I, G48V, F53L, I54V, R57K, I62V, L63P, A71V, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11VG+p.G16GW+p.N37S+p.L63P+p.H69Q+p.A71V+p.G73S+p.V77I+p.L90M+p.I93L
Missense mutation 0.7 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11VG, G16GW, N37S, L63P, H69Q, A71V, G73S, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IM+p.I13V+p.Q18H+p.N37D+p.M46I+p.K55KR+p.Q61QH+p.L63P+p.A71T+p.I72T+p.V77I+p.N88S+p.L90M+p.I93L
Missense mutation 1 Susceptible [8]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IM, I13V, Q18H, N37D, M46I, K55KR, Q61QH, L63P, A71T, I72T, V77I, N88S, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.I13V+p.K14KR+p.I15V+p.L24I+p.M36MI+p.N37E+p.M46I+p.I54V+p.L63P+p.A71VI+p.V82AT+p.I93IL
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13V, K14KR, I15V, L24I, M36MI, N37E, M46I, I54V, L63P, A71VI, V82AT, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.K20I+p.N37D+p.M46I+p.K55R+p.D60E+p.I62IV+p.L63P+p.I64V+p.T74S+p.V77I+p.L90M+p.I93L
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, K20I, N37D, M46I, K55R, D60E, I62IV, L63P, I64V, T74S, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.L19I+p.M36I+p.N37T+p.R41K+p.K45KR+p.R57G+p.I62M+p.L63P+p.I64M+p.A71V+p.I93L
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, L19I, M36I, N37T, R41K, K45KR, R57G, I62M, L63P, I64M, A71V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LF+p.A22AV+p.E35D+p.M36MI+p.R41K+p.D60DE+p.I62IV+p.L63P+p.C67CY+p.H69HR+p.K70KT+p.A71V+p.I72T+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LF, A22AV, E35D, M36MI, R41K, D60DE, I62IV, L63P, C67CY, H69HR, K70KT, A71V, I72T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LF+p.I13V+p.I15V+p.G16GA+p.K20X+p.M36MI+p.N37T+p.I54IV+p.R57K+p.L63LP+p.I64V+p.K70R+p.V82VA+p.L90LM
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LF, I13V, I15V, G16GA, K20X, M36MI, N37T, I54IV, R57K, L63LP, I64V, K70R, V82VA, L90LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LF+p.K14KE+p.E35D+p.N37ND+p.R57RK+p.L63P
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LF, K14KE, E35D, N37ND, R57RK, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LF+p.T12E+p.I13V+p.K20KT+p.E35EK+p.M36I+p.N37DE+p.M46MI+p.I62IV+p.I64V+p.L90LM+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LF, T12E, I13V, K20KT, E35EK, M36I, N37DE, M46MI, I62IV, I64V, L90LM, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LF+p.T12TI+p.I13IV+p.K14K*+p.I15IV+p.G16X+p.D30DN+p.E35D+p.M36MI+p.N37ND+p.M46MI+p.R57K+p.I62V+p.L63P+p.A71T+p.V82VA+p.N88D
Missense mutation 0.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LF, T12TI, I13IV, K14K*, I15IV, G16X, D30DN, E35D, M36MI, N37ND, M46MI, R57K, I62V, L63P, A71T, V82VA, N88D.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LFI+p.L19Q+p.K20KR+p.L23LI+p.E35ED+p.M36MI+p.I54IM+p.R57G+p.I62IV+p.L63LP+p.I64V+p.G73GC+p.T74TS+p.V77VI+p.I84IV+p.L90LM+p.I93IL
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LFI, L19Q, K20KR, L23LI, E35ED, M36MI, I54IM, R57G, I62IV, L63LP, I64V, G73GC, T74TS, V77VI, I84IV, L90LM, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.E35D+p.M36I+p.I62V+p.L63A+p.V77I
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, E35D, M36I, I62V, L63A, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.I13IV+p.I15V+p.E35ED+p.N37C+p.R41RK+p.I62IL+p.L63LP+p.A71AV+p.V77I
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I13IV, I15V, E35ED, N37C, R41RK, I62IL, L63LP, A71AV, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.I13IV+p.K14KR+p.R57G+p.L63P+p.H69Q+p.I72IM+p.V77VI+p.I93IM
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I13IV, K14KR, R57G, L63P, H69Q, I72IM, V77VI, I93IM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.I13V+p.D30N+p.L63P+p.K70R+p.A71T+p.V77I+p.N88D
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I13V, D30N, L63P, K70R, A71T, V77I, N88D.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.I13V+p.K14KR+p.K20KT+p.E35D+p.M36I+p.R41KN+p.H69K+p.V77VI+p.L89M
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I13V, K14KR, K20KT, E35D, M36I, R41KN, H69K, V77VI, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.I13V+p.L33LF+p.M36MI+p.N37NS+p.R41K+p.Q58QE+p.Q61N+p.L63LP+p.V82VA+p.N88NS
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I13V, L33LF, M36MI, N37NS, R41K, Q58QE, Q61N, L63LP, V82VA, N88NS.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.T12PS+p.I15IV+p.K20KM+p.M36MI+p.N37ND+p.K45KR+p.I54IV+p.R57G+p.I62IV+p.L63P+p.A71AT+p.G73X+p.V82X+p.I85IV+p.L90LM
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, T12PS, I15IV, K20KM, M36MI, N37ND, K45KR, I54IV, R57G, I62IV, L63P, A71AT, G73X, V82X, I85IV, L90LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.T12TA+p.R57G+p.I62IV+p.L63AST+p.V77VI+p.I93L
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, T12TA, R57G, I62IV, L63AST, V77VI, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.T12TP+p.K14KR+p.N37X+p.R41RK+p.R57G+p.I62V+p.L63T+p.I64L+p.C67S+p.V77I+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, T12TP, K14KR, N37X, R41RK, R57G, I62V, L63T, I64L, C67S, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.V32VI+p.L33M+p.R41K+p.K43KR+p.M46I+p.I62V+p.L63P+p.C67CF+p.A71IT+p.I72V+p.G73GC+p.T74P+p.V77I+p.L90M+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, V32VI, L33M, R41K, K43KR, M46I, I62V, L63P, C67CF, A71IT, I72V, G73GC, T74P, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LR+p.Q18H+p.L19LI+p.L33LF+p.M46ML+p.I54IL+p.I62V+p.L63P+p.A71AV+p.I72ILM+p.G73X+p.V77I+p.I84IV+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LR, Q18H, L19LI, L33LF, M46ML, I54IL, I62V, L63P, A71AV, I72ILM, G73X, V77I, I84IV, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LV+p.I13V+p.K20R+p.M36I+p.N37K+p.R41A+p.H69K+p.L89M
Missense mutation 0.7 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, I13V, K20R, M36I, N37K, R41A, H69K, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LV+p.K14KR+p.I64IV
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, K14KR, I64IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LV+p.T12P+p.I13V+p.K14KR+p.N37D+p.R57G+p.L63Q+p.I64V+p.E65D
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, T12P, I13V, K14KR, N37D, R57G, L63Q, I64V, E65D.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LV+p.T12TKN+p.K14KR+p.I15V+p.L19I+p.R41K+p.R57G+p.L63CS+p.E65ED+p.V77I+p.I93IL
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, T12TKN, K14KR, I15V, L19I, R41K, R57G, L63CS, E65ED, V77I, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LV+p.T12TS+p.K14NS+p.I15IV+p.L19LI+p.N37ND+p.R41RK+p.K45KR+p.D60DE+p.L63LP+p.I64V
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, T12TS, K14NS, I15IV, L19LI, N37ND, R41RK, K45KR, D60DE, L63LP, I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.E35D+p.N37D+p.M46I+p.K55KR+p.L63P+p.A71V+p.G73S+p.V77I+p.L90M+p.I93L
Missense mutation 0.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, E35D, N37D, M46I, K55KR, L63P, A71V, G73S, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13A+p.K14R+p.K20I+p.L33IV+p.E35EG+p.M36I+p.R41K+p.M46I+p.F53L+p.K55R+p.L63P+p.H69K+p.L76V+p.V82I+p.L89I+p.L90M
Missense mutation 1.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13A, K14R, K20I, L33IV, E35EG, M36I, R41K, M46I, F53L, K55R, L63P, H69K, L76V, V82I, L89I, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13IV+p.L33V+p.E35D+p.L63P+p.R87RG
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13IV, L33V, E35D, L63P, R87RG.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.K14R+p.L19P+p.K20I+p.M36I+p.R41K+p.L63P+p.H69K+p.K70R+p.I72M+p.L89M
Missense mutation 1 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K14R, L19P, K20I, M36I, R41K, L63P, H69K, K70R, I72M, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.L33F+p.N37D+p.K43T+p.G48V+p.I50V+p.I54A+p.Q61HN+p.I62V+p.L63P+p.I64IL+p.H69Y+p.A71V+p.V77I+p.V82A+p.L90M+p.I93L
Missense mutation 1.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, L33F, N37D, K43T, G48V, I50V, I54A, Q61HN, I62V, L63P, I64IL, H69Y, A71V, V77I, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I15V+p.G16GR+p.K20T+p.D25DN+p.R41RK+p.M46I+p.F53L+p.D60E+p.L63P+p.A71V+p.G73S+p.V77I+p.L90M
Missense mutation 1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I15V, G16GR, K20T, D25DN, R41RK, M46I, F53L, D60E, L63P, A71V, G73S, V77I, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I15V+p.L19I+p.E35D+p.N37D+p.R57G+p.L63P+p.I64L+p.H69Y
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I15V, L19I, E35D, N37D, R57G, L63P, I64L, H69Y.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I15V+p.M36I+p.N37D+p.R41K+p.L63S+p.I72T
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I15V, M36I, N37D, R41K, L63S, I72T.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.M36I+p.K43T+p.G48V+p.I54V+p.I62V+p.I64V+p.T74S+p.V82A
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, M36I, K43T, G48V, I54V, I62V, I64V, T74S, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.M46I+p.I62V+p.I64V+p.K70R+p.T74A+p.V77I+p.L90M+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, M46I, I62V, I64V, K70R, T74A, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.T12S+p.I13V+p.K14KR+p.K20I+p.M36I+p.R41K+p.M46I+p.I62V+p.L63P+p.A71T+p.I72IT+p.T74S+p.L90M+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, T12S, I13V, K14KR, K20I, M36I, R41K, M46I, I62V, L63P, A71T, I72IT, T74S, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.T12S+p.L19Q+p.L23I+p.M46I+p.I54L+p.K55R+p.L63P+p.A71IV+p.G73S+p.V77I+p.V82T+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, T12S, L19Q, L23I, M46I, I54L, K55R, L63P, A71IV, G73S, V77I, V82T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.T12TP+p.K14R+p.I15V+p.K20KT+p.L24I+p.L33F+p.M46L+p.G52GA+p.I54V+p.K55KQ+p.Q58E+p.I62IV+p.L63P+p.A71V+p.I72L+p.V82A
Missense mutation 1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, T12TP, K14R, I15V, K20KT, L24I, L33F, M46L, G52GA, I54V, K55KQ, Q58E, I62IV, L63P, A71V, I72L, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.V11VI+p.T12TA+p.I13V+p.K20R+p.L33I+p.E35D+p.M36I+p.N37D+p.K43I+p.M46MI+p.I50V+p.I54V+p.D60N+p.I62V+p.L63P+p.A71V+p.V82M+p.L90M
Missense mutation 1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, V11VI, T12TA, I13V, K20R, L33I, E35D, M36I, N37D, K43I, M46MI, I50V, I54V, D60N, I62V, L63P, A71V, V82M, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19I+p.E35D+p.R57G+p.L63A
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, E35D, R57G, L63A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19I+p.L63S+p.E65D+p.I72V+p.V77I
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, L63S, E65D, I72V, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19I+p.M36I+p.N37D+p.R41K+p.R57G+p.Q61E+p.I64V+p.E65ED+p.C67CW
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, M36I, N37D, R41K, R57G, Q61E, I64V, E65ED, C67CW.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19I+p.M36I+p.N37D+p.R41K+p.R57G+p.Y59H+p.Q61E+p.I62V+p.L63T+p.I64V+p.A71V+p.I93L
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, M36I, N37D, R41K, R57G, Y59H, Q61E, I62V, L63T, I64V, A71V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19I+p.M36MT+p.I62IV+p.L63LP+p.I72M+p.V77VI
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, M36MT, I62IV, L63LP, I72M, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19I+p.R57K+p.L63S+p.I64V+p.E65D
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, R57K, L63S, I64V, E65D.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19LI+p.N37S
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19LI, N37S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19LP+p.R41K+p.L63P+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19LP, R41K, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19LV+p.Q61E+p.L63LP+p.I64IV
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19LV, Q61E, L63LP, I64IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19Q+p.E35D+p.M36MI+p.N37NS+p.R41K+p.K55R+p.R57RK+p.L63P+p.V75VI
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19Q, E35D, M36MI, N37NS, R41K, K55R, R57RK, L63P, V75VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19Q+p.K20T+p.D30N+p.L33V+p.R57G+p.A71V+p.N88D
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19Q, K20T, D30N, L33V, R57G, A71V, N88D.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19Q+p.R57G+p.D60DE+p.L63LP+p.I64V+p.K70KR
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19Q, R57G, D60DE, L63LP, I64V, K70KR.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L23I+p.R57K+p.L63P+p.H69Y+p.A71V+p.N88S+p.Q92R+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L23I, R57K, L63P, H69Y, A71V, N88S, Q92R, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L23LI+p.V32VI+p.I50IL+p.I62V+p.L63P+p.A71AV+p.G73CS+p.V77I+p.L90M+p.I93L
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L23LI, V32VI, I50IL, I62V, L63P, A71AV, G73CS, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L33I+p.I62V+p.L63T+p.I64L+p.A71V+p.I72T+p.I93L
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L33I, I62V, L63T, I64L, A71V, I72T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L33LV+p.N37C+p.P39PS+p.L63P+p.H69HY
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L33LV, N37C, P39PS, L63P, H69HY.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L38I+p.K43R+p.I62V+p.L63P+p.V77I+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L38I, K43R, I62V, L63P, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L5F+p.L10I+p.I13V+p.G16GA+p.K20KR+p.V32I+p.L33F+p.E35ED+p.M36I+p.N37D+p.K43T+p.M46I+p.I47V+p.F53L+p.I54L+p.D60E+p.L63P+p.A71M+p.G73S+p.V82I+p.L90M+p.I93L
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L5F, L10I, I13V, G16GA, K20KR, V32I, L33F, E35ED, M36I, N37D, K43T, M46I, I47V, F53L, I54L, D60E, L63P, A71M, G73S, V82I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L5LH+p.L10I+p.I13V+p.I15V+p.D30N+p.K45R+p.M46ML+p.I62V+p.L63P+p.I64M+p.V77I+p.N88D+p.I93L
Missense mutation 0.6 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L5LH, L10I, I13V, I15V, D30N, K45R, M46ML, I62V, L63P, I64M, V77I, N88D, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L63P+p.H69Q+p.K70R+p.V77I
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, H69Q, K70R, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L63P+p.I64L
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, I64L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L63P+p.I72T+p.V77I+p.I93L
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, I72T, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L63P+p.I72T
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, I72T.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L63P+p.K70R
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, K70R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L63P+p.K70T+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, K70T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L63P+p.V77I+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L63T+p.V77I
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63T, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M36I+p.I62V+p.L63A+p.I72IM
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, I62V, L63A, I72IM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M36I+p.I62V+p.L63P+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, I62V, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M36I+p.R41K+p.I93L
Missense mutation 0.6 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, R41K, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M36I+p.R41K+p.R57G+p.I64V
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, R41K, R57G, I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M36I+p.R57K+p.L63P+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, R57K, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M36MI+p.I62V+p.L63P+p.I64L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36MI, I62V, L63P, I64L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M36MI+p.K45R+p.R57G+p.I62M+p.L63P+p.A71T+p.I72E+p.I93IM
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36MI, K45R, R57G, I62M, L63P, A71T, I72E, I93IM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M36MI+p.N37S+p.R41K+p.L63LP+p.I64IV+p.I72IV+p.V77VI
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36MI, N37S, R41K, L63LP, I64IV, I72IV, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M36MI+p.Q58E+p.I62IV+p.L63X+p.I64IV+p.K70R+p.V77VI+p.L90LM
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36MI, Q58E, I62IV, L63X, I64IV, K70R, V77VI, L90LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M36MI+p.R41RK+p.I62IV+p.V77VI
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36MI, R41RK, I62IV, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M46L+p.K55R+p.L63P+p.H69Y+p.A71T+p.I84V+p.L90M
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M46L, K55R, L63P, H69Y, A71T, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N37D+p.D60E+p.I62V+p.L63P+p.G68E+p.V77I+p.I93L
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37D, D60E, I62V, L63P, G68E, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N37D+p.K43KR+p.L63C+p.T74TS+p.V77I+p.L90LM+p.I93L
Missense mutation 0.6 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37D, K43KR, L63C, T74TS, V77I, L90LM, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N37D+p.R57G+p.L63P+p.V77I+p.I93L
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37D, R57G, L63P, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N37E+p.L63P+p.K70T+p.I72R
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37E, L63P, K70T, I72R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N37NS+p.G48GE+p.Q61E+p.L63S+p.E65D+p.I72V+p.V77I
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37NS, G48GE, Q61E, L63S, E65D, I72V, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N37NS+p.R41RK
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37NS, R41RK.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N37S+p.L63T+p.V77I
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37S, L63T, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N37S+p.R41K+p.R57G+p.D60DE+p.L63P
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37S, R41K, R57G, D60DE, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N37S+p.R41K+p.R57G+p.L63A+p.Q92K
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37S, R41K, R57G, L63A, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N37S+p.R41RK+p.R57G+p.L63A+p.Q92QK
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37S, R41RK, R57G, L63A, Q92QK.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N37S+p.R57G+p.Q61E+p.L63P+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37S, R57G, Q61E, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N37T+p.R57G+p.L63P
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37T, R57G, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N37Y+p.R41K+p.R57K+p.V77I+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N37Y, R41K, R57K, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.NULL
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included NULL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q18E+p.R57G+p.I62IV+p.L63S+p.I72V+p.V77I
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q18E, R57G, I62IV, L63S, I72V, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q18QE+p.L19IV+p.N37HQ+p.R41RK+p.I62IV+p.L63LP+p.I64V+p.L90LM
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q18QE, L19IV, N37HQ, R41RK, I62IV, L63LP, I64V, L90LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q58E+p.L63P+p.K70R
Missense mutation 0.8 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q58E, L63P, K70R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q61E+p.I62V+p.L63T+p.E65D+p.V77I
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q61E, I62V, L63T, E65D, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q7K+p.E21EV+p.D30N+p.N37S+p.P39Q+p.M46I+p.L63P+p.I72IK+p.V77I+p.R87RI+p.N88D+p.I93L
Missense mutation 0.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q7K, E21EV, D30N, N37S, P39Q, M46I, L63P, I72IK, V77I, R87RI, N88D, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q7R+p.T12S+p.K14R+p.R41K+p.I62V+p.L63P+p.I64M
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q7R, T12S, K14R, R41K, I62V, L63P, I64M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R41K+p.D60E+p.I64V+p.V77I
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41K, D60E, I64V, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R41K+p.L63P+p.V77I
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41K, L63P, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R41K+p.R57G+p.I62V+p.L63P+p.V77I+p.I93L
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41K, R57G, I62V, L63P, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R41K+p.R57G+p.L63P+p.T74TA+p.V77I+p.L90LM+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41K, R57G, L63P, T74TA, V77I, L90LM, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R41RK+p.H69HY
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41RK, H69HY.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R41RK+p.I62IV+p.L63A+p.V77I
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41RK, I62IV, L63A, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57G+p.I62V+p.L63P+p.V77I+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, I62V, L63P, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57G+p.K70R
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, K70R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57G+p.L63H+p.V77I+p.L89I+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63H, V77I, L89I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57G+p.L63P+p.I64IL
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63P, I64IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57G+p.L63P+p.I64L+p.A71T+p.I72T+p.V77I
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63P, I64L, A71T, I72T, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57G+p.L63P
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57G+p.L63Q
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63Q.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57G+p.V77I
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57G
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57K+p.D60E+p.L63P+p.I64V+p.G73C+p.V77I+p.L90M
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, D60E, L63P, I64V, G73C, V77I, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57K+p.I62IV+p.L63AP+p.I64IM+p.H69HY+p.K70KR+p.A71AT
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, I62IV, L63AP, I64IM, H69HY, K70KR, A71AT.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57K+p.L63A+p.V77I
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, L63A, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57K+p.L63P+p.E65D
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, L63P, E65D.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57K+p.L63P+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57K+p.L63Q
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, L63Q.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57K+p.V77I
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57K+p.Y59YH+p.L63P+p.I72IL
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57K, Y59YH, L63P, I72IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R8RQ+p.L10F+p.T12S+p.I15V+p.L19V+p.L24I+p.L33F+p.M46I+p.F53FL+p.I54V+p.I62V+p.L63P+p.A71V+p.G73S+p.V82A
Missense mutation 0.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R8RQ, L10F, T12S, I15V, L19V, L24I, L33F, M46I, F53FL, I54V, I62V, L63P, A71V, G73S, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R8RQ+p.T12S+p.I15IV+p.L19I+p.N37S+p.I62IV+p.L63X+p.V77VI
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R8RQ, T12S, I15IV, L19I, N37S, I62IV, L63X, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12A+p.I13V+p.L63P+p.I64V+p.V77VI
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, I13V, L63P, I64V, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12A+p.I15V+p.G16E+p.P39S+p.R57G+p.L63P+p.A71T+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, I15V, G16E, P39S, R57G, L63P, A71T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12A+p.I15V+p.R41K+p.I62V+p.L63P+p.V77I+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, I15V, R41K, I62V, L63P, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12A+p.K14KR+p.M36I+p.R57K+p.I62V+p.L63P+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, K14KR, M36I, R57K, I62V, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12A+p.L19I+p.L63P+p.I64IV
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, L19I, L63P, I64IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12A+p.N37E+p.R57G+p.I62V+p.L63P+p.A71T+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, N37E, R57G, I62V, L63P, A71T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12E+p.I13V+p.D30N+p.N37NS+p.M46MI+p.L63P+p.V77I+p.N88D+p.I93IL
Missense mutation 0.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12E, I13V, D30N, N37NS, M46MI, L63P, V77I, N88D, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12E+p.K14KR+p.K43KR+p.R57K+p.L63P+p.A71T
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12E, K14KR, K43KR, R57K, L63P, A71T.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12I+p.G16E+p.P39S+p.L63T+p.V77I
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12I, G16E, P39S, L63T, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12I+p.I15V+p.E35D+p.N37D+p.R57RK+p.L63P
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12I, I15V, E35D, N37D, R57RK, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12I+p.N37D+p.K45KR+p.R57G+p.L63Q+p.V77I+p.I93L
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12I, N37D, K45KR, R57G, L63Q, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12N+p.K14R+p.I15V+p.G16E+p.K20M+p.M36I+p.P39Q+p.L63S+p.I64V+p.K70R
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12N, K14R, I15V, G16E, K20M, M36I, P39Q, L63S, I64V, K70R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12N+p.L19I+p.L63P+p.C67D+p.I72MT+p.V77I
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12N, L19I, L63P, C67D, I72MT, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12N+p.L63P+p.H69Q+p.V77I+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12N, L63P, H69Q, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12P+p.I13IV+p.K14R+p.L19V+p.K20R+p.M36MI+p.R41K+p.M46I+p.R57G+p.L63HQ+p.I64V+p.V82L+p.I84V+p.I93L
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, I13IV, K14R, L19V, K20R, M36MI, R41K, M46I, R57G, L63HQ, I64V, V82L, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12P+p.I13V+p.K14R+p.E35D+p.N37S+p.Q61E+p.L63P+p.I64IV+p.A71AT+p.I72IV+p.I93IL
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, I13V, K14R, E35D, N37S, Q61E, L63P, I64IV, A71AT, I72IV, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12P+p.K14KR+p.N37S+p.R41K+p.R57G+p.L63P+p.I64IV+p.H69HQ+p.A71AT+p.I72L+p.V77I+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, K14KR, N37S, R41K, R57G, L63P, I64IV, H69HQ, A71AT, I72L, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12P+p.K14R+p.E35D+p.N37DE+p.R57G+p.L63P+p.A71T+p.I93L
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, K14R, E35D, N37DE, R57G, L63P, A71T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12P+p.K14R+p.L63P+p.G68E+p.A71T
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, K14R, L63P, G68E, A71T.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12P+p.K14R+p.N37S+p.R41K+p.R57G+p.L63P+p.I64IV+p.H69HQ+p.A71AT+p.I72L+p.V77I+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, K14R, N37S, R41K, R57G, L63P, I64IV, H69HQ, A71AT, I72L, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12P+p.L19I+p.R57G+p.L63P+p.C67D+p.V77I
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, L19I, R57G, L63P, C67D, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12P+p.Q61E+p.I62V+p.L63P+p.C67Y+p.V77I+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, Q61E, I62V, L63P, C67Y, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12Q+p.I13V+p.K20KR+p.L63Q+p.I64V+p.I72IMV+p.V77I
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12Q, I13V, K20KR, L63Q, I64V, I72IMV, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12R+p.I15V+p.L19I+p.R41K+p.H69Y
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12R, I15V, L19I, R41K, H69Y.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12S+p.I13V+p.K14KR+p.L63P
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, I13V, K14KR, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12S+p.I15V+p.L19IV+p.M36I+p.R41K+p.R57G+p.L63P+p.H69K+p.L89M+p.I93L
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, I15V, L19IV, M36I, R41K, R57G, L63P, H69K, L89M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12S+p.I62V+p.L63P+p.V77I+p.L90M+p.I93L
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, I62V, L63P, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12S+p.K14R+p.R41K+p.I62V+p.L63P+p.I64M
Missense mutation 0.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, K14R, R41K, I62V, L63P, I64M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12S+p.L19I+p.M36I+p.R41K+p.L63V+p.H69K+p.T74S+p.V77I+p.L89M+p.I93L
Missense mutation 0.8 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, L19I, M36I, R41K, L63V, H69K, T74S, V77I, L89M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12S+p.L19I+p.N37S+p.R57G+p.L63A+p.V77I
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, L19I, N37S, R57G, L63A, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12TA+p.K14KR+p.K20KE+p.E35D+p.R41RK+p.R57G+p.I62V+p.L63P+p.V77VI+p.I93IL
Missense mutation 0.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12TA, K14KR, K20KE, E35D, R41RK, R57G, I62V, L63P, V77VI, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12TK+p.N37X+p.R41RK+p.L63Q
Missense mutation 0.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12TK, N37X, R41RK, L63Q.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12TP+p.I13V+p.M36I+p.R57G+p.I64V
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12TP, I13V, M36I, R57G, I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12TS+p.I13V+p.K14KR+p.L19X+p.N37ND+p.L63P+p.V77I
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12TS, I13V, K14KR, L19X, N37ND, L63P, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T4P+p.L10F+p.Q18QH+p.L19I+p.L33F+p.E34Q+p.N37D+p.M46I+p.I54L+p.L63P+p.A71I+p.I72L+p.V77I+p.N88G+p.L90M+p.I93L
Missense mutation 0.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4P, L10F, Q18QH, L19I, L33F, E34Q, N37D, M46I, I54L, L63P, A71I, I72L, V77I, N88G, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T4P+p.L10V+p.I13AV+p.L19P+p.K20I+p.E35G+p.M36I+p.N37S+p.R41K+p.M46I+p.I54IV+p.L63LP+p.H69K+p.K70R+p.A71T+p.G73GS+p.L89V+p.L90M
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4P, L10V, I13AV, L19P, K20I, E35G, M36I, N37S, R41K, M46I, I54IV, L63LP, H69K, K70R, A71T, G73GS, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T4S+p.L10I+p.K20R+p.E35D+p.M36I+p.L63P+p.H69Q+p.L90M
Missense mutation 1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4S, L10I, K20R, E35D, M36I, L63P, H69Q, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V11I+p.I13V+p.L19V+p.K20R+p.L33I+p.E35D+p.M36I+p.N37D+p.I54V+p.R57K+p.D60E+p.I62V+p.L63P+p.H69Y+p.A71I+p.I72M+p.V82A+p.N88D+p.L90M
Missense mutation 0.6 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V11I, I13V, L19V, K20R, L33I, E35D, M36I, N37D, I54V, R57K, D60E, I62V, L63P, H69Y, A71I, I72M, V82A, N88D, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V77I+p.I93L
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6P+p.R41K+p.R57G+p.I62V+p.C67S+p.H69Y+p.V77I
Missense mutation 0.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6P, R41K, R57G, I62V, C67S, H69Y, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6R+p.L10I+p.K20R+p.L33F+p.E34R+p.E35D+p.M36I+p.R41K+p.K43T+p.G48V+p.I50V+p.I54T+p.D60E+p.Q61E+p.I62IV+p.L63P+p.A71T+p.V82A+p.I93L
Missense mutation 0.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6R, L10I, K20R, L33F, E34R, E35D, M36I, R41K, K43T, G48V, I50V, I54T, D60E, Q61E, I62IV, L63P, A71T, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6W*+p.L10I+p.K20R+p.E35D+p.M36I+p.R41K+p.M46I+p.I50V+p.I54L+p.L63P+p.V77I+p.V82I+p.I93L+p.N98NK
Missense mutation 0.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6W*, L10I, K20R, E35D, M36I, R41K, M46I, I50V, I54L, L63P, V77I, V82I, I93L, N98NK.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6WL+p.L10I+p.I13V+p.G16GE+p.L19I+p.K20R+p.M36I+p.N37ND+p.R41K+p.M46I+p.I54V+p.Q61N+p.L63PS+p.H69K+p.T74S+p.L76V+p.V82A+p.L89M+p.I93L
Missense mutation 0.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6WL, L10I, I13V, G16GE, L19I, K20R, M36I, N37ND, R41K, M46I, I54V, Q61N, L63PS, H69K, T74S, L76V, V82A, L89M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6WR+p.L10F+p.T12I+p.I15V+p.L24LF+p.D30N+p.L33F+p.E34ED+p.E35D+p.M36L+p.N37D+p.R41K+p.F53L+p.I54L+p.I62V+p.L63P+p.A71V+p.N88D+p.L90M
Missense mutation 0.7 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6WR, L10F, T12I, I15V, L24LF, D30N, L33F, E34ED, E35D, M36L, N37D, R41K, F53L, I54L, I62V, L63P, A71V, N88D, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6WR+p.L10I+p.E21EDV+p.L24I+p.T26TI+p.V32I+p.E35D+p.M36V+p.N37S+p.K43T+p.M46I+p.I47V+p.R57K+p.I62V+p.L63P+p.H69Q+p.A71T+p.V77I+p.V82A
Missense mutation 1.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6WR, L10I, E21EDV, L24I, T26TI, V32I, E35D, M36V, N37S, K43T, M46I, I47V, R57K, I62V, L63P, H69Q, A71T, V77I, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6WR+p.L38LF+p.I54IL+p.L63LP+p.I64V+p.L90LM
Missense mutation 1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6WR, L38LF, I54IL, L63LP, I64V, L90LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6X+p.V11VA+p.I62IV+p.L63PS+p.H69HY+p.K70R+p.I72V+p.V77VI+p.I84IV
Missense mutation 0.6 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6X, V11VA, I62IV, L63PS, H69HY, K70R, I72V, V77VI, I84IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A22AV+p.R41K+p.R57G+p.D60E+p.L63P+p.V77I+p.Q92E
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A22AV, R41K, R57G, D60E, L63P, V77I, Q92E.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A22V+p.E35D+p.R41K+p.I62V+p.L63P+p.K70R+p.A71V+p.L90M
Missense mutation 1.9 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A22V, E35D, R41K, I62V, L63P, K70R, A71V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D30N+p.L33F+p.I62V+p.L63P+p.I64L+p.A71AV+p.V77I+p.N88D+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included D30N, L33F, I62V, L63P, I64L, A71AV, V77I, N88D, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.L63P
Missense mutation 1.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.M36I+p.L63P
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.M36I+p.N37ND+p.R41K+p.R57RK+p.I62IV+p.L63P+p.A71V+p.L90M+p.I93L
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, N37ND, R41K, R57RK, I62IV, L63P, A71V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.M36I+p.R41K+p.I62V+p.L63P+p.V77I+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36I, R41K, I62V, L63P, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.M36MI+p.L63P
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, M36MI, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.N37D+p.L63P+p.A71T+p.I93L
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37D, L63P, A71T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.N37D+p.R57G+p.L63P+p.A71AV
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37D, R57G, L63P, A71AV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.N37D+p.R57G+p.L63P+p.I64IV
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37D, R57G, L63P, I64IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.N37D+p.R57K+p.L63P+p.A71T+p.I72V+p.V77I+p.I93L
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, N37D, R57K, L63P, A71T, I72V, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E35D+p.R57RK+p.L63P+p.I64IV
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E35D, R57RK, L63P, I64IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G16E+p.N37S+p.I62V+p.L63T+p.I72V+p.V77I
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G16E, N37S, I62V, L63T, I72V, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.I15V+p.R41K+p.F53FL+p.I64V+p.H69Y
Missense mutation 1.6 Susceptible [9]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, I15V, R41K, F53FL, I64V, H69Y.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.I15V+p.V32I+p.L33F+p.L63P+p.C67F+p.A71V+p.G73S+p.I84V+p.L90M+p.I93L
Missense mutation 2.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, I15V, V32I, L33F, L63P, C67F, A71V, G73S, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.N37NT+p.R57K+p.Q58QE+p.D60E+p.Q61QE+p.L63P+p.I64IL+p.V77VI+p.N88NS
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, N37NT, R57K, Q58QE, D60E, Q61QE, L63P, I64IL, V77VI, N88NS.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13IV+p.V32VI+p.L33F+p.E35D+p.M36MI+p.R41K+p.I47IV+p.K55N+p.R57K+p.L63P+p.I64M+p.A71AV+p.L90M+p.I93IL
Missense mutation 5.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13IV, V32VI, L33F, E35D, M36MI, R41K, I47IV, K55N, R57K, L63P, I64M, A71AV, L90M, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.D30N+p.E35D+p.M36I+p.N37NS+p.D60DE+p.I62IV+p.L63P+p.A71T+p.I72T+p.N88D
Missense mutation 1.2 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, D30N, E35D, M36I, N37NS, D60DE, I62IV, L63P, A71T, I72T, N88D.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.G16GA+p.K20R+p.V32I+p.L33F+p.M36I+p.K43T+p.M46I+p.I47V+p.I54V+p.K55KR+p.R57K+p.L63P+p.A71V+p.G73S+p.V82A+p.L90M
Missense mutation 7.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, G16GA, K20R, V32I, L33F, M36I, K43T, M46I, I47V, I54V, K55KR, R57K, L63P, A71V, G73S, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.I15V+p.K20I+p.E35Q+p.M36I+p.N37D+p.R41K+p.R57K+p.C67E+p.H69K+p.V82I+p.L89M
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15V, K20I, E35Q, M36I, N37D, R41K, R57K, C67E, H69K, V82I, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.I15V+p.K20T+p.E35D+p.M36I+p.R41K+p.I62V+p.L63P+p.H69K+p.A71T+p.T74S+p.L89I
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, I15V, K20T, E35D, M36I, R41K, I62V, L63P, H69K, A71T, T74S, L89I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14KR+p.I15IV+p.K20I+p.M36I+p.R41K+p.I64M+p.H69K+p.K70R+p.V82I+p.L89M
Missense mutation 1.2 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14KR, I15IV, K20I, M36I, R41K, I64M, H69K, K70R, V82I, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.E35D+p.M36I+p.R41K+p.R57K+p.H69K+p.L89M
Missense mutation 2.2 Susceptible [9]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, E35D, M36I, R41K, R57K, H69K, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.I15V+p.Q18QK+p.K20RT+p.V32I+p.E35D+p.M36I+p.N37D+p.R57K+p.L63P+p.I64IV+p.A71IMT+p.I72V+p.V77I+p.V82VI+p.L90M+p.I93L
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, I15V, Q18QK, K20RT, V32I, E35D, M36I, N37D, R57K, L63P, I64IV, A71IMT, I72V, V77I, V82VI, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K14R+p.L19P+p.K20I+p.E35D+p.M36I+p.R41K+p.H69K+p.V82I+p.L89M
Missense mutation 1.3 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K14R, L19P, K20I, E35D, M36I, R41K, H69K, V82I, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K20I+p.E35DN+p.M36V+p.I62V+p.L63P+p.T74TS+p.V75VI+p.L90M+p.I93L
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K20I, E35DN, M36V, I62V, L63P, T74TS, V75VI, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K20M+p.L33I+p.E35D+p.N37A+p.K43R+p.R57K+p.L63H+p.L89I
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K20M, L33I, E35D, N37A, K43R, R57K, L63H, L89I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K20T+p.E35D+p.M36I+p.I62V+p.L63P+p.A71T+p.T74S+p.L90M+p.Q92K
Missense mutation 4.8 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K20T, E35D, M36I, I62V, L63P, A71T, T74S, L90M, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.K20T+p.E35N+p.M36I+p.N37E+p.I62V+p.L63P+p.K70R+p.A71I+p.T74S+p.L90M+p.I93L
Missense mutation 3.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, K20T, E35N, M36I, N37E, I62V, L63P, K70R, A71I, T74S, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.L33LF+p.M36ML+p.N37ND+p.K45KN+p.I50IL+p.I54IV+p.L63LP+p.I64V+p.I72IT+p.V82VA
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, L33LF, M36ML, N37ND, K45KN, I50IL, I54IV, L63LP, I64V, I72IT, V82VA.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.M36I+p.R41K+p.Q61K
Missense mutation 1.3 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, M36I, R41K, Q61K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.M46I+p.L63P+p.T74S+p.V82T
Missense mutation 2.4 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, M46I, L63P, T74S, V82T.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.R41K+p.D60E+p.L63P
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, R41K, D60E, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.R57G+p.I62IV+p.L63P
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, R57G, I62IV, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.R57G+p.L63P
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, R57G, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.V32I+p.L33F+p.E34Q+p.M46I+p.I47V+p.F53L+p.I54V+p.K55KR+p.L63P+p.A71V+p.V82A+p.L90M+p.I93L
Missense mutation 2.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, V32I, L33F, E34Q, M46I, I47V, F53L, I54V, K55KR, L63P, A71V, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I13V+p.V32I+p.L33F+p.M36L+p.K43T+p.M46V+p.I54V+p.K55R+p.R57RK+p.L63P+p.I64V+p.A71V+p.V82A+p.N83D+p.L90M
Missense mutation 5.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I13V, V32I, L33F, M36L, K43T, M46V, I54V, K55R, R57RK, L63P, I64V, A71V, V82A, N83D, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.A22AP+p.M36MI+p.P39PQ+p.R41K+p.D60E+p.L63P+p.L90LM
Missense mutation 1.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, A22AP, M36MI, P39PQ, R41K, D60E, L63P, L90LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.E35D+p.R57K+p.L63P+p.A71V+p.I72V+p.V77I+p.V82F+p.L90M+p.I93L
Missense mutation 1.7 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, E35D, R57K, L63P, A71V, I72V, V77I, V82F, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.G16E+p.D60E+p.Q61QE+p.I62V+p.L63KQ+p.I72EV+p.V77I
Missense mutation 2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, G16E, D60E, Q61QE, I62V, L63KQ, I72EV, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.G16GE+p.L19V+p.M36L+p.N37ND+p.R57K+p.L63LP
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, G16GE, L19V, M36L, N37ND, R57K, L63LP.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.G17D+p.K20R+p.E35D+p.M36I+p.R41K+p.R57K+p.Q61N+p.E65D+p.I72T
Missense mutation 2.1 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, G17D, K20R, E35D, M36I, R41K, R57K, Q61N, E65D, I72T.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.K20KR+p.M36I+p.R57RK+p.I62V+p.L63P+p.I72IV+p.V82L+p.I93L
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, K20KR, M36I, R57RK, I62V, L63P, I72IV, V82L, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.K20R+p.E35D+p.M36I+p.N37D+p.R41K+p.R57K+p.V82I+p.I93L
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, K20R, E35D, M36I, N37D, R41K, R57K, V82I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.K20R+p.V32I+p.M36I+p.M46I+p.I47IV+p.F53L+p.I54V+p.L63P+p.A71I+p.V82A+p.L90M+p.I93L
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, K20R, V32I, M36I, M46I, I47IV, F53L, I54V, L63P, A71I, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.K20T+p.D30N+p.E35D+p.M36I+p.K43KT+p.R57G+p.Q58E+p.I62V+p.L63P+p.V77I+p.N88D
Missense mutation 2.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, K20T, D30N, E35D, M36I, K43KT, R57G, Q58E, I62V, L63P, V77I, N88D.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.K20T+p.L33F+p.E35N+p.M36IL+p.N37ND+p.R41KN+p.M46L+p.I50L+p.R57K+p.Q58E+p.I62V+p.L63P+p.I64V+p.A71V+p.T74S+p.V82M+p.L90M+p.I93L
Missense mutation 4.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, K20T, L33F, E35N, M36IL, N37ND, R41KN, M46L, I50L, R57K, Q58E, I62V, L63P, I64V, A71V, T74S, V82M, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.L19I+p.R57G+p.L63P+p.P79A
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, L19I, R57G, L63P, P79A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.L19T+p.K20R+p.M36I+p.R41K+p.I62V+p.K70R+p.V82L
Missense mutation 2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, L19T, K20R, M36I, R41K, I62V, K70R, V82L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.M36I+p.I64V+p.V82L
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36I, I64V, V82L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.M36I+p.N37D+p.R57G+p.L63P+p.I93L
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, M36I, N37D, R57G, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I15V+p.R41K+p.L63A+p.I64V+p.K70R
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I15V, R41K, L63A, I64V, K70R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I3V+p.T12I+p.L33V+p.K45R+p.R57K+p.L63P+p.I64V
Missense mutation 1.6 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I3V, T12I, L33V, K45R, R57K, L63P, I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.I15V+p.G16E+p.K20KT+p.M36I+p.P39S+p.D60E+p.I62V+p.L63P+p.I72V
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, I15V, G16E, K20KT, M36I, P39S, D60E, I62V, L63P, I72V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.I15V+p.R41K+p.L63P
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, I15V, R41K, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.L33V+p.R41K+p.I64V
Missense mutation 2.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K14R, L33V, R41K, I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20KR+p.E35D+p.M36I+p.R57RK+p.I62V+p.L63APS+p.L90M
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20KR, E35D, M36I, R57RK, I62V, L63APS, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20KR+p.V32I+p.E35D+p.M36I+p.K43T+p.M46I+p.R57G+p.L63P+p.A71V+p.V82A+p.I84IV+p.L90LM
Missense mutation 2.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20KR, V32I, E35D, M36I, K43T, M46I, R57G, L63P, A71V, V82A, I84IV, L90LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20R+p.E35D+p.M36I+p.R41K+p.K43KR+p.R57K+p.D60E+p.I62V+p.L63P+p.A71V+p.I72T+p.P79D+p.I93L
Missense mutation 1.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20R, E35D, M36I, R41K, K43KR, R57K, D60E, I62V, L63P, A71V, I72T, P79D, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K20R+p.E35D+p.P39PS+p.R57G+p.L63LP+p.A71V+p.I72IV+p.V77VIM+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included K20R, E35D, P39PS, R57G, L63LP, A71V, I72IV, V77VIM, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10CF+p.T12P+p.K14R+p.K20R+p.E35D+p.M36I+p.N37D+p.M46I+p.I54V+p.Q58E+p.L63T+p.A71V+p.I72T+p.V82A+p.I84V+p.I93L
Missense mutation 7.7 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10CF, T12P, K14R, K20R, E35D, M36I, N37D, M46I, I54V, Q58E, L63T, A71V, I72T, V82A, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.D29DN+p.V32I+p.L33F+p.R41RK+p.M46I+p.I47V+p.I54M+p.I64V+p.A71V+p.V82A
Missense mutation 2.4 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, D29DN, V32I, L33F, R41RK, M46I, I47V, I54M, I64V, A71V, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.E35D+p.L63P+p.A71V+p.T74P+p.I84V+p.L90M+p.I93L
Missense mutation 1.5 Susceptible [8]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, E35D, L63P, A71V, T74P, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.G16GA+p.K20KR+p.V32I+p.L33F+p.M36MIL+p.N37ND+p.M46I+p.I47V+p.I54M+p.Q58E+p.L63P+p.A71V+p.V82A+p.I93L
Missense mutation 6.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, G16GA, K20KR, V32I, L33F, M36MIL, N37ND, M46I, I47V, I54M, Q58E, L63P, A71V, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13IM+p.K14KR+p.K20I+p.L24I+p.E35D+p.M36I+p.R41K+p.M46L+p.G48GA+p.I54V+p.K55KR+p.D60E+p.I62V+p.L63P+p.I64IV+p.A71V+p.V82A+p.I84V+p.T91TS
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13IM, K14KR, K20I, L24I, E35D, M36I, R41K, M46L, G48GA, I54V, K55KR, D60E, I62V, L63P, I64IV, A71V, V82A, I84V, T91TS.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13IV+p.I15V+p.L33F+p.E35D+p.M36I+p.N37ND+p.R41K+p.M46ML+p.I54V+p.I62V+p.L63P+p.A71V+p.I72L+p.G73S+p.V82A+p.L90M
Missense mutation 3.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13IV, I15V, L33F, E35D, M36I, N37ND, R41K, M46ML, I54V, I62V, L63P, A71V, I72L, G73S, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13M+p.K20I+p.L24F+p.L33V+p.M36MI+p.R41RK+p.M46I+p.I54V+p.Q61QH+p.I62IV+p.L63P+p.I64V+p.I66V+p.K70R+p.A71V+p.G73C+p.V77VI+p.I84V+p.L90M+p.T91N+p.Q92K+p.I93L
Missense mutation 2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13M, K20I, L24F, L33V, M36MI, R41RK, M46I, I54V, Q61QH, I62IV, L63P, I64V, I66V, K70R, A71V, G73C, V77VI, I84V, L90M, T91N, Q92K, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13M+p.K20I+p.M36I+p.N37D+p.M46I+p.I54V+p.I62V+p.L63P+p.I66IV+p.C67F+p.A71T+p.I72T+p.G73T+p.I84V+p.L90M+p.I93L
Missense mutation 4.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13M, K20I, M36I, N37D, M46I, I54V, I62V, L63P, I66IV, C67F, A71T, I72T, G73T, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13M+p.L19LI+p.K20I+p.M36I+p.N37S+p.M46I+p.I54V+p.I62V+p.L63P+p.I64IV+p.I66V+p.C67F+p.H69HQ+p.I72IT+p.G73T+p.I84V+p.L90M+p.I93L
Missense mutation 2.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13M, L19LI, K20I, M36I, N37S, M46I, I54V, I62V, L63P, I64IV, I66V, C67F, H69HQ, I72IT, G73T, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.G16A+p.L19IT+p.K20T+p.M46I+p.I54V+p.R57G+p.L63P+p.A71V+p.I72L+p.G73S+p.I84V+p.L90M+p.I93L
Missense mutation 2.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, G16A, L19IT, K20T, M46I, I54V, R57G, L63P, A71V, I72L, G73S, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.I15V+p.D30N+p.L33F+p.E35D+p.M36L+p.N37D+p.K45I+p.F53FL+p.I54V+p.I62V+p.L63P+p.V82A+p.N88D+p.I93L
Missense mutation 3.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, I15V, D30N, L33F, E35D, M36L, N37D, K45I, F53FL, I54V, I62V, L63P, V82A, N88D, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.I15V+p.K20V+p.L33F+p.E35D+p.M36I+p.N37E+p.M46I+p.I54V+p.R57G+p.Q61QE+p.I62V+p.L63P+p.A71AT+p.I72IL+p.G73CS+p.V75VI+p.V82A+p.L90M
Missense mutation 3.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, I15V, K20V, L33F, E35D, M36I, N37E, M46I, I54V, R57G, Q61QE, I62V, L63P, A71AT, I72IL, G73CS, V75VI, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K14KT+p.I15V+p.L19T+p.K20T+p.V32I+p.L33F+p.E35D+p.M36I+p.N37NH+p.K43IT+p.M46I+p.F53L+p.K55KR+p.R57G+p.L63P+p.C67F+p.H69HLQ+p.K70T+p.A71V+p.P79A+p.I84V+p.L90M+p.Q92R
Missense mutation 9.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K14KT, I15V, L19T, K20T, V32I, L33F, E35D, M36I, N37NH, K43IT, M46I, F53L, K55KR, R57G, L63P, C67F, H69HLQ, K70T, A71V, P79A, I84V, L90M, Q92R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K14N+p.L24F+p.L33F+p.E34Q+p.M46I+p.Q61H+p.I62V+p.L63P+p.A71V+p.I72T+p.G73ST+p.V77I+p.P79A+p.I84V+p.L90M+p.I93L
Missense mutation 2.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K14N, L24F, L33F, E34Q, M46I, Q61H, I62V, L63P, A71V, I72T, G73ST, V77I, P79A, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K20I+p.L24I+p.M36I+p.M46I+p.I54V+p.D60E+p.L63P+p.I64V+p.I66V+p.A71T+p.I72T+p.G73C+p.I84V+p.T91S
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20I, L24I, M36I, M46I, I54V, D60E, L63P, I64V, I66V, A71T, I72T, G73C, I84V, T91S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K20I+p.L24I+p.V32VI+p.M36I+p.M46I+p.I54V+p.D60E+p.I64V+p.I66V+p.A71F+p.I72T+p.G73C+p.I84V+p.T91S
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20I, L24I, V32VI, M36I, M46I, I54V, D60E, I64V, I66V, A71F, I72T, G73C, I84V, T91S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K20R+p.L33F+p.E35D+p.M36I+p.N37D+p.K43I+p.M46I+p.I54V+p.I62V+p.L63P+p.I64V+p.A71V+p.V82A+p.N88D+p.L90M+p.T91A
Missense mutation 6.8 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20R, L33F, E35D, M36I, N37D, K43I, M46I, I54V, I62V, L63P, I64V, A71V, V82A, N88D, L90M, T91A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K20T+p.L24I+p.D30N+p.L33F+p.E35D+p.M36I+p.N37S+p.K43T+p.F53L+p.K55N+p.L63P+p.V77VI+p.N88D+p.L89M
Missense mutation 1.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20T, L24I, D30N, L33F, E35D, M36I, N37S, K43T, F53L, K55N, L63P, V77VI, N88D, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.K20T+p.V32I+p.L33F+p.E35DN+p.M36I+p.K43T+p.M46I+p.I47V+p.I54L+p.R57K+p.I62IV+p.L63P+p.I66F+p.A71V+p.V82A+p.L90M
Missense mutation 2.7 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, K20T, V32I, L33F, E35DN, M36I, K43T, M46I, I47V, I54L, R57K, I62IV, L63P, I66F, A71V, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.L19I+p.K20R+p.V32I+p.L33F+p.E35D+p.M36V+p.N37S+p.R41K+p.I47IV+p.I54L+p.Q58E+p.D60X+p.I62V+p.L63LP+p.I66F+p.A71V+p.I72L+p.G73NS+p.P79PS+p.I84V+p.L90M+p.I93IV+p.N98V
Missense mutation 9.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L19I, K20R, V32I, L33F, E35D, M36V, N37S, R41K, I47IV, I54L, Q58E, D60X, I62V, L63LP, I66F, A71V, I72L, G73NS, P79PS, I84V, L90M, I93IV, N98V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.L19P+p.D30N+p.L33F+p.E35D+p.M36I+p.K43T+p.M46I+p.I54V+p.K55R+p.R57K+p.I62V+p.L63P+p.A71T+p.I72IM+p.V75I+p.V82A+p.N88D+p.L89V+p.Q92K
Missense mutation 2.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L19P, D30N, L33F, E35D, M36I, K43T, M46I, I54V, K55R, R57K, I62V, L63P, A71T, I72IM, V75I, V82A, N88D, L89V, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.L19T+p.K20KR+p.L33F+p.E35D+p.M36I+p.P39KT+p.I54L+p.I62V+p.L63P+p.A71V+p.T74P+p.I84V+p.I93L
Missense mutation 1.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L19T, K20KR, L33F, E35D, M36I, P39KT, I54L, I62V, L63P, A71V, T74P, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.L24I+p.L33F+p.M36MI+p.M46I+p.L63P+p.A71V+p.P79D+p.V82T+p.I93L
Missense mutation 1.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L24I, L33F, M36MI, M46I, L63P, A71V, P79D, V82T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.L33F+p.E34Q+p.K43T+p.M46L+p.I54V+p.L63P+p.K70KR+p.A71AV+p.T74S+p.V77I+p.P79S+p.I84V+p.N88D+p.L89M+p.L90M+p.T91S+p.I93L
Missense mutation 5.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, L33F, E34Q, K43T, M46L, I54V, L63P, K70KR, A71AV, T74S, V77I, P79S, I84V, N88D, L89M, L90M, T91S, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.N37ND+p.K45KR+p.M46I+p.R57G+p.I62IV+p.L63P+p.K70R+p.A71IT+p.I72T+p.G73S+p.V82T+p.I84V+p.I93L
Missense mutation 2.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, N37ND, K45KR, M46I, R57G, I62IV, L63P, K70R, A71IT, I72T, G73S, V82T, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I13V+p.V32I+p.L33I+p.M36I+p.I54V+p.L63P+p.A71I+p.I85V+p.L90M
Missense mutation 2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I13V, V32I, L33I, M36I, I54V, L63P, A71I, I85V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I15V+p.K20I+p.M36I+p.M46I+p.I47V+p.I54V+p.I62V+p.L63P+p.A71V+p.I72T+p.G73S+p.I84V+p.I85V+p.L90M+p.I93L
Missense mutation 6.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I15V, K20I, M36I, M46I, I47V, I54V, I62V, L63P, A71V, I72T, G73S, I84V, I85V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I15V+p.K20KR+p.M36I+p.N37S+p.M46I+p.F53Y+p.I54V+p.I62V+p.L63P+p.I64IL+p.I66IV+p.C67CW+p.I84V+p.I85V+p.N88D+p.L90M+p.T91S+p.Q92R+p.I93L+p.C95F+p.T96TS
Missense mutation 9.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I15V, K20KR, M36I, N37S, M46I, F53Y, I54V, I62V, L63P, I64IL, I66IV, C67CW, I84V, I85V, N88D, L90M, T91S, Q92R, I93L, C95F, T96TS.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I15V+p.L19IT+p.K20M+p.E35G+p.M36I+p.N37E+p.P39Q+p.K43T+p.M46I+p.I54V+p.K55R+p.R57K+p.I62V+p.L63P+p.A71V+p.I72R+p.N83S+p.I84V+p.I85V+p.N88D+p.L90M+p.T91S
Missense mutation 6.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I15V, L19IT, K20M, E35G, M36I, N37E, P39Q, K43T, M46I, I54V, K55R, R57K, I62V, L63P, A71V, I72R, N83S, I84V, I85V, N88D, L90M, T91S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.I15V+p.R41K+p.M46I+p.K55R+p.I62IV+p.L63P+p.A71T+p.G73GS+p.V82T+p.I84V+p.I85V+p.L89LM
Missense mutation 2.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, I15V, R41K, M46I, K55R, I62IV, L63P, A71T, G73GS, V82T, I84V, I85V, L89LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.K20KR+p.E21E*+p.L24I+p.E35D+p.M36I+p.N37D+p.M46L+p.I54V+p.K55R+p.R57K+p.I62V+p.L63P+p.A71V+p.T74S+p.V82A
Missense mutation 1.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, K20KR, E21E*, L24I, E35D, M36I, N37D, M46L, I54V, K55R, R57K, I62V, L63P, A71V, T74S, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.L19I+p.K20KM+p.L24I+p.E35D+p.M36IL+p.N37S+p.R41K+p.M46I+p.I54S+p.R57K+p.Q61QH+p.L63P+p.I64V+p.A71V+p.V82C
Missense mutation 6 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, L19I, K20KM, L24I, E35D, M36IL, N37S, R41K, M46I, I54S, R57K, Q61QH, L63P, I64V, A71V, V82C.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.L19V+p.K20R+p.V32I+p.L33F+p.E35D+p.M36L+p.N37D+p.M46I+p.I54M+p.R57K+p.I62V+p.L63P+p.I66T+p.A71I+p.I72R+p.G73C+p.V77I+p.I84V+p.L89V+p.L90M
Missense mutation 4.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, L19V, K20R, V32I, L33F, E35D, M36L, N37D, M46I, I54M, R57K, I62V, L63P, I66T, A71I, I72R, G73C, V77I, I84V, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.L33F+p.E35D+p.M36I+p.I54L+p.I62V+p.L63P+p.A71V+p.G73S+p.I84V+p.L90M
Missense mutation 2.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, L33F, E35D, M36I, I54L, I62V, L63P, A71V, G73S, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.T12P+p.I13V+p.L24F+p.L33F+p.E34Q+p.N37S+p.R41K+p.M46I+p.I54V+p.R57G+p.I62V+p.L63P+p.A71V+p.I72IT+p.G73S+p.P79D+p.I84V+p.L90M+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, T12P, I13V, L24F, L33F, E34Q, N37S, R41K, M46I, I54V, R57G, I62V, L63P, A71V, I72IT, G73S, P79D, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11I+p.I13IV+p.K20R+p.V32I+p.L33F+p.E35D+p.M36I+p.N37Q+p.M46I+p.I47V+p.I54L+p.R57K+p.Q58E+p.D60E+p.I62V+p.L63P+p.A71V+p.G73S+p.V77T+p.I84V+p.L89V+p.L90M+p.I93L
Missense mutation 4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I13IV, K20R, V32I, L33F, E35D, M36I, N37Q, M46I, I47V, I54L, R57K, Q58E, D60E, I62V, L63P, A71V, G73S, V77T, I84V, L89V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11I+p.I13V+p.G16A+p.L19LV+p.L33F+p.E34Q+p.K43I+p.M46L+p.G51A+p.I54M+p.L63P+p.I64M+p.C67Y+p.A71V+p.I72M+p.G73A+p.I84V+p.L90M
Missense mutation 9.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I13V, G16A, L19LV, L33F, E34Q, K43I, M46L, G51A, I54M, L63P, I64M, C67Y, A71V, I72M, G73A, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11I+p.I13V+p.I15IV+p.K20T+p.V32I+p.L33F+p.E35D+p.M36I+p.R41K+p.I54L+p.Q58E+p.D60E+p.I62V+p.L63P+p.A71V+p.V77VI+p.P79H+p.I84V+p.L89V+p.L90M
Missense mutation 5.5 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I13V, I15IV, K20T, V32I, L33F, E35D, M36I, R41K, I54L, Q58E, D60E, I62V, L63P, A71V, V77VI, P79H, I84V, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11I+p.I13V+p.I15V+p.G16A+p.K20I+p.L23I+p.E34D+p.E35K+p.M36I+p.N37D+p.K43T+p.M46I+p.I47IV+p.G51A+p.F53L+p.K55R+p.R57G+p.I62V+p.L63P+p.A71I+p.G73S+p.L76V+p.L89V+p.L90M+p.T91S
Missense mutation 2.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I13V, I15V, G16A, K20I, L23I, E34D, E35K, M36I, N37D, K43T, M46I, I47IV, G51A, F53L, K55R, R57G, I62V, L63P, A71I, G73S, L76V, L89V, L90M, T91S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11I+p.I13V+p.K20V+p.E35D+p.M36I+p.K43T+p.M46I+p.G48GW+p.I50V+p.I54V+p.I62V+p.A71V+p.G73S+p.T74S+p.V82A+p.L89V+p.L90M
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I13V, K20V, E35D, M36I, K43T, M46I, G48GW, I50V, I54V, I62V, A71V, G73S, T74S, V82A, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11I+p.I13V+p.L19Q+p.K20M+p.V32I+p.L33V+p.E35A+p.M36I+p.M46I+p.I47V+p.I54M+p.R57K+p.I62V+p.L63P+p.I64V+p.G73T+p.T74A+p.I84V+p.L89V+p.L90M
Missense mutation 8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I13V, L19Q, K20M, V32I, L33V, E35A, M36I, M46I, I47V, I54M, R57K, I62V, L63P, I64V, G73T, T74A, I84V, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11I+p.I13V+p.V32I+p.L33F+p.E34Q+p.N37S+p.K43KT+p.M46L+p.I54L+p.Q61E+p.I62V+p.L63P+p.A71IV+p.T74P+p.V77I+p.I84V+p.N88G+p.L90M
Missense mutation 2.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, I13V, V32I, L33F, E34Q, N37S, K43KT, M46L, I54L, Q61E, I62V, L63P, A71IV, T74P, V77I, I84V, N88G, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11I+p.T12P+p.I13V+p.I15V+p.L19P+p.K20I+p.E35G+p.M36I+p.M46I+p.I54V+p.L63P+p.A71V+p.I72L+p.G73S+p.I84V+p.L90M+p.I93L
Missense mutation 5.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, T12P, I13V, I15V, L19P, K20I, E35G, M36I, M46I, I54V, L63P, A71V, I72L, G73S, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11I+p.T12P+p.I13V+p.I15V+p.L19P+p.K20T+p.V32I+p.L33F+p.E35G+p.M36I+p.I54IV+p.I62V+p.L63P+p.K70T+p.A71I+p.G73S+p.P79A+p.I84V+p.L89V+p.L90M
Missense mutation 9.8 Susceptible [10]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, T12P, I13V, I15V, L19P, K20T, V32I, L33F, E35G, M36I, I54IV, I62V, L63P, K70T, A71I, G73S, P79A, I84V, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11I+p.T12P+p.I13V+p.K20I+p.L24M+p.E35D+p.M36I+p.M46I+p.Q61QR+p.I62V+p.L63E+p.C67Y+p.A71I+p.I72T+p.G73S+p.T74P+p.P79A+p.I84V+p.L89V+p.L90M+p.Q92K+p.I93L
Missense mutation 5.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, T12P, I13V, K20I, L24M, E35D, M36I, M46I, Q61QR, I62V, L63E, C67Y, A71I, I72T, G73S, T74P, P79A, I84V, L89V, L90M, Q92K, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11I+p.T12P+p.I13V+p.L19Q+p.K20M+p.V32I+p.E35EG+p.M36IT+p.K43T+p.M46I+p.I47V+p.I54M+p.K55R+p.R57G+p.L63P+p.C67CY+p.H69Q+p.A71I+p.V82A+p.L89V+p.L90M
Missense mutation 7.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11I, T12P, I13V, L19Q, K20M, V32I, E35EG, M36IT, K43T, M46I, I47V, I54M, K55R, R57G, L63P, C67CY, H69Q, A71I, V82A, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11VI+p.T12TA+p.I13V+p.K14KR+p.K20R+p.D30N+p.V32I+p.L33F+p.E35D+p.M36V+p.N37T+p.K43Q+p.M46I+p.I47V+p.F53L+p.I54L+p.K55KR+p.R57K+p.I62V+p.L63P+p.I66IV+p.C67W+p.A71V+p.I72V+p.V77I+p.I84V+p.I85IL+p.N88D+p.L89LV+p.L90M
Missense mutation 7.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11VI, T12TA, I13V, K14KR, K20R, D30N, V32I, L33F, E35D, M36V, N37T, K43Q, M46I, I47V, F53L, I54L, K55KR, R57K, I62V, L63P, I66IV, C67W, A71V, I72V, V77I, I84V, I85IL, N88D, L89LV, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V11VL+p.I13IV+p.V32I+p.L33F+p.K43T+p.M46I+p.I47V+p.F53L+p.I54L+p.K55KR+p.D60DE+p.I62V+p.L63P+p.I66L+p.C67CW+p.A71T+p.I72T+p.G73C+p.V77I+p.V82C+p.L90M+p.I93L
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V11VL, I13IV, V32I, L33F, K43T, M46I, I47V, F53L, I54L, K55KR, D60DE, I62V, L63P, I66L, C67CW, A71T, I72T, G73C, V77I, V82C, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V32I+p.L33F+p.M36L+p.N37S+p.R41RK+p.M46I+p.I54L+p.K55R+p.R57K+p.I62V+p.L63P+p.I64V+p.I66V+p.G73I+p.I84V+p.L90M
Missense mutation 2.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V32I, L33F, M36L, N37S, R41RK, M46I, I54L, K55R, R57K, I62V, L63P, I64V, I66V, G73I, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V32I+p.L33F+p.M36L+p.N37T+p.I47V+p.I54M+p.Q58E+p.I62V+p.L63P+p.I64IV+p.A71V+p.G73T+p.L89V+p.L90M+p.I93L
Missense mutation 4.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V32I, L33F, M36L, N37T, I47V, I54M, Q58E, I62V, L63P, I64IV, A71V, G73T, L89V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10F+p.V32I+p.L33F+p.P39PS+p.M46MI+p.I47V+p.L63P+p.A71I+p.I72KR+p.G73S+p.I84V+p.L90M
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10F, V32I, L33F, P39PS, M46MI, I47V, L63P, A71I, I72KR, G73S, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10FI+p.I13IV+p.K14KR+p.G16GA+p.D30DN+p.L33LF+p.N37NH+p.M46MI+p.I54V+p.R57K+p.L63P+p.G68GE+p.K70KE+p.A71AV+p.V82A+p.N88ND+p.Q92QK+p.I93IL+p.G94X
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10FI, I13IV, K14KR, G16GA, D30DN, L33LF, N37NH, M46MI, I54V, R57K, L63P, G68GE, K70KE, A71AV, V82A, N88ND, Q92QK, I93IL, G94X.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10FI+p.V11VI+p.I13V+p.I15V+p.Q18QH+p.K20I+p.M36I+p.N37D+p.M46L+p.I54M+p.L63P+p.A71IV+p.V82A+p.L90M+p.I93L
Missense mutation 2.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10FI, V11VI, I13V, I15V, Q18QH, K20I, M36I, N37D, M46L, I54M, L63P, A71IV, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10FIV+p.I13IV+p.D30N+p.E35D+p.M36IV+p.N37X+p.R41RK+p.Q58E+p.I62V+p.L63P+p.I64V+p.N88D+p.I93IL
Missense mutation 2.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10FIV, I13IV, D30N, E35D, M36IV, N37X, R41RK, Q58E, I62V, L63P, I64V, N88D, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.A22V+p.R57G+p.L63P+p.A71V+p.I72L+p.G73S+p.V77I+p.I84V+p.I85V+p.L90M
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, A22V, R57G, L63P, A71V, I72L, G73S, V77I, I84V, I85V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.A28AP+p.L33LF+p.R41K+p.K43KR+p.M46L+p.I54V+p.K55KR+p.R57K+p.Q61N+p.L63T+p.I64IM+p.E65ED+p.A71V+p.I72V+p.L76LV+p.V82A+p.I85IV+p.I93L
Missense mutation 2.4 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, A28AP, L33LF, R41K, K43KR, M46L, I54V, K55KR, R57K, Q61N, L63T, I64IM, E65ED, A71V, I72V, L76LV, V82A, I85IV, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.E35D+p.K43T+p.I54M+p.D60E+p.I62V+p.L63P+p.I72V+p.V82M+p.L90M+p.I93L
Missense mutation 3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E35D, K43T, I54M, D60E, I62V, L63P, I72V, V82M, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.E35D+p.M36I+p.N37S+p.R41K+p.R57G+p.I62V+p.L63P+p.A71V+p.G73S+p.L90M+p.I93L
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E35D, M36I, N37S, R41K, R57G, I62V, L63P, A71V, G73S, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.E35D+p.M36I+p.R41K+p.I62V+p.L63P+p.A71V+p.T74P+p.L90M+p.I93L
Missense mutation 1.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E35D, M36I, R41K, I62V, L63P, A71V, T74P, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.E35D+p.M36I+p.R41K+p.R57G+p.I62V+p.L63P+p.I64V+p.I85V+p.L90M+p.I93L
Missense mutation 2.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E35D, M36I, R41K, R57G, I62V, L63P, I64V, I85V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.G16A+p.K20R+p.M36I+p.G48V+p.I54T+p.L63P+p.A71V+p.T74S+p.V82T+p.I93L
Missense mutation 2.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16A, K20R, M36I, G48V, I54T, L63P, A71V, T74S, V82T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.G16A+p.L19Q+p.V32I+p.N37S+p.R41K+p.K45R+p.M46I+p.I47A+p.L63P+p.A71V+p.I72V+p.V82A+p.L90M+p.Q92K+p.I93L
Missense mutation 4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16A, L19Q, V32I, N37S, R41K, K45R, M46I, I47A, L63P, A71V, I72V, V82A, L90M, Q92K, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.G16A+p.L33LF+p.E34Q+p.G48V+p.F53L+p.I54T+p.L63P+p.A71V+p.I72IV+p.T74S+p.V77I+p.V82A+p.L90M+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16A, L33LF, E34Q, G48V, F53L, I54T, L63P, A71V, I72IV, T74S, V77I, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.G16E+p.L63PT+p.T74P+p.I93L
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16E, L63PT, T74P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.G16GR+p.K20R+p.L24I+p.L33F+p.E35D+p.M36I+p.N37H+p.R41K+p.K43T+p.M46L+p.I54V+p.K55R+p.R57K+p.D60E+p.Q61E+p.L63P+p.A71V+p.I72IT+p.V82A+p.I93L
Missense mutation 8.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16GR, K20R, L24I, L33F, E35D, M36I, N37H, R41K, K43T, M46L, I54V, K55R, R57K, D60E, Q61E, L63P, A71V, I72IT, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.G16GR+p.L33F+p.G48M+p.F53L+p.I54A+p.R57K+p.I62V+p.L63P+p.A71IT+p.I72V+p.V75VI+p.V77I+p.V82A+p.I93L
Missense mutation 2.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16GR, L33F, G48M, F53L, I54A, R57K, I62V, L63P, A71IT, I72V, V75VI, V77I, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.G16GW+p.E35D+p.M36I+p.N37T+p.K43T+p.G48V+p.I54V+p.R57K+p.I62V+p.L63P+p.H69HY+p.A71V+p.I72E+p.V77I+p.V82A+p.I93L
Missense mutation 1.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16GW, E35D, M36I, N37T, K43T, G48V, I54V, R57K, I62V, L63P, H69HY, A71V, I72E, V77I, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.G16GW+p.L19I+p.L33F+p.E34Q+p.G48V+p.I54A+p.Q58E+p.I62V+p.L63P+p.I66V+p.H69R+p.A71T+p.V77I+p.V82A+p.L90M+p.I93L+p.C95F
Missense mutation 1.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16GW, L19I, L33F, E34Q, G48V, I54A, Q58E, I62V, L63P, I66V, H69R, A71T, V77I, V82A, L90M, I93L, C95F.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.G16GW+p.L33F+p.N37E+p.M46I+p.I54V+p.R57K+p.Q61H+p.L63P+p.I64V+p.G73A+p.V77I+p.V82F+p.L90M+p.I93L
Missense mutation 3.4 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, G16GW, L33F, N37E, M46I, I54V, R57K, Q61H, L63P, I64V, G73A, V77I, V82F, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13IV+p.I15IL+p.G16GA+p.Q18QK+p.L19LP+p.K20R+p.A22AP+p.L24I+p.D29DE+p.L33F+p.E35D+p.M36I+p.N37S+p.P39PS+p.R41RK+p.K43T+p.F53L+p.I54L+p.K55N+p.D60E+p.I62V+p.L63P+p.A71V+p.I72IM+p.G73GC+p.V82A
Missense mutation 1.2 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13IV, I15IL, G16GA, Q18QK, L19LP, K20R, A22AP, L24I, D29DE, L33F, E35D, M36I, N37S, P39PS, R41RK, K43T, F53L, I54L, K55N, D60E, I62V, L63P, A71V, I72IM, G73GC, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13IV+p.K20I+p.M46I+p.L63P+p.I64V+p.C67F+p.H69R+p.G73T+p.V77I+p.P79A+p.I84V+p.L90M
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13IV, K20I, M46I, L63P, I64V, C67F, H69R, G73T, V77I, P79A, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13IV+p.L24F+p.L33F+p.E35D+p.M36I+p.N37ND+p.R41RK+p.K43KT+p.M46MI+p.I54V+p.K55KR+p.I62V+p.L63P+p.A71V+p.I72IV+p.G73S+p.V82A+p.L90M+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13IV, L24F, L33F, E35D, M36I, N37ND, R41RK, K43KT, M46MI, I54V, K55KR, I62V, L63P, A71V, I72IV, G73S, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13IV+p.V32I+p.E35D+p.M36MI+p.N37S+p.K43T+p.M46I+p.I47V+p.L63P+p.V77VI+p.V82T+p.I85V
Missense mutation 7.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13IV, V32I, E35D, M36MI, N37S, K43T, M46I, I47V, L63P, V77VI, V82T, I85V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13IV+p.V32I+p.L33F+p.K43KT+p.I54L+p.L63P+p.A71V+p.G73T+p.V77I+p.P79A+p.I84V+p.L90M
Missense mutation 4.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13IV, V32I, L33F, K43KT, I54L, L63P, A71V, G73T, V77I, P79A, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13LV+p.K14R+p.G16GRW+p.L33F+p.I54L+p.L63P+p.C67CS+p.V77I+p.I84V+p.Q92K+p.I93L
Missense mutation 1.7 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13LV, K14R, G16GRW, L33F, I54L, L63P, C67CS, V77I, I84V, Q92K, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.D60E+p.I62V+p.L63A+p.I64L+p.A71T+p.I72V+p.V77I
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, D60E, I62V, L63A, I64L, A71T, I72V, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.G16A+p.K20KR+p.L24F+p.V32I+p.L33F+p.M36MI+p.R41RK+p.K43T+p.M46I+p.F53L+p.K55KR+p.L63P+p.A71V+p.T74P+p.V77VI+p.V82A+p.L90M+p.I93L
Missense mutation 4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, G16A, K20KR, L24F, V32I, L33F, M36MI, R41RK, K43T, M46I, F53L, K55KR, L63P, A71V, T74P, V77VI, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.G16A+p.K20R+p.L24F+p.L33F+p.M36I+p.R41RK+p.K43KT+p.M46I+p.I54L+p.K55R+p.I62V+p.L63P+p.I64M+p.A71I+p.I72L+p.G73A+p.V82A+p.L90M+p.I93L
Missense mutation 2.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, G16A, K20R, L24F, L33F, M36I, R41RK, K43KT, M46I, I54L, K55R, I62V, L63P, I64M, A71I, I72L, G73A, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.G16A+p.L24F+p.L33F+p.E34Q+p.I54A+p.I62V+p.L63P+p.A71V+p.I72L+p.G73S+p.V77I+p.V82A+p.L90M
Missense mutation 2.7 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, G16A, L24F, L33F, E34Q, I54A, I62V, L63P, A71V, I72L, G73S, V77I, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.G16GR+p.E35D+p.L63P+p.A71T+p.I84V
Missense mutation 1.8 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, G16GR, E35D, L63P, A71T, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.I15IV+p.L19LV+p.L24I+p.V32I+p.L33F+p.K43E+p.M46L+p.I54LV+p.D60E+p.L63P+p.A71V+p.I72V+p.V82A+p.I84V
Missense mutation 7.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15IV, L19LV, L24I, V32I, L33F, K43E, M46L, I54LV, D60E, L63P, A71V, I72V, V82A, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.I15IV+p.Q18H+p.K20V+p.A22AV+p.L33LIV+p.M36I+p.M46MI+p.I54V+p.K55KR+p.R57K+p.I62V+p.L63P+p.C67W+p.A71V+p.I72L+p.G73S+p.I84V+p.I85IV+p.L90M
Missense mutation 4.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15IV, Q18H, K20V, A22AV, L33LIV, M36I, M46MI, I54V, K55KR, R57K, I62V, L63P, C67W, A71V, I72L, G73S, I84V, I85IV, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.I15V+p.G16E+p.K20R+p.L33F+p.E35D+p.M36I+p.P39S+p.R41K+p.K43T+p.M46L+p.I50V+p.D60E+p.I62V+p.L63Q+p.I64V+p.E65D+p.I72V+p.T74TS+p.V82A+p.I85V
Missense mutation 2.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15V, G16E, K20R, L33F, E35D, M36I, P39S, R41K, K43T, M46L, I50V, D60E, I62V, L63Q, I64V, E65D, I72V, T74TS, V82A, I85V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.I15V+p.K20MT+p.L33F+p.E35G+p.M36I+p.L38LW+p.R41K+p.I54L+p.D60E+p.I62V+p.L63P+p.I66FL+p.C67Y+p.A71T+p.I72T+p.G73GA+p.L89LV+p.L90M+p.N98NK
Missense mutation 2.8 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15V, K20MT, L33F, E35G, M36I, L38LW, R41K, I54L, D60E, I62V, L63P, I66FL, C67Y, A71T, I72T, G73GA, L89LV, L90M, N98NK.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.I15V+p.K20R+p.L24I+p.D29DN+p.L33F+p.E35D+p.M36L+p.N37D+p.R41K+p.F53FL+p.I54V+p.L63P+p.I72M+p.G73C+p.V82A
Missense mutation 4.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15V, K20R, L24I, D29DN, L33F, E35D, M36L, N37D, R41K, F53FL, I54V, L63P, I72M, G73C, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.I15V+p.K20R+p.L24I+p.L33F+p.E35D+p.M36I+p.N37E+p.K45R+p.G48GA+p.F53FI+p.I54V+p.R57K+p.Y59YC+p.I62V+p.L63P+p.G68E+p.A71T+p.I72T+p.G73C+p.V82A+p.I93L
Missense mutation 2.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15V, K20R, L24I, L33F, E35D, M36I, N37E, K45R, G48GA, F53FI, I54V, R57K, Y59YC, I62V, L63P, G68E, A71T, I72T, G73C, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.I15V+p.L19V+p.L24I+p.V32I+p.L33F+p.K43E+p.M46L+p.I54L+p.D60E+p.L63P+p.A71V+p.I72V+p.V82A+p.I84V
Missense mutation 2.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, I15V, L19V, L24I, V32I, L33F, K43E, M46L, I54L, D60E, L63P, A71V, I72V, V82A, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K14R+p.I15V+p.K20I+p.E35Q+p.M36I+p.R41K+p.R57K+p.C67E+p.H69K+p.V82I+p.L89M
Missense mutation 1.3 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K14R, I15V, K20I, E35Q, M36I, R41K, R57K, C67E, H69K, V82I, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20I+p.E35Q+p.M36I+p.R41K+p.R57K+p.L63S+p.C67E+p.H69K+p.V82I+p.L89M
Missense mutation 2 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20I, E35Q, M36I, R41K, R57K, L63S, C67E, H69K, V82I, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20R+p.L24I+p.L33F+p.E34V+p.E35D+p.M36I+p.N37E+p.G48M+p.I50V+p.F53L+p.I54A+p.R57G+p.D60E+p.I62V+p.L63P+p.A71V+p.V77I+p.V82A+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20R, L24I, L33F, E34V, E35D, M36I, N37E, G48M, I50V, F53L, I54A, R57G, D60E, I62V, L63P, A71V, V77I, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20R+p.L33F+p.E34KR+p.E35D+p.M36I+p.G40GE+p.R41K+p.K43T+p.G48M+p.I54S+p.I62V+p.I72IMT+p.V82A
Missense mutation 4.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20R, L33F, E34KR, E35D, M36I, G40GE, R41K, K43T, G48M, I54S, I62V, I72IMT, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.K20R+p.M36I+p.M46L+p.I54V+p.L63P+p.A71V+p.V82A+p.I84V
Missense mutation 2.7 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, K20R, M36I, M46L, I54V, L63P, A71V, V82A, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L19I+p.K20R+p.D30N+p.E35D+p.M36I+p.R41K+p.K45R+p.I54V+p.R57K+p.I62V+p.L63P+p.H69Y+p.A71T+p.T74TS+p.V82A+p.N88D+p.L90M+p.Q92R+p.I93L
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L19I, K20R, D30N, E35D, M36I, R41K, K45R, I54V, R57K, I62V, L63P, H69Y, A71T, T74TS, V82A, N88D, L90M, Q92R, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L19V+p.K20T+p.M46I+p.I54V+p.I62V+p.L63P+p.A71V+p.I72L+p.G73S+p.V82T+p.L90M
Missense mutation 3.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L19V, K20T, M46I, I54V, I62V, L63P, A71V, I72L, G73S, V82T, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L19V+p.L24I+p.V32I+p.L33F+p.K43E+p.M46L+p.I54V+p.D60E+p.L63P+p.A71V+p.I72V+p.V82A+p.I84V
Missense mutation 5.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L19V, L24I, V32I, L33F, K43E, M46L, I54V, D60E, L63P, A71V, I72V, V82A, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L24F+p.L33F+p.E34Q+p.K43T+p.M46L+p.I54M+p.I62V+p.L63P+p.A71V+p.I72IM+p.G73S+p.V77I+p.V82A+p.L90M
Missense mutation 3.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L24F, L33F, E34Q, K43T, M46L, I54M, I62V, L63P, A71V, I72IM, G73S, V77I, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L24I+p.L33F+p.E35D+p.M36I+p.N37S+p.M46I+p.I54M+p.L63P+p.A71V+p.V82VI+p.I84V+p.I93L
Missense mutation 2.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L24I, L33F, E35D, M36I, N37S, M46I, I54M, L63P, A71V, V82VI, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L24I+p.L33F+p.M36L+p.K43T+p.M46I+p.I54V+p.D60E+p.I62V+p.L63P+p.A71V+p.T74S+p.V82A+p.N83D+p.I93L
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L24I, L33F, M36L, K43T, M46I, I54V, D60E, I62V, L63P, A71V, T74S, V82A, N83D, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L24I+p.V32VI+p.L33F+p.N37ND+p.M46I+p.I54L+p.I62IV+p.L63P+p.A71V+p.G73V+p.T74P+p.V82A+p.I84V+p.I93L
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L24I, V32VI, L33F, N37ND, M46I, I54L, I62IV, L63P, A71V, G73V, T74P, V82A, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L33F+p.E35D+p.K43T+p.I54L+p.L63P+p.I64L+p.V77I+p.L90M
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L33F, E35D, K43T, I54L, L63P, I64L, V77I, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L33F+p.E35D+p.M36I+p.P39PL+p.K43KT+p.F53PS+p.I54L+p.R57G+p.Q58E+p.I62V+p.A71V+p.T74S+p.V82F+p.L90M+p.I93L
Missense mutation 2.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L33F, E35D, M36I, P39PL, K43KT, F53PS, I54L, R57G, Q58E, I62V, A71V, T74S, V82F, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L33F+p.K43T+p.M46I+p.G48V+p.F53Y+p.I54S+p.R57G+p.D60E+p.Q61E+p.I62V+p.L63T+p.A71V+p.I72V+p.T74P+p.V82A+p.L89M+p.I93L
Missense mutation 2.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L33F, K43T, M46I, G48V, F53Y, I54S, R57G, D60E, Q61E, I62V, L63T, A71V, I72V, T74P, V82A, L89M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L33F+p.N37S+p.M46L+p.I54V+p.Q58E+p.I62V+p.L63P+p.I64IV+p.A71V+p.T74PS+p.V77I+p.V82A+p.I84V+p.L90M+p.I93L
Missense mutation 7.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L33F, N37S, M46L, I54V, Q58E, I62V, L63P, I64IV, A71V, T74PS, V77I, V82A, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L33F+p.P39PQ+p.M46L+p.G48M+p.I54S+p.K55KT+p.Q58E+p.L63P+p.A71V+p.T74P+p.V82A+p.I93L
Missense mutation 6.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L33F, P39PQ, M46L, G48M, I54S, K55KT, Q58E, L63P, A71V, T74P, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.L63P+p.H69Q+p.I72V+p.V77I
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, L63P, H69Q, I72V, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.N37ND+p.R41K+p.M46I+p.I47V+p.L63P+p.A71T+p.I72V+p.V77I+p.N88G+p.L90M
Missense mutation 2.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, N37ND, R41K, M46I, I47V, L63P, A71T, I72V, V77I, N88G, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.R41H+p.M46I+p.I54L+p.D60E+p.L63P+p.I64IV+p.K70R+p.V77I+p.I84V+p.I93L
Missense mutation 1.4 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, R41H, M46I, I54L, D60E, L63P, I64IV, K70R, V77I, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.R57G+p.D60E+p.I62IV+p.L63A+p.I64ILM+p.A71AT+p.I72IV+p.V77I
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, R57G, D60E, I62IV, L63A, I64ILM, A71AT, I72IV, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.V32I+p.L33F+p.N37S+p.P39PS+p.R41RK+p.I54L+p.R57G+p.L63PS+p.A71V+p.P79X+p.I84V
Missense mutation 4.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, V32I, L33F, N37S, P39PS, R41RK, I54L, R57G, L63PS, A71V, P79X, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15IV+p.G16GR+p.L19I+p.K20R+p.L24I+p.L33F+p.E35D+p.M36I+p.N37S+p.R41K+p.I54A+p.K55KQ+p.I62V+p.L63P+p.I64V+p.A71V+p.T74S+p.V82A+p.I93L
Missense mutation 5.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15IV, G16GR, L19I, K20R, L24I, L33F, E35D, M36I, N37S, R41K, I54A, K55KQ, I62V, L63P, I64V, A71V, T74S, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15IV+p.K20M+p.L24I+p.V32I+p.L33F+p.M36I+p.R41K+p.M46I+p.I47V+p.I54M+p.I62V+p.L63P+p.K70KR+p.I72V+p.T74S+p.V82I+p.I84V+p.L89M
Missense mutation 4.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15IV, K20M, L24I, V32I, L33F, M36I, R41K, M46I, I47V, I54M, I62V, L63P, K70KR, I72V, T74S, V82I, I84V, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15IV+p.L19LI+p.M36MV+p.R41K+p.M46I+p.I54V+p.D60E+p.I62IV+p.L63P+p.A71V+p.G73GS+p.V82A+p.L90M+p.I93L
Missense mutation 4 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15IV, L19LI, M36MV, R41K, M46I, I54V, D60E, I62IV, L63P, A71V, G73GS, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.E21EK+p.M46L+p.G48V+p.I54S+p.I62V+p.L63P+p.I64L+p.A71V+p.I72V+p.V82A+p.I93L
Missense mutation 1.4 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, E21EK, M46L, G48V, I54S, I62V, L63P, I64L, A71V, I72V, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.G16A+p.K20R+p.V32I+p.M36I+p.M46I+p.F53L+p.I54V+p.K55R+p.Q58E+p.L63P+p.A71V+p.I72V+p.L76V+p.V82A+p.L90M+p.I93L
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, G16A, K20R, V32I, M36I, M46I, F53L, I54V, K55R, Q58E, L63P, A71V, I72V, L76V, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.G16E+p.L19I+p.K20R+p.L24I+p.E35D+p.M36I+p.I54V+p.I62V+p.L63C+p.A71V+p.V82T+p.I84V
Missense mutation 5.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, G16E, L19I, K20R, L24I, E35D, M36I, I54V, I62V, L63C, A71V, V82T, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.I54L+p.I62V+p.L63P+p.I93L
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, I54L, I62V, L63P, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.K20M+p.L63P+p.A71V+p.G73S+p.P79AD+p.I84V+p.R87RK+p.L90M+p.I93L
Missense mutation 2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, K20M, L63P, A71V, G73S, P79AD, I84V, R87RK, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.K20R+p.V32I+p.M36I+p.M46I+p.F53L+p.I54V+p.K55R+p.D60E+p.Q61E+p.I62V+p.L63P+p.A71V+p.G73A+p.L76V+p.V82T+p.L89V+p.L90M
Missense mutation 3.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, K20R, V32I, M36I, M46I, F53L, I54V, K55R, D60E, Q61E, I62V, L63P, A71V, G73A, L76V, V82T, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.K20T+p.E35D+p.M36I+p.M46I+p.I54V+p.K55KR+p.R57RK+p.Q58E+p.D60DE+p.I62V+p.L63P+p.A71T+p.I72IT+p.N83ND+p.I85V+p.N88S+p.L90M
Missense mutation 9.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, K20T, E35D, M36I, M46I, I54V, K55KR, R57RK, Q58E, D60DE, I62V, L63P, A71T, I72IT, N83ND, I85V, N88S, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.L19I+p.K20R+p.E35D+p.M36I+p.N37E+p.R41K+p.I54V+p.Q58E+p.D60N+p.I62V+p.L63P+p.K70R+p.A71V+p.G73S+p.V82A+p.L90M+p.I93L
Missense mutation 3.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L19I, K20R, E35D, M36I, N37E, R41K, I54V, Q58E, D60N, I62V, L63P, K70R, A71V, G73S, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.L19L*+p.K20R+p.E35D+p.M36I+p.N37D+p.R41K+p.I54V+p.I62V+p.L63P+p.C67S+p.A71V+p.V82S+p.L90M
Missense mutation 4.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L19L*, K20R, E35D, M36I, N37D, R41K, I54V, I62V, L63P, C67S, A71V, V82S, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.L19Q+p.K20R+p.V32I+p.E35D+p.M36I+p.K43T+p.M46L+p.I54V+p.I62V+p.L63P+p.I64V+p.A71V+p.G73S+p.V82A+p.L90M
Missense mutation 5.8 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L19Q, K20R, V32I, E35D, M36I, K43T, M46L, I54V, I62V, L63P, I64V, A71V, G73S, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.L24F+p.L33F+p.E35D+p.R41K+p.M46I+p.I54V+p.I62V+p.L63P+p.A71V+p.G73S+p.V82A+p.L90M+p.I93L
Missense mutation 2.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L24F, L33F, E35D, R41K, M46I, I54V, I62V, L63P, A71V, G73S, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.L24I+p.M46L+p.I54V+p.L63P+p.A71V+p.V77I+p.V82A+p.I84V
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L24I, M46L, I54V, L63P, A71V, V77I, V82A, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I15V+p.L63T+p.I93L
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I15V, L63T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I54IM+p.L63P+p.V77VI+p.V82A+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I54IM, L63P, V77VI, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K14E+p.L63P+p.I64V+p.E65K+p.H69Q+p.I72L+p.V77I+p.I93IL
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14E, L63P, I64V, E65K, H69Q, I72L, V77I, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K14KR+p.G16GE+p.G17GE+p.R57K+p.L63T+p.A71T+p.I93L
Missense mutation 3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14KR, G16GE, G17GE, R57K, L63T, A71T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K14R+p.I15IV+p.E35D+p.M36I+p.R41K+p.M46L+p.I54V+p.Q58E+p.I62V+p.L63P+p.C67F+p.H69HR+p.A71V+p.I72KR+p.G73S+p.V82A+p.L90M+p.C95L
Missense mutation 3.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14R, I15IV, E35D, M36I, R41K, M46L, I54V, Q58E, I62V, L63P, C67F, H69HR, A71V, I72KR, G73S, V82A, L90M, C95L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K14R+p.I15V+p.G16AS+p.L33F+p.R41K+p.I54L+p.Q61E+p.I62V+p.L63P+p.A71I+p.I72IT+p.G73S+p.V82A+p.I85IF+p.L90M+p.I93L
Missense mutation 1.8 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14R, I15V, G16AS, L33F, R41K, I54L, Q61E, I62V, L63P, A71I, I72IT, G73S, V82A, I85IF, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K14R+p.I15V+p.L63Q+p.I72V+p.V77I+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14R, I15V, L63Q, I72V, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K14R+p.I15V+p.R57G+p.L63Q+p.I72V+p.V77I+p.I93L
Missense mutation 1.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14R, I15V, R57G, L63Q, I72V, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K14R+p.L63X+p.I72V+p.V77I+p.I93L
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14R, L63X, I72V, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K14R+p.V32I+p.R41K+p.G48M+p.F53L+p.I54M+p.I62V+p.L63A+p.C67D+p.H69R+p.A71L+p.I72V+p.V77I+p.V82A+p.I84V+p.L90M+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14R, V32I, R41K, G48M, F53L, I54M, I62V, L63A, C67D, H69R, A71L, I72V, V77I, V82A, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K14T+p.K20R+p.L24I+p.V32I+p.L33F+p.E35D+p.M36I+p.R41RK+p.K43T+p.M46L+p.I47V+p.I54L+p.I62V+p.L63P+p.I64V+p.A71V+p.V82X
Missense mutation 1.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K14T, K20R, L24I, V32I, L33F, E35D, M36I, R41RK, K43T, M46L, I47V, I54L, I62V, L63P, I64V, A71V, V82X.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20I+p.E35D+p.M36I+p.K43T+p.G48M+p.I54V+p.L63Q+p.I64V+p.H69R+p.A71V+p.I72V+p.P79Q+p.I84V+p.I85V+p.L90M+p.I93L
Missense mutation 2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20I, E35D, M36I, K43T, G48M, I54V, L63Q, I64V, H69R, A71V, I72V, P79Q, I84V, I85V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20KR+p.E35D+p.M36I+p.R41K+p.M46MI+p.L63P+p.H69Y+p.A71T+p.I72T+p.I84V+p.L90M+p.Q92K
Missense mutation 2.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20KR, E35D, M36I, R41K, M46MI, L63P, H69Y, A71T, I72T, I84V, L90M, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20M+p.E35D+p.M36I+p.M46L+p.G48V+p.I54V+p.Q58E+p.I62V+p.L63T+p.I72T+p.T74S+p.V82A+p.I84V+p.L89M
Missense mutation 6 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20M, E35D, M36I, M46L, G48V, I54V, Q58E, I62V, L63T, I72T, T74S, V82A, I84V, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.E35D+p.M36I+p.N37D+p.I54V+p.R57K+p.D60E+p.L63P+p.A71V+p.I72T+p.V77VI+p.V82A+p.I93L
Missense mutation 2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36I, N37D, I54V, R57K, D60E, L63P, A71V, I72T, V77VI, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.E35D+p.M36I+p.N37D+p.M46L+p.G48V+p.I54V+p.D60E+p.I62V+p.L63P+p.A71V+p.I72V+p.V77I+p.V82S+p.L90M+p.I93L
Missense mutation 4.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36I, N37D, M46L, G48V, I54V, D60E, I62V, L63P, A71V, I72V, V77I, V82S, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.E35D+p.M36I+p.N37D+p.R41K+p.M46I+p.I54V+p.I62V+p.L63P+p.V82A+p.L90M+p.I93L+p.C95F
Missense mutation 3.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36I, N37D, R41K, M46I, I54V, I62V, L63P, V82A, L90M, I93L, C95F.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.E35D+p.M36I+p.N37S+p.R41K+p.M46V+p.G48V+p.I54T+p.D60DE+p.L63P+p.H69HR+p.K70KT+p.A71V+p.P79PAS+p.V82A+p.I84IV+p.I93L
Missense mutation 2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36I, N37S, R41K, M46V, G48V, I54T, D60DE, L63P, H69HR, K70KT, A71V, P79PAS, V82A, I84IV, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.E35D+p.M36I+p.N37S+p.R41K+p.M46V+p.G48V+p.I54T+p.D60E+p.I62IV+p.L63P+p.A71IV+p.I72IT+p.V82A+p.I93L
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36I, N37S, R41K, M46V, G48V, I54T, D60E, I62IV, L63P, A71IV, I72IT, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.E35D+p.M36MI+p.N37ND+p.R41K+p.I54V+p.I62IV+p.L63P+p.H69HR+p.A71AV+p.V82VA+p.L90LM
Missense mutation 2.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, E35D, M36MI, N37ND, R41K, I54V, I62IV, L63P, H69HR, A71AV, V82VA, L90LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.L24I+p.E35D+p.M36I+p.N37E+p.M46I+p.I54V+p.Q61N+p.I62V+p.L63P+p.I64V+p.A71V+p.I72V+p.T74S+p.L76V+p.V82T+p.I93L
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, L24I, E35D, M36I, N37E, M46I, I54V, Q61N, I62V, L63P, I64V, A71V, I72V, T74S, L76V, V82T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.L24I+p.E35D+p.N37DE+p.M46I+p.I54V+p.R57RK+p.Q61H+p.I62V+p.L63P+p.I64V+p.A71V+p.I72V+p.T74S+p.L76V+p.V82T+p.I93L
Missense mutation 1.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, L24I, E35D, N37DE, M46I, I54V, R57RK, Q61H, I62V, L63P, I64V, A71V, I72V, T74S, L76V, V82T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.L24I+p.L33F+p.E35D+p.M36I+p.N37D+p.M46L+p.I54V+p.L63P+p.A71T+p.V82A+p.T91S
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, L24I, L33F, E35D, M36I, N37D, M46L, I54V, L63P, A71T, V82A, T91S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.L24I+p.L33F+p.E35D+p.M36I+p.N37H+p.R41N+p.M46L+p.I54V+p.K55R+p.I62V+p.L63P+p.A71V+p.G73S+p.V82T
Missense mutation 6.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, L24I, L33F, E35D, M36I, N37H, R41N, M46L, I54V, K55R, I62V, L63P, A71V, G73S, V82T.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.L33F+p.E34A+p.E35D+p.M36I+p.N37D+p.K43T+p.M46I+p.G48V+p.I50V+p.I54T+p.I62V+p.L63P+p.A71V+p.I72V+p.V77I+p.V82A+p.I85V+p.I93L
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, L33F, E34A, E35D, M36I, N37D, K43T, M46I, G48V, I50V, I54T, I62V, L63P, A71V, I72V, V77I, V82A, I85V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.L33F+p.E34EA+p.E35D+p.M36I+p.N37E+p.M46I+p.F53L+p.I62V+p.L63P+p.A71I+p.G73S+p.V82A+p.I84V+p.L90M+p.I93L
Missense mutation 6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, L33F, E34EA, E35D, M36I, N37E, M46I, F53L, I62V, L63P, A71I, G73S, V82A, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.M36I+p.I54V+p.I62IMV+p.L63P+p.A71V+p.V82T+p.L90M
Missense mutation 4.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, M36I, I54V, I62IMV, L63P, A71V, V82T, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.V32I+p.E35D+p.M36I+p.R41RK+p.K43T+p.M46I+p.I47V+p.F53FL+p.I54V+p.K55R+p.L63P+p.A71V+p.V82A+p.L90M
Missense mutation 2.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, V32I, E35D, M36I, R41RK, K43T, M46I, I47V, F53FL, I54V, K55R, L63P, A71V, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K20R+p.V32I+p.L33F+p.E34K+p.E35D+p.M36V+p.N37S+p.M46I+p.I47V+p.G48E+p.I54M+p.R57K+p.Q58E+p.I62V+p.L63P+p.A71T+p.V77T+p.I84V+p.L90M+p.I93L
Missense mutation 2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K20R, V32I, L33F, E34K, E35D, M36V, N37S, M46I, I47V, G48E, I54M, R57K, Q58E, I62V, L63P, A71T, V77T, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K43S+p.M46I+p.I54V+p.R57K+p.I62V+p.L63P+p.A71V+p.G73T+p.V77I+p.V82F+p.L90M+p.I93L
Missense mutation 3.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K43S, M46I, I54V, R57K, I62V, L63P, A71V, G73T, V77I, V82F, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.K43T+p.M46L+p.K55R+p.R57G+p.A71V+p.V82A+p.N83P+p.L90M
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, K43T, M46L, K55R, R57G, A71V, V82A, N83P, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L19I+p.K20M+p.V32I+p.L33LF+p.M36I+p.M46I+p.I47V+p.F53L+p.I54V+p.I62V+p.L63A+p.I64IM+p.A71V+p.V82A+p.L90M
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19I, K20M, V32I, L33LF, M36I, M46I, I47V, F53L, I54V, I62V, L63A, I64IM, A71V, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L19I+p.K20R+p.E35D+p.M36I+p.R41K+p.M46I+p.I54V+p.L63P+p.I64V+p.G73T+p.V82A+p.L90M+p.I93L+p.C95F
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19I, K20R, E35D, M36I, R41K, M46I, I54V, L63P, I64V, G73T, V82A, L90M, I93L, C95F.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L19Q+p.R41K+p.I54V+p.D60E+p.I62V+p.L63PT+p.A71V+p.V82A+p.I93M
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19Q, R41K, I54V, D60E, I62V, L63PT, A71V, V82A, I93M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L19V+p.K20R+p.L24I+p.L33F+p.E35D+p.M36I+p.N37D+p.K43T+p.M46L+p.I54V+p.R57K+p.D60E+p.I62V+p.L63P+p.A71T+p.I72T+p.V82A+p.G86GR
Missense mutation 2.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L19V, K20R, L24I, L33F, E35D, M36I, N37D, K43T, M46L, I54V, R57K, D60E, I62V, L63P, A71T, I72T, V82A, G86GR.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L24I+p.R41K+p.M46I+p.L63P+p.I64V+p.V82A+p.I84V
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24I, R41K, M46I, L63P, I64V, V82A, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L24LF+p.D29DV+p.R41K+p.G48V+p.I54V+p.L63P+p.I66IN+p.H69Y+p.A71V+p.V77I+p.V82A+p.I84V+p.I85V+p.I93L
Missense mutation 2.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24LF, D29DV, R41K, G48V, I54V, L63P, I66IN, H69Y, A71V, V77I, V82A, I84V, I85V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L24LI+p.L33LF+p.M36MIL+p.R41K+p.M46ML+p.G48GV+p.I54IV+p.K55KR+p.R57G+p.Q58E+p.I62IV+p.L63P+p.I64IV+p.G73AT+p.V82VA+p.I84IV+p.L90LM+p.T91TA
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L24LI, L33LF, M36MIL, R41K, M46ML, G48GV, I54IV, K55KR, R57G, Q58E, I62IV, L63P, I64IV, G73AT, V82VA, I84IV, L90LM, T91TA.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L33F+p.G48V+p.I54S+p.Q58QE+p.D60E+p.L63P+p.A71V+p.V77I+p.V82A+p.T91A
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L33F, G48V, I54S, Q58QE, D60E, L63P, A71V, V77I, V82A, T91A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L33F+p.M46I+p.F53L+p.I54L+p.I62V+p.L63P+p.A71V+p.T74P+p.I84V+p.L90M+p.I93L
Missense mutation 5.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L33F, M46I, F53L, I54L, I62V, L63P, A71V, T74P, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L33F+p.M46L+p.I54V+p.L63P+p.A71V+p.G73S+p.V77I+p.I84V+p.L90M+p.I93L
Missense mutation 3.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L33F, M46L, I54V, L63P, A71V, G73S, V77I, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L33LF+p.M36L+p.N37D+p.M46I+p.I47V+p.F53L+p.I54V+p.Q58E+p.Q61H+p.I62V+p.L63C+p.A71V+p.V82A+p.I93L
Missense mutation 2.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L33LF, M36L, N37D, M46I, I47V, F53L, I54V, Q58E, Q61H, I62V, L63C, A71V, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.M46L+p.G48T+p.I54A+p.I62V+p.L63P+p.I64V+p.A71V+p.T74S+p.V77I+p.V82F+p.L90M+p.I93L
Missense mutation 1.8 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, M46L, G48T, I54A, I62V, L63P, I64V, A71V, T74S, V77I, V82F, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.N37S+p.M46I+p.I62V+p.L63P+p.A71V+p.T74P+p.V77I+p.I84V+p.L90M+p.Q92R+p.I93L
Missense mutation 1.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, N37S, M46I, I62V, L63P, A71V, T74P, V77I, I84V, L90M, Q92R, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.Q18QH+p.L24LF+p.L33F+p.N37X+p.I54V+p.Q58E+p.L63P+p.A71I+p.I72L+p.G73AT+p.V77I+p.V82F+p.L90M+p.I93L
Missense mutation 3.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, Q18QH, L24LF, L33F, N37X, I54V, Q58E, L63P, A71I, I72L, G73AT, V77I, V82F, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.Q18R+p.K20I+p.M46I+p.I62V+p.L63P+p.I64IV+p.C67F+p.I72L+p.G73C+p.I84V+p.L90M+p.I93L
Missense mutation 2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, Q18R, K20I, M46I, I62V, L63P, I64IV, C67F, I72L, G73C, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12A+p.E35D+p.R41RK+p.L63P+p.A71T+p.V77VI+p.I93L
Missense mutation 1.6 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12A, E35D, R41RK, L63P, A71T, V77VI, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12D+p.L19I+p.E34EK+p.M36MI+p.M46I+p.L63P+p.E65EK+p.A71V+p.G73S+p.V77I+p.I84V+p.L90M+p.I93L
Missense mutation 3.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12D, L19I, E34EK, M36MI, M46I, L63P, E65EK, A71V, G73S, V77I, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12I+p.I13V+p.G16GV+p.K43T+p.M46L+p.G48V+p.I54V+p.I64V+p.T74S+p.V77I+p.V82A+p.I84V+p.T91S
Missense mutation 2.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12I, I13V, G16GV, K43T, M46L, G48V, I54V, I64V, T74S, V77I, V82A, I84V, T91S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12I+p.I15IT+p.G16AS+p.L33F+p.G48M+p.F53FL+p.I54S+p.R57RK+p.I62V+p.L63P+p.A71V+p.G73GS+p.V82A+p.G94GCW
Missense mutation 2.7 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12I, I15IT, G16AS, L33F, G48M, F53FL, I54S, R57RK, I62V, L63P, A71V, G73GS, V82A, G94GCW.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12K+p.I15V+p.N37H+p.R41RK+p.K55N+p.L63P+p.A71V+p.V77I+p.I84V+p.I85V+p.N88D+p.L90M
Missense mutation 3.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12K, I15V, N37H, R41RK, K55N, L63P, A71V, V77I, I84V, I85V, N88D, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12P+p.I15V+p.K20R+p.V32VI+p.M36I+p.N37D+p.M46L+p.I54L+p.L63P+p.A71V+p.T74TS+p.P79S+p.V82VA+p.I84V+p.I85V+p.L90M+p.I93L
Missense mutation 6.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12P, I15V, K20R, V32VI, M36I, N37D, M46L, I54L, L63P, A71V, T74TS, P79S, V82VA, I84V, I85V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12P+p.L19V+p.L33F+p.M46L+p.G48M+p.I54M+p.L63T+p.A71V+p.I72T+p.T74A+p.V82A+p.I84V+p.I93L
Missense mutation 5.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12P, L19V, L33F, M46L, G48M, I54M, L63T, A71V, I72T, T74A, V82A, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.I13IV+p.E35D+p.M36I+p.R41K+p.M46L+p.L63P+p.A71V+p.I84V+p.L90M+p.Q92K+p.I93L
Missense mutation 2.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13IV, E35D, M36I, R41K, M46L, L63P, A71V, I84V, L90M, Q92K, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.I13V+p.A22V+p.V32I+p.R41K+p.M46I+p.K55R+p.I62V+p.L63P+p.I64V+p.H69Q+p.A71V+p.V82A+p.I84V
Missense mutation 7.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, A22V, V32I, R41K, M46I, K55R, I62V, L63P, I64V, H69Q, A71V, V82A, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.I13V+p.G16A+p.L33F+p.N37D+p.M46L+p.I54V+p.R57G+p.I62V+p.L63P+p.I72L+p.G73S+p.V77I+p.V82A+p.L90M+p.I93L
Missense mutation 4.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, G16A, L33F, N37D, M46L, I54V, R57G, I62V, L63P, I72L, G73S, V77I, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.I13V+p.I15IV+p.Q18H+p.K20I+p.N37NT+p.M46I+p.I54V+p.L63P+p.A71V+p.I72M+p.G73S+p.I84V+p.L90M
Missense mutation 3.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, I15IV, Q18H, K20I, N37NT, M46I, I54V, L63P, A71V, I72M, G73S, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.I13V+p.I15V+p.G16E+p.K20I+p.E35D+p.M36I+p.F53L+p.I54V+p.R57K+p.I62V+p.L63S+p.A71V+p.V82A+p.L89I+p.L90M
Missense mutation 1.4 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, I15V, G16E, K20I, E35D, M36I, F53L, I54V, R57K, I62V, L63S, A71V, V82A, L89I, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.I13V+p.K14KE+p.K20R+p.V32I+p.L33F+p.E35D+p.M36I+p.N37S+p.R41K+p.K43T+p.M46I+p.I47V+p.F53L+p.I54L+p.K55R+p.R57G+p.D60E+p.I62V+p.L63P+p.K70KE+p.A71V+p.G73C+p.V82I+p.I84V+p.L90M
Missense mutation 5.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, K14KE, K20R, V32I, L33F, E35D, M36I, N37S, R41K, K43T, M46I, I47V, F53L, I54L, K55R, R57G, D60E, I62V, L63P, K70KE, A71V, G73C, V82I, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.I13V+p.Q18H+p.K20I+p.M46I+p.I54L+p.L63P+p.A71V+p.I72IM+p.G73GS+p.I84V+p.L90M
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I13V, Q18H, K20I, M46I, I54L, L63P, A71V, I72IM, G73GS, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.I15V+p.Q18H+p.L19I+p.K20I+p.M36I+p.N37D+p.M46I+p.K55R+p.K70R+p.A71V+p.I72M+p.P79D+p.I84V+p.N88T+p.L90M
Missense mutation 2.8 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, I15V, Q18H, L19I, K20I, M36I, N37D, M46I, K55R, K70R, A71V, I72M, P79D, I84V, N88T, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.K14R+p.I15V+p.L19LP+p.K20I+p.E35N+p.M36I+p.I54V+p.R57K+p.Q58E+p.I62V+p.L63P+p.A71V+p.I72IL+p.G73S+p.V82A+p.L90M
Missense mutation 3.4 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, K14R, I15V, L19LP, K20I, E35N, M36I, I54V, R57K, Q58E, I62V, L63P, A71V, I72IL, G73S, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.T12P+p.I13V+p.K14R+p.V32I+p.L33F+p.N37T+p.K43Q+p.M46I+p.I47V+p.I54L+p.L63P+p.I66F+p.H69Y+p.A71V+p.I72M+p.G73C+p.V77I+p.P79S+p.V82I+p.I84V+p.N88D+p.L89T+p.Q92K
Missense mutation 3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, T12P, I13V, K14R, V32I, L33F, N37T, K43Q, M46I, I47V, I54L, L63P, I66F, H69Y, A71V, I72M, G73C, V77I, P79S, V82I, I84V, N88D, L89T, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11I+p.T12TP+p.I13V+p.K20KR+p.E35D+p.M36I+p.R41K+p.M46L+p.I62IV+p.L63P+p.A71V+p.I84V+p.L90M+p.Q92K+p.I93L
Missense mutation 5.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11I, T12TP, I13V, K20KR, E35D, M36I, R41K, M46L, I62IV, L63P, A71V, I84V, L90M, Q92K, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11IL+p.T12PS+p.I13V+p.K14KR+p.L19V+p.L33F+p.M46L+p.G48M+p.K55R+p.L63T+p.A71V+p.I72T+p.T74P+p.V82A+p.I84V+p.I93L
Missense mutation 7.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11IL, T12PS, I13V, K14KR, L19V, L33F, M46L, G48M, K55R, L63T, A71V, I72T, T74P, V82A, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11L+p.I13V+p.K14R+p.A22V+p.E35D+p.M36I+p.N37D+p.G48M+p.F53L+p.I54V+p.I62V+p.L63P+p.A71V+p.T74S+p.V82A+p.I84V+p.T91S+p.Q92K
Missense mutation 2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11L, I13V, K14R, A22V, E35D, M36I, N37D, G48M, F53L, I54V, I62V, L63P, A71V, T74S, V82A, I84V, T91S, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11L+p.I13V+p.Q18H+p.L19I+p.K20L+p.E35D+p.M36I+p.N37D+p.M46L+p.I54V+p.K55KR+p.Q58E+p.D60Q+p.I62IV+p.L63P+p.H69Y+p.A71V+p.I72L+p.I84V+p.L89V+p.L90M+p.I93L
Missense mutation 7.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11L, I13V, Q18H, L19I, K20L, E35D, M36I, N37D, M46L, I54V, K55KR, Q58E, D60Q, I62IV, L63P, H69Y, A71V, I72L, I84V, L89V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11VA+p.G16GR+p.L33LF+p.K43T+p.M46L+p.G48V+p.I54V+p.D60E+p.I62V+p.L63P+p.H69HY+p.A71T+p.I72E+p.V82A+p.I84V+p.I93L
Missense mutation 3.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11VA, G16GR, L33LF, K43T, M46L, G48V, I54V, D60E, I62V, L63P, H69HY, A71T, I72E, V82A, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11VI+p.I13IV+p.K20R+p.V32VI+p.L33F+p.E35D+p.M36I+p.N37D+p.K43KT+p.M46LS+p.I54L+p.K55R+p.R57K+p.I62V+p.L63T+p.A71V+p.I72V+p.T74PS+p.V82X+p.I84IV+p.L89LF+p.L90M+p.I93L
Missense mutation 4.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11VI, I13IV, K20R, V32VI, L33F, E35D, M36I, N37D, K43KT, M46LS, I54L, K55R, R57K, I62V, L63T, A71V, I72V, T74PS, V82X, I84IV, L89LF, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11VI+p.K14KR+p.I15V+p.G16A+p.L33LF+p.R41RK+p.I54LV+p.Q61E+p.I62V+p.L63P+p.A71I+p.I72IT+p.G73S+p.V82A+p.L90M+p.I93L
Missense mutation 1.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11VI, K14KR, I15V, G16A, L33LF, R41RK, I54LV, Q61E, I62V, L63P, A71I, I72IT, G73S, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V11VI+p.L19LV+p.K20I+p.E35D+p.M36I+p.N37D+p.K43KR+p.G49GR+p.R57K+p.L63P+p.H69R+p.A71IV+p.V77VI+p.I85IV+p.L90M+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V11VI, L19LV, K20I, E35D, M36I, N37D, K43KR, G49GR, R57K, L63P, H69R, A71IV, V77VI, I85IV, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V32I+p.L33F+p.K43Q+p.I47V+p.I54M+p.R57G+p.L63P+p.A71V+p.G73S+p.V77I+p.V82M+p.L90M
Missense mutation 5.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V32I, L33F, K43Q, I47V, I54M, R57G, L63P, A71V, G73S, V77I, V82M, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V32I+p.L33F+p.K43T+p.M46I+p.I54M+p.D60E+p.L63P+p.I64M+p.A71V+p.V82A+p.L89M+p.L90M+p.I93L
Missense mutation 4.4 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V32I, L33F, K43T, M46I, I54M, D60E, L63P, I64M, A71V, V82A, L89M, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V32VI+p.L33LF+p.E34EQ+p.I47IV+p.I54IM+p.D60E+p.L63P+p.K70T+p.A71AV+p.I72IK+p.G73GS+p.V77I+p.L90LM+p.I93L
Missense mutation 3.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V32VI, L33LF, E34EQ, I47IV, I54IM, D60E, L63P, K70T, A71AV, I72IK, G73GS, V77I, L90LM, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IT+p.I13V+p.V32I+p.L33F+p.M36I+p.R41RK+p.M46MIL+p.I47A+p.L63P+p.K70E+p.A71V+p.V82A+p.L90M+p.I93L
Missense mutation 3.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IT, I13V, V32I, L33F, M36I, R41RK, M46MIL, I47A, L63P, K70E, A71V, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.I13IV+p.I15V+p.L33F+p.E34Q+p.M36L+p.N37D+p.R41RK+p.M46L+p.G48V+p.I54T+p.I62V+p.L63P+p.A71V+p.I72V+p.T74D+p.V75I+p.V82A+p.L90M+p.I93L
Missense mutation 3.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13IV, I15V, L33F, E34Q, M36L, N37D, R41RK, M46L, G48V, I54T, I62V, L63P, A71V, I72V, T74D, V75I, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.I13IV+p.K20R+p.M36I+p.I54V+p.I62V+p.L63P+p.I64IL+p.A71V+p.I72IV+p.V82AT+p.L90LM
Missense mutation 1.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13IV, K20R, M36I, I54V, I62V, L63P, I64IL, A71V, I72IV, V82AT, L90LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.I13V+p.A22AP+p.L33F+p.M46I+p.I54V+p.Q58QE+p.D60DN+p.Q61QH+p.I62V+p.L63P+p.A71IT+p.I72IM+p.V77I+p.V82A+p.N88G
Missense mutation 2.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13V, A22AP, L33F, M46I, I54V, Q58QE, D60DN, Q61QH, I62V, L63P, A71IT, I72IM, V77I, V82A, N88G.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.I13V+p.G16A+p.L33F+p.R41RK+p.M46L+p.I54V+p.Q58E+p.I62V+p.L63P+p.I66F+p.A71V+p.I72L+p.G73S+p.V77I+p.P79PA+p.V82T+p.I84IV+p.L90M
Missense mutation 9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13V, G16A, L33F, R41RK, M46L, I54V, Q58E, I62V, L63P, I66F, A71V, I72L, G73S, V77I, P79PA, V82T, I84IV, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.I13V+p.G16E+p.K20R+p.D30N+p.L33F+p.E35D+p.M36I+p.N37T+p.K45R+p.I54V+p.R57K+p.Q58E+p.I62IV+p.L63T+p.E65D+p.I72V+p.V82A+p.N88D
Missense mutation 3.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, I13V, G16E, K20R, D30N, L33F, E35D, M36I, N37T, K45R, I54V, R57K, Q58E, I62IV, L63T, E65D, I72V, V82A, N88D.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.K14K*+p.D25DE+p.L33F+p.N37D+p.R41K+p.M46I+p.I54V+p.K55R+p.I62V+p.L63P+p.I64L+p.V82A+p.L90M+p.I93L
Missense mutation 1.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, K14K*, D25DE, L33F, N37D, R41K, M46I, I54V, K55R, I62V, L63P, I64L, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.K14R+p.I15V+p.M36I+p.G48V+p.I54V+p.D60E+p.I62V+p.I64V+p.T74A+p.V82A+p.I84V
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, K14R, I15V, M36I, G48V, I54V, D60E, I62V, I64V, T74A, V82A, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.K20R+p.L24IK+p.E35D+p.M36V+p.N37S+p.K43T+p.F53L+p.I54V+p.K55R+p.R57K+p.I62V+p.L63P+p.A71V+p.V77VI+p.V82A+p.T96TI+p.N98NI
Missense mutation 1.8 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, K20R, L24IK, E35D, M36V, N37S, K43T, F53L, I54V, K55R, R57K, I62V, L63P, A71V, V77VI, V82A, T96TI, N98NI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.T12TK+p.I13IV+p.I15EV+p.L19LV+p.K20T+p.V32I+p.M36I+p.P39PQ+p.M46I+p.I47A+p.Q58E+p.I62IV+p.L63P+p.V77I+p.V82I+p.I93L
Missense mutation 4.6 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, T12TK, I13IV, I15EV, L19LV, K20T, V32I, M36I, P39PQ, M46I, I47A, Q58E, I62IV, L63P, V77I, V82I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.V11I+p.G16GE+p.V32I+p.L33F+p.K43R+p.M46L+p.I54M+p.R57K+p.L63P+p.K70T+p.A71V+p.G73S+p.V77I+p.I84V+p.I93L
Missense mutation 6.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, V11I, G16GE, V32I, L33F, K43R, M46L, I54M, R57K, L63P, K70T, A71V, G73S, V77I, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.V32I+p.L33F+p.E35D+p.M36MI+p.N37S+p.M46I+p.I47V+p.F53FL+p.I54L+p.K55R+p.R57RK+p.L63P+p.I64V+p.I66V+p.A71IV+p.G73T+p.P79PA+p.I84V+p.L90M+p.I93IL
Missense mutation 3.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, V32I, L33F, E35D, M36MI, N37S, M46I, I47V, F53FL, I54L, K55R, R57RK, L63P, I64V, I66V, A71IV, G73T, P79PA, I84V, L90M, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10IV+p.V32VI+p.M46I+p.I47V+p.L63P+p.V77I+p.Q92QKR+p.I93L+p.C95F
Missense mutation 2.2 Susceptible [8]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10IV, V32VI, M46I, I47V, L63P, V77I, Q92QKR, I93L, C95F.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LF+p.G16A+p.L19I+p.G27GE+p.L33F+p.N37NS+p.M46I+p.G51A+p.K55R+p.Q58E+p.D60E+p.L63P+p.A71V+p.I72IM+p.G73S+p.V77I+p.V82A+p.L90M
Missense mutation 2.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LF, G16A, L19I, G27GE, L33F, N37NS, M46I, G51A, K55R, Q58E, D60E, L63P, A71V, I72IM, G73S, V77I, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LF+p.L19LI+p.L33F+p.N37E+p.K45R+p.R57K+p.L63P+p.I64IV+p.C67E+p.I72V+p.V77I+p.V82S+p.L89M
Missense mutation 8.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LF, L19LI, L33F, N37E, K45R, R57K, L63P, I64IV, C67E, I72V, V77I, V82S, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LFI+p.V11VI+p.I13V+p.L33F+p.E35D+p.N37D+p.M46L+p.I54L+p.Q58E+p.I62V+p.L63P+p.A71T+p.I72V+p.L90M+p.Q92R
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LFI, V11VI, I13V, L33F, E35D, N37D, M46L, I54L, Q58E, I62V, L63P, A71T, I72V, L90M, Q92R.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.I15V+p.M36I+p.N37D+p.K43R+p.R57RK+p.L63P+p.I72V+p.P79PS
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I15V, M36I, N37D, K43R, R57RK, L63P, I72V, P79PS.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.L19LI+p.M36MI+p.N37NS+p.R41K+p.I54IV+p.Q58QE+p.I62V+p.L63DN+p.A71AV+p.I72IT+p.V82VA+p.I93IL
Missense mutation 2.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, L19LI, M36MI, N37NS, R41K, I54IV, Q58QE, I62V, L63DN, A71AV, I72IT, V82VA, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.L19LI+p.V32VI+p.L33F+p.N37T+p.M46MI+p.I50IL+p.I54IV+p.I62IMV+p.I64IV+p.A71AV+p.V82VA+p.I84IV
Missense mutation 2.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, L19LI, V32VI, L33F, N37T, M46MI, I50IL, I54IV, I62IMV, I64IV, A71AV, V82VA, I84IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.L33LF+p.M36I+p.R41K+p.M46MIL+p.L63T+p.V82VI+p.I84V
Missense mutation 2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, L33LF, M36I, R41K, M46MIL, L63T, V82VI, I84V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.T12PS+p.L19I+p.V32I+p.E35D+p.M36I+p.R41RK+p.M46ML+p.I47A+p.Q61QH+p.L63P+p.I64V+p.A71AV+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, T12PS, L19I, V32I, E35D, M36I, R41RK, M46ML, I47A, Q61QH, L63P, I64V, A71AV, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.V11VI+p.I13V+p.L19LV+p.K20R+p.L33I+p.E35D+p.M36I+p.N37D+p.I54V+p.R57K+p.D60E+p.I62V+p.L63P+p.H69Y+p.A71FI+p.I72T+p.V82A+p.N88D+p.L90IM
Missense mutation 3.7 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, V11VI, I13V, L19LV, K20R, L33I, E35D, M36I, N37D, I54V, R57K, D60E, I62V, L63P, H69Y, A71FI, I72T, V82A, N88D, L90IM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.V32VI+p.E34EQ+p.N37NS+p.M46MV+p.I47IV+p.I54IM+p.K55KR+p.I62IV+p.L63LP+p.A71AV+p.T74X+p.V77VI+p.V82VA+p.L90LM+p.I93IL
Missense mutation 3.4 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, V32VI, E34EQ, N37NS, M46MV, I47IV, I54IM, K55KR, I62IV, L63LP, A71AV, T74X, V77VI, V82VA, L90LM, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LV+p.I15V+p.M36MI+p.N37X+p.R41K+p.L63S+p.I72T
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LV, I15V, M36MI, N37X, R41K, L63S, I72T.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10M+p.I13V+p.K14R+p.K20I+p.E35Q+p.M36I+p.R41K+p.R57K+p.C67E+p.H69K+p.V82VI+p.L89M
Missense mutation 1.8 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10M, I13V, K14R, K20I, E35Q, M36I, R41K, R57K, C67E, H69K, V82VI, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10R+p.V32I+p.N37H+p.R41K+p.M46I+p.I47V+p.I50L+p.L63P+p.A71I+p.I72V+p.V77I+p.V82T+p.L90M+p.I93L
Missense mutation 4.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10R, V32I, N37H, R41K, M46I, I47V, I50L, L63P, A71I, I72V, V77I, V82T, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.G16E+p.L19LI+p.K20R+p.E35D+p.M36I+p.M46L+p.G48V+p.L63S+p.I64V+p.I72V+p.V82AT+p.I84V+p.I85V
Missense mutation 5.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, G16E, L19LI, K20R, E35D, M36I, M46L, G48V, L63S, I64V, I72V, V82AT, I84V, I85V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13IV+p.I15V+p.L19I+p.V32I+p.L33LF+p.M46I+p.I47A+p.K55KN+p.Q58QE+p.L63P+p.K70KE+p.A71V+p.V77I+p.V82A+p.I93L
Missense mutation 5.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13IV, I15V, L19I, V32I, L33LF, M46I, I47A, K55KN, Q58QE, L63P, K70KE, A71V, V77I, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.K14R+p.G16E+p.L19I+p.K20IT+p.E35D+p.M36I+p.P39T+p.F53FL+p.I54V+p.I62V+p.I66F+p.H69K+p.A71AV+p.T74S+p.L89M
Missense mutation 2.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K14R, G16E, L19I, K20IT, E35D, M36I, P39T, F53FL, I54V, I62V, I66F, H69K, A71AV, T74S, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.K20KR+p.V32I+p.L33LI+p.M36IL+p.N37D+p.M46I+p.F53L+p.R57G+p.I62V+p.L63P+p.K70KNT+p.A71I+p.V82A+p.I85IM+p.L89V+p.L90M
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K20KR, V32I, L33LI, M36IL, N37D, M46I, F53L, R57G, I62V, L63P, K70KNT, A71I, V82A, I85IM, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.K20R+p.D30N+p.L33F+p.E35D+p.M36I+p.N37D+p.R41K+p.I54V+p.R57G+p.L63P+p.I64V+p.N88D+p.L90M+p.I93L
Missense mutation 4.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K20R, D30N, L33F, E35D, M36I, N37D, R41K, I54V, R57G, L63P, I64V, N88D, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.K20T+p.L33F+p.M46I+p.Q58E+p.I62V+p.L63P+p.V77I+p.N88G
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, K20T, L33F, M46I, Q58E, I62V, L63P, V77I, N88G.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.L24I+p.L33F+p.M36L+p.K43T+p.M46L+p.I54V+p.I62IV+p.L63P+p.I64V+p.V82AT+p.N83D
Missense mutation 9.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, L24I, L33F, M36L, K43T, M46L, I54V, I62IV, L63P, I64V, V82AT, N83D.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.L33V+p.M36MI+p.R41K+p.I64V+p.R87RK
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, L33V, M36MI, R41K, I64V, R87RK.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.N37S+p.M46I+p.L63P+p.A71T+p.V77I+p.L90M
Missense mutation 1.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, N37S, M46I, L63P, A71T, V77I, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.Q18H+p.L19V+p.K20R+p.L33I+p.M36I+p.N37S+p.K45KR+p.I62IV+p.L63P+p.I64V+p.A71AV+p.N83ND+p.I84V+p.T91TS+p.Q92K
Missense mutation 3.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, Q18H, L19V, K20R, L33I, M36I, N37S, K45KR, I62IV, L63P, I64V, A71AV, N83ND, I84V, T91TS, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I13V+p.Q18H+p.L19V+p.K20R+p.L33I+p.M36I+p.N37S+p.R57G+p.L63P+p.I64V+p.I84V+p.Q92K
Missense mutation 3.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I13V, Q18H, L19V, K20R, L33I, M36I, N37S, R57G, L63P, I64V, I84V, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I15V+p.E35D+p.M36I+p.R41K+p.R57K+p.Q61DN+p.L63CS+p.I93L
Missense mutation 1.3 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I15V, E35D, M36I, R41K, R57K, Q61DN, L63CS, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I15V+p.K20R+p.V32I+p.M36I+p.R41K+p.M46L+p.I54V+p.K55R+p.Q58E+p.D60E+p.L63P+p.A71V+p.I72T+p.G73C+p.V82A+p.L90M
Missense mutation 4 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I15V, K20R, V32I, M36I, R41K, M46L, I54V, K55R, Q58E, D60E, L63P, A71V, I72T, G73C, V82A, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I15V+p.L19I+p.L24I+p.M46L+p.I54V+p.K55R+p.I62V+p.L63A+p.A71V+p.V77I+p.V82A
Missense mutation 1.4 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I15V, L19I, L24I, M46L, I54V, K55R, I62V, L63A, A71V, V77I, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.K14KR+p.R57K+p.I62IV+p.L63P+p.A71V+p.G73GS+p.V77I+p.L90M+p.I93L
Missense mutation 1.2 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, K14KR, R57K, I62IV, L63P, A71V, G73GS, V77I, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.K20R+p.L33F+p.M36I+p.M46L+p.I54LV+p.L63P+p.A71V+p.V82A+p.L90M+p.I93L
Missense mutation 2.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, K20R, L33F, M36I, M46L, I54LV, L63P, A71V, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.L23I+p.L24M+p.N37NH+p.K43KT+p.M46I+p.F53L+p.I54V+p.K55R+p.D60E+p.I62V+p.L63P+p.A71V+p.I72V+p.G73ST+p.V77I+p.L90M
Missense mutation 3.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, L23I, L24M, N37NH, K43KT, M46I, F53L, I54V, K55R, D60E, I62V, L63P, A71V, I72V, G73ST, V77I, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.L24I+p.M46I+p.I54V+p.K55KR+p.R57G+p.Q58E+p.D60E+p.L63P+p.I64V+p.I72V+p.V77I+p.V82A
Missense mutation 1.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, L24I, M46I, I54V, K55KR, R57G, Q58E, D60E, L63P, I64V, I72V, V77I, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.L33IV+p.M46L+p.I54V+p.D60E+p.L63P+p.A71V+p.V82T+p.I84V+p.L90M+p.I93L
Missense mutation 5.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, L33IV, M46L, I54V, D60E, L63P, A71V, V82T, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.N37D+p.K43KT+p.M46MI+p.G48LV+p.F53FY+p.I54S+p.I62V+p.L63P+p.H69Y+p.A71V+p.T74S+p.V77I+p.V82A+p.I93L
Missense mutation 3.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, N37D, K43KT, M46MI, G48LV, F53FY, I54S, I62V, L63P, H69Y, A71V, T74S, V77I, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.T12P+p.K14R+p.E35D+p.M36MI+p.R41K+p.M46I+p.I54M+p.Q58E+p.L63P+p.V77I+p.V82F+p.I93L
Missense mutation 3.2 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, T12P, K14R, E35D, M36MI, R41K, M46I, I54M, Q58E, L63P, V77I, V82F, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.T12P+p.K14R+p.L24I+p.M36MI+p.N37ND+p.K43IT+p.M46I+p.K55KR+p.L63P+p.I64IV+p.V82T+p.L89LM+p.I93L+p.T96TP
Missense mutation 1.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, T12P, K14R, L24I, M36MI, N37ND, K43IT, M46I, K55KR, L63P, I64IV, V82T, L89LM, I93L, T96TP.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.T12R+p.I15V+p.K20T+p.N37D+p.M46I+p.K55KR+p.I62V+p.L63P+p.A71T+p.G73S+p.T74S+p.V77I+p.T80TA+p.V82T+p.I85V+p.L90M+p.I93L+p.C95F
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, T12R, I15V, K20T, N37D, M46I, K55KR, I62V, L63P, A71T, G73S, T74S, V77I, T80TA, V82T, I85V, L90M, I93L, C95F.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.T12X+p.K14KR+p.I15IV+p.Q18QE+p.K20KR+p.V32I+p.L33LF+p.E34EQ+p.E35ED+p.M36I+p.M46I+p.I47A+p.R57K+p.L63P+p.A71V+p.I72V+p.V82A+p.I93L
Missense mutation 7.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, T12X, K14KR, I15IV, Q18QE, K20KR, V32I, L33LF, E34EQ, E35ED, M36I, M46I, I47A, R57K, L63P, A71V, I72V, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.V11I+p.I13V+p.K14R+p.I15V+p.K20T+p.V32I+p.L33F+p.M36I+p.R41K+p.M46L+p.I54L+p.R57K+p.D60E+p.L63P+p.G68E+p.K70T+p.A71I+p.I72M+p.G73S+p.I84V+p.L89V+p.L90M+p.I93L
Missense mutation 7.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, V11I, I13V, K14R, I15V, K20T, V32I, L33F, M36I, R41K, M46L, I54L, R57K, D60E, L63P, G68E, K70T, A71I, I72M, G73S, I84V, L89V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.V11I+p.T12K+p.I15V+p.E35D+p.M36I+p.N37D+p.M46I+p.I54V+p.R57K+p.I62V+p.L63P+p.A71V+p.I72L+p.G73S+p.V82AT+p.R87RG+p.L90M
Missense mutation 5.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, V11I, T12K, I15V, E35D, M36I, N37D, M46I, I54V, R57K, I62V, L63P, A71V, I72L, G73S, V82AT, R87RG, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10X+p.E35D+p.M36I+p.N37E+p.R41RK+p.R57RK+p.I62IV+p.I64IV+p.H69HY+p.I84IV
Missense mutation 2.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10X, E35D, M36I, N37E, R41RK, R57RK, I62IV, I64IV, H69HY, I84IV.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10Y+p.G16E+p.V32I+p.L33LI+p.E35D+p.M36I+p.N37V+p.M46V+p.I47V+p.F53L+p.K55KR+p.R57G+p.L63A+p.I93L
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10Y, G16E, V32I, L33LI, E35D, M36I, N37V, M46V, I47V, F53L, K55KR, R57G, L63A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10Y+p.V11VI+p.I13V+p.Q18QH+p.K20IM+p.E21ED+p.L24LIM+p.L33I+p.M36I+p.R41RK+p.M46I+p.I47IV+p.F53FL+p.I54M+p.I62V+p.L63P+p.I64V+p.I72IM+p.G73V+p.T74PS+p.I84V+p.L89V+p.L90M
Missense mutation 3.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10Y, V11VI, I13V, Q18QH, K20IM, E21ED, L24LIM, L33I, M36I, R41RK, M46I, I47IV, F53FL, I54M, I62V, L63P, I64V, I72IM, G73V, T74PS, I84V, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19I+p.L63P+p.A71AT+p.I72E
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19I, L63P, A71AT, I72E.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19IV+p.M36MI+p.R57G+p.I64V
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19IV, M36MI, R57G, I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19Q+p.M36I+p.N37C+p.I62V+p.L63P+p.I64V
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19Q, M36I, N37C, I62V, L63P, I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L19T+p.N37D+p.K43R+p.R57G+p.L63X
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L19T, N37D, K43R, R57G, L63X.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L33F+p.K43T+p.L63C+p.H69Q+p.V77I
Missense mutation 3.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L33F, K43T, L63C, H69Q, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L33F+p.M36L+p.P39Q+p.R41K+p.K43R+p.I54V+p.I62V+p.L63P+p.A71V+p.V82L+p.I93L
Missense mutation 8.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L33F, M36L, P39Q, R41K, K43R, I54V, I62V, L63P, A71V, V82L, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L33V+p.N37C+p.R41K+p.R57G+p.L63P+p.I64V+p.I93L
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L33V, N37C, R41K, R57G, L63P, I64V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L5LF+p.W6WC+p.L10F+p.I13IV+p.I15IV+p.K20M+p.A22AS+p.L24I+p.L33F+p.E35G+p.M36I+p.I54V+p.I62V+p.L63P+p.A71V+p.G73C+p.P79A+p.I84V+p.T91S
Missense mutation 5.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L5LF, W6WC, L10F, I13IV, I15IV, K20M, A22AS, L24I, L33F, E35G, M36I, I54V, I62V, L63P, A71V, G73C, P79A, I84V, T91S.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L5LF+p.W6WL+p.L10F+p.V32I+p.L33F+p.E35D+p.M36I+p.N37D+p.K43T+p.I54L+p.L63P+p.T74S+p.I85V+p.L89M+p.L90M+p.I93L
Missense mutation 1.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L5LF, W6WL, L10F, V32I, L33F, E35D, M36I, N37D, K43T, I54L, L63P, T74S, I85V, L89M, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L5LH+p.L10I+p.I13IV+p.A28AE+p.E35D+p.M36L+p.P39Q+p.R41K+p.M46ML+p.I62V+p.L63P+p.K70KR
Missense mutation 1.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L5LH, L10I, I13IV, A28AE, E35D, M36L, P39Q, R41K, M46ML, I62V, L63P, K70KR.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L5LV+p.L10V+p.G17D+p.L33F+p.G48L+p.F53L+p.I54V+p.R57RK+p.Q58E+p.I62V+p.L63P+p.A71V+p.I72V+p.V82A+p.L90M+p.I93L
Missense mutation 1.2 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L5LV, L10V, G17D, L33F, G48L, F53L, I54V, R57RK, Q58E, I62V, L63P, A71V, I72V, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L63P+p.I64V+p.L90LM
Missense mutation 1.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P, I64V, L90LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L63P
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L63PS+p.V77VI
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L63PS, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M36I+p.N37C+p.R57G+p.L63P
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, N37C, R57G, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M36I+p.N37D+p.K43KR+p.R57K+p.D60E+p.Q61QE+p.I62IV+p.L63P+p.A71T+p.I72IV+p.I93L
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, N37D, K43KR, R57K, D60E, Q61QE, I62IV, L63P, A71T, I72IV, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M36I+p.R57G+p.D60DE+p.Q61E+p.I62V+p.L63P+p.A71AT+p.V77VI+p.I93L
Missense mutation 1.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M36I, R57G, D60DE, Q61E, I62V, L63P, A71AT, V77VI, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q18H+p.R41K+p.L63PS+p.A71V+p.I93L
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q18H, R41K, L63PS, A71V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q18L+p.E35D+p.M36I+p.I62IV+p.L63P+p.K70KR
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q18L, E35D, M36I, I62IV, L63P, K70KR.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q7QR+p.L10LV+p.I13IV+p.K14R+p.E35D+p.N37DE+p.P39PS+p.R57K+p.I62IV+p.L63P+p.I64V
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q7QR, L10LV, I13IV, K14R, E35D, N37DE, P39PS, R57K, I62IV, L63P, I64V.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R41K+p.Q58QH+p.L63P+p.I72IM+p.V77I+p.I93L
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R41K, Q58QH, L63P, I72IM, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57G+p.L63LP+p.I64IV+p.K70KR+p.V77VI
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63LP, I64IV, K70KR, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57G+p.L63S+p.V77VI+p.L89M
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57G, L63S, V77VI, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R57RK+p.L63P+p.E65ED+p.A71T+p.V77I+p.I93L
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R57RK, L63P, E65ED, A71T, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R8R*+p.P9PS+p.L10I+p.I15V+p.K20RT+p.L33F+p.E34Q+p.E35D+p.M36L+p.N37DE+p.R41K+p.I54L+p.R57RK+p.I62V+p.L63P+p.A71V+p.I72T+p.G73S+p.V77I+p.V82A+p.I85IV+p.L90M
Missense mutation 7.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R8R*, P9PS, L10I, I15V, K20RT, L33F, E34Q, E35D, M36L, N37DE, R41K, I54L, R57RK, I62V, L63P, A71V, I72T, G73S, V77I, V82A, I85IV, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R8RQ+p.L10I+p.T12K+p.I13V+p.I15V+p.K20R+p.E35D+p.M36I+p.N37D+p.R41K+p.F53FL+p.I54V+p.R57K+p.D60E+p.Q61N+p.V77I+p.V82F+p.L89I+p.I93L
Missense mutation 6.6 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R8RQ, L10I, T12K, I13V, I15V, K20R, E35D, M36I, N37D, R41K, F53FL, I54V, R57K, D60E, Q61N, V77I, V82F, L89I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12A+p.I13V+p.L63P
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, I13V, L63P.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12A+p.I15V+p.L19I+p.R41K+p.L63P+p.V77I+p.V82L+p.I93L
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, I15V, L19I, R41K, L63P, V77I, V82L, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12A+p.K14R+p.R57K+p.L63P+p.I72V+p.V77I+p.L89I+p.I93L
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12A, K14R, R57K, L63P, I72V, V77I, L89I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12AP+p.K14KR+p.I15IV+p.G16E+p.V77VI
Missense mutation 1.2 Susceptible [3]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12AP, K14KR, I15IV, G16E, V77VI.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12AS+p.I15IV+p.L19LI+p.M36I+p.N37D+p.I62V+p.L63P+p.I72IM
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12AS, I15IV, L19LI, M36I, N37D, I62V, L63P, I72IM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12E+p.I15V+p.L19I+p.E35D+p.M36I+p.R41K+p.I62V+p.L63PS+p.A71AT+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12E, I15V, L19I, E35D, M36I, R41K, I62V, L63PS, A71AT, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12K+p.I13V+p.L19I+p.M36IV+p.R41K+p.R57G+p.I62V+p.L63P+p.I72IM
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12K, I13V, L19I, M36IV, R41K, R57G, I62V, L63P, I72IM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12LS+p.I15V+p.L19I+p.M36I+p.R41K+p.R57G+p.I62V+p.H69K+p.A71T+p.I93L
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12LS, I15V, L19I, M36I, R41K, R57G, I62V, H69K, A71T, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12N+p.K14R+p.I15V+p.L19IM+p.K20R+p.E35D+p.M36I+p.R41K+p.R57K+p.L63T+p.E65D+p.I72T+p.G73GD+p.T74S+p.L89M
Missense mutation 2.7 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12N, K14R, I15V, L19IM, K20R, E35D, M36I, R41K, R57K, L63T, E65D, I72T, G73GD, T74S, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12P+p.I13V+p.K14R+p.L19V+p.K20R+p.M36I+p.R41K+p.R57G+p.L63Q+p.I64V+p.A71V+p.V82M+p.I84V+p.I93L
Missense mutation 2.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, I13V, K14R, L19V, K20R, M36I, R41K, R57G, L63Q, I64V, A71V, V82M, I84V, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12P+p.K20R+p.V32I+p.E35D+p.M36I+p.N37S+p.R41K+p.L63P+p.I64V+p.C67CW+p.A71V+p.I85IV+p.I93L
Missense mutation 2.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12P, K20R, V32I, E35D, M36I, N37S, R41K, L63P, I64V, C67CW, A71V, I85IV, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12S+p.I13V+p.I15V+p.L19I+p.K20T+p.M36I+p.R41RK+p.M46MI+p.K55KR+p.R57RK+p.D60E+p.I62V+p.L63P+p.I64V+p.L90M+p.I93IL
Missense mutation 2.4 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, I13V, I15V, L19I, K20T, M36I, R41RK, M46MI, K55KR, R57RK, D60E, I62V, L63P, I64V, L90M, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12S+p.I15V+p.L19I+p.M36I+p.N37D+p.L63V+p.H69K+p.T74A+p.L89M+p.I93L
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, I15V, L19I, M36I, N37D, L63V, H69K, T74A, L89M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12S+p.I15V+p.L19I+p.M36I+p.R41K+p.L63V+p.H69K+p.K70R+p.P79PT+p.L89M
Missense mutation 1.4 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, I15V, L19I, M36I, R41K, L63V, H69K, K70R, P79PT, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12S+p.L19LI+p.L63P+p.I72V+p.V77I+p.I93L
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12S, L19LI, L63P, I72V, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12TS+p.I13V+p.I15IV+p.K20KLM+p.E35D+p.M36I+p.N37D+p.K45R+p.R57G+p.I64V+p.I72IT+p.L90LM
Missense mutation 1.8 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12TS, I13V, I15IV, K20KLM, E35D, M36I, N37D, K45R, R57G, I64V, I72IT, L90LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T12V+p.E35D+p.M36I+p.R41K+p.R57K+p.Q61N
Missense mutation 1.6 Susceptible [6]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T12V, E35D, M36I, R41K, R57K, Q61N.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T4S+p.L10H+p.I13V+p.E35D+p.M36V+p.N37S+p.M46I+p.I62V+p.L63P+p.I64V+p.A71V+p.L90M+p.I93L
Missense mutation 5.1 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4S, L10H, I13V, E35D, M36V, N37S, M46I, I62V, L63P, I64V, A71V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T4TA+p.L10F+p.I15IV+p.K20KT+p.E35D+p.M46I+p.I54V+p.L63P+p.I64V+p.A71V+p.I72L+p.G73T+p.V77VI+p.I84V+p.I85V+p.L90M
Missense mutation 6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4TA, L10F, I15IV, K20KT, E35D, M46I, I54V, L63P, I64V, A71V, I72L, G73T, V77VI, I84V, I85V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T4TN+p.I13V+p.L33F+p.M36I+p.R41K+p.R57K+p.E65D+p.H69K+p.L89M
Missense mutation 2.7 Susceptible [9]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4TN, I13V, L33F, M36I, R41K, R57K, E65D, H69K, L89M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T4TN+p.L10I+p.T12P+p.K14KR+p.L19V+p.K20R+p.L23I+p.M36MI+p.R41K+p.I54V+p.L63P+p.A71T+p.V77I+p.V82A+p.L90LM+p.I93L
Missense mutation 1.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4TN, L10I, T12P, K14KR, L19V, K20R, L23I, M36MI, R41K, I54V, L63P, A71T, V77I, V82A, L90LM, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T4TS+p.L10F+p.I13V+p.L19V+p.K20R+p.L33I+p.E35D+p.M36I+p.N37ND+p.K43T+p.M46I+p.I54V+p.R57K+p.D60E+p.I62V+p.L63P+p.A71T+p.I72M+p.G73S+p.V82A+p.L90M+p.I93L
Missense mutation 6.9 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4TS, L10F, I13V, L19V, K20R, L33I, E35D, M36I, N37ND, K43T, M46I, I54V, R57K, D60E, I62V, L63P, A71T, I72M, G73S, V82A, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T4TS+p.L10F+p.V11I+p.T12P+p.I13V+p.I15IV+p.K20IT+p.L24M+p.E35D+p.M36I+p.M46I+p.F53FL+p.Q58QE+p.I62V+p.L63E+p.C67CY+p.A71I+p.I72T+p.G73S+p.T74P+p.P79AG+p.I84AV+p.L89V+p.L90M+p.Q92K+p.I93L
Missense mutation 4.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T4TS, L10F, V11I, T12P, I13V, I15IV, K20IT, L24M, E35D, M36I, M46I, F53FL, Q58QE, I62V, L63E, C67CY, A71I, I72T, G73S, T74P, P79AG, I84AV, L89V, L90M, Q92K, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V11VI+p.I13V+p.V32I+p.L33F+p.E34Q+p.M46I+p.I47V+p.F53L+p.I54V+p.L63P+p.A71V+p.V82A+p.L90M+p.I93IL
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V11VI, I13V, V32I, L33F, E34Q, M46I, I47V, F53L, I54V, L63P, A71V, V82A, L90M, I93IL.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V11VI+p.I15V+p.K20I+p.L24F+p.M46I+p.F53L+p.L63P+p.H69R+p.A71V+p.G73S+p.V77I+p.L90M
Missense mutation 1.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V11VI, I15V, K20I, L24F, M46I, F53L, L63P, H69R, A71V, G73S, V77I, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V11VI+p.N37S+p.R41K+p.L63PS+p.V77I
Missense mutation 1.2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V11VI, N37S, R41K, L63PS, V77I.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V11VI+p.T12TA+p.I13IV+p.L19I+p.K20I+p.D30N+p.E35N+p.M36I+p.N37DE+p.F53FL+p.I54IV+p.Q58QE+p.D60E+p.Q61E+p.L63P+p.A71V+p.I72T+p.N83ND+p.N88D+p.L90M
Missense mutation 1.3 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V11VI, T12TA, I13IV, L19I, K20I, D30N, E35N, M36I, N37DE, F53FL, I54IV, Q58QE, D60E, Q61E, L63P, A71V, I72T, N83ND, N88D, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V32I+p.L33F+p.E34Q+p.M36A+p.P39S+p.M46I+p.F53L+p.I54L+p.K55KR+p.I62V+p.L63P+p.A71V+p.I84V+p.L90M
Missense mutation 4.9 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V32I, L33F, E34Q, M36A, P39S, M46I, F53L, I54L, K55KR, I62V, L63P, A71V, I84V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V32I+p.M46I+p.I47V+p.I62V+p.L63P+p.I72Y+p.G73S+p.V77I+p.I93L
Missense mutation 1.6 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V32I, M46I, I47V, I62V, L63P, I72Y, G73S, V77I, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6GV+p.L10I+p.I15V+p.K20R+p.V32I+p.M36I+p.M46I+p.F53L+p.I54V+p.K55R+p.D60E+p.Q61E+p.I62V+p.L63P+p.A71V+p.G73A+p.L76V+p.V82A+p.L89V+p.L90M
Missense mutation 2.2 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6GV, L10I, I15V, K20R, V32I, M36I, M46I, F53L, I54V, K55R, D60E, Q61E, I62V, L63P, A71V, G73A, L76V, V82A, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6S+p.L10I+p.I13V+p.K14KE+p.K20R+p.V32I+p.M36MI+p.N37NS+p.R41N+p.M46I+p.I47V+p.I54M+p.D60E+p.L63P+p.I64V+p.A71V+p.V82A
Missense mutation 5.3 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6S, L10I, I13V, K14KE, K20R, V32I, M36MI, N37NS, R41N, M46I, I47V, I54M, D60E, L63P, I64V, A71V, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6WLS+p.L10I+p.I13V+p.A22V+p.V32I+p.L33I+p.E35D+p.M36I+p.N37S+p.M46L+p.I47V+p.I54M+p.D60E+p.I62V+p.L63P+p.A71V+p.L89V+p.L90M
Missense mutation 9.5 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6WLS, L10I, I13V, A22V, V32I, L33I, E35D, M36I, N37S, M46L, I47V, I54M, D60E, I62V, L63P, A71V, L89V, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6WR+p.L10FI+p.I13V+p.M46MI+p.I54IV+p.L63AP+p.C67CF+p.A71T+p.I72IV+p.I84IV+p.N88ND+p.L90LM+p.I93L+p.C95CF
Missense mutation 2 Susceptible [1]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6WR, L10FI, I13V, M46MI, I54IV, L63AP, C67CF, A71T, I72IV, I84IV, N88ND, L90LM, I93L, C95CF.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6WR+p.L10I+p.I13V+p.L33F+p.M36ML+p.G48V+p.I54ST+p.I62V+p.I64V+p.T74S+p.V82A
Missense mutation 3.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6WR, L10I, I13V, L33F, M36ML, G48V, I54ST, I62V, I64V, T74S, V82A.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6WR+p.P9PAS+p.L10I+p.I15V+p.L33LF+p.E35D+p.N37D+p.M46L+p.I54L+p.Q58E+p.I62V+p.L63P+p.V82A+p.I93L
Missense mutation 2.1 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6WR, P9PAS, L10I, I15V, L33LF, E35D, N37D, M46L, I54L, Q58E, I62V, L63P, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.W6WS+p.L10F+p.I13V+p.L19LI+p.K20R+p.V32I+p.L33F+p.M36I+p.K43T+p.M46MIV+p.I47V+p.I54M+p.L63P+p.A71V+p.I72IV+p.V82A+p.L89IM+p.L90M
Missense mutation 8.6 Susceptible [2]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included W6WS, L10F, I13V, L19LI, K20R, V32I, L33F, M36I, K43T, M46MIV, I47V, I54M, L63P, A71V, I72IV, V82A, L89IM, L90M.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.E34Q+p.G48V+p.I54S+p.I62V+p.L63P+p.A71V+p.T74S+p.V77I+p.V82A+p.I93L
Missense mutation 1.5 Susceptible [4]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, E34Q, G48V, I54S, I62V, L63P, A71V, T74S, V77I, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.I13V+p.G16A+p.Q18H+p.L33F+p.N37D+p.M46I+p.I54V+p.Q61H+p.L63P+p.A71L+p.I72T+p.L76V+p.V77I+p.N88G+p.L90M+p.I93L
Missense mutation 0.8 Susceptible [11]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, I13V, G16A, Q18H, L33F, N37D, M46I, I54V, Q61H, L63P, A71L, I72T, L76V, V77I, N88G, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L33F+p.M46I+p.I54V+p.L63P+p.A71V+p.T74P+p.I84V+p.L90M+p.I93L
Missense mutation 6.2 Susceptible [4]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L33F, M46I, I54V, L63P, A71V, T74P, I84V, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.L33LF+p.E34Q+p.M46MIV+p.G48V+p.I50V+p.I54S+p.I62V+p.L63P+p.A71V+p.I72V+p.T74S+p.V77I+p.V82A+p.I93L
Missense mutation 0.4 Susceptible [4]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, L33LF, E34Q, M46MIV, G48V, I50V, I54S, I62V, L63P, A71V, I72V, T74S, V77I, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.T12TK+p.E35D+p.M36MI+p.M46I+p.I54V+p.I62V+p.L63P+p.I64IV+p.G73GC+p.T74S+p.V82A+p.L90M+p.I93L+p.C95F
Missense mutation 3.2 Susceptible [4]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, T12TK, E35D, M36MI, M46I, I54V, I62V, L63P, I64IV, G73GC, T74S, V82A, L90M, I93L, C95F.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10I+p.V32I+p.M46I+p.I47A+p.I62V+p.L63P+p.V77I+p.V82I+p.Q92K+p.I93L+p.C95F
Missense mutation 1.7 Susceptible [4]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10I, V32I, M46I, I47A, I62V, L63P, V77I, V82I, Q92K, I93L, C95F.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.I15IV+p.G17DE+p.K20IMR+p.R41RK+p.I62IV+p.L63P+p.A71V+p.G73X+p.V77VI+p.I84IV+p.I85IV+p.L90M+p.I93L
Missense mutation 1.3 Susceptible [4]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I15IV, G17DE, K20IMR, R41RK, I62IV, L63P, A71V, G73X, V77VI, I84IV, I85IV, L90M, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.I15V+p.G16GE+p.K20R+p.E35D+p.M36I+p.R41K+p.I54IV+p.R57K+p.Q61N+p.L63LH+p.I64IM+p.K70KR+p.L89M+p.L90LM
Missense mutation 3.3 Susceptible [4]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, I15V, G16GE, K20R, E35D, M36I, R41K, I54IV, R57K, Q61N, L63LH, I64IM, K70KR, L89M, L90LM.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10LI+p.L24I+p.R41K+p.M46L+p.I54V+p.I62V+p.L63P+p.A71V+p.T74A+p.V77I+p.V82A+p.I93L
Missense mutation 0.8 Susceptible [4]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10LI, L24I, R41K, M46L, I54V, I62V, L63P, A71V, T74A, V77I, V82A, I93L.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L10V+p.I15V+p.G16E+p.K20R+p.E35D+p.M36I+p.R41K+p.M46I+p.I50V+p.I54V+p.K55R+p.R57K+p.Q61N+p.I64IL+p.A71V+p.I72R+p.V82A+p.L89I+p.L90M+p.Q92K
Missense mutation 1.2 Susceptible [4]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L10V, I15V, G16E, K20R, E35D, M36I, R41K, M46I, I50V, I54V, K55R, R57K, Q61N, I64IL, A71V, I72R, V82A, L89I, L90M, Q92K.
Key Molecule: HIV1 Protease (HIV1 PR)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.V32I+p.I47V+p.Q61E+p.L63P+p.V82A+p.I93L
Missense mutation 0.4 Susceptible [4]
Sensitive Drug Tipranavir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included V32I, I47V, Q61E, L63P, V82A, I93L.
References
Ref 1 HIV-1 protease mutations and protease inhibitor cross-resistanceAntimicrob Agents Chemother. 2010 Oct;54(10):4253-61. doi: 10.1128/AAC.00574-10. Epub 2010 Jul 26.
Ref 2 Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavirJ Virol. 2006 Nov;80(21):10794-801. doi: 10.1128/JVI.00712-06. Epub 2006 Aug 23.
Ref 3 Genotypic predictors of human immunodeficiency virus type 1 drug resistanceProc Natl Acad Sci U S A. 2006 Nov 14;103(46):17355-60. doi: 10.1073/pnas.0607274103. Epub 2006 Oct 25.
Ref 4 Phenotypic susceptibility to TMC-114 and tipranavir before and after lopinavir/ritonavir-based treatment in subjects demonstrating evolution of lopinavir resistance.
Ref 5 Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110). J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):318-26. doi: 10.1097/QAI.0000000000000017.
Ref 6 Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypesAIDS. 2008 Mar 12;22(5):611-6. doi: 10.1097/QAD.0b013e3282f51eb9.
Ref 7 Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlatesJ Virol. 2005 Mar;79(6):3329-38. doi: 10.1128/JVI.79.6.3329-3338.2005.
Ref 8 Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patientsJ Virol. 2001 Aug;75(16):7462-9. doi: 10.1128/JVI.75.16.7462-7469.2001.
Ref 9 Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, UgandaAIDS. 2009 Apr 27;23(7):845-52. doi: 10.1097/QAD.0b013e328327957a.
Ref 10 HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillanceJ Infect Dis. 2005 Aug 1;192(3):456-65. doi: 10.1086/431601. Epub 2005 Jul 5.
Ref 11 Patterns of protease inhibitor cross resistance in viral isolates with reduced susceptibility to lopinavir.
insuranceusa.com
visits since 2022

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.